Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 30, 2018 | Feb. 22, 2019 | Jun. 29, 2018 | |
Document and Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2,018 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | PERKINELMER INC | ||
Trading Symbol | PKI | ||
Entity Central Index Key | 31,791 | ||
Current Fiscal Year End Date | --12-30 | ||
Document Period End Date | Dec. 30, 2018 | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Common Stock, Shares Outstanding | 110,800,020 | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | false | ||
Entity Shell Company | false | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Public Float | $ 7,944,359,992 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | ||
Revenue | ||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 2,777,996 | $ 2,256,982 | $ 2,115,517 | |||||||||
Cost of Goods and Services Sold | 1,437,057 | |||||||||||
Selling, general and administrative expenses | 811,913 | 626,018 | 590,471 | |||||||||
Research and development expenses | 193,998 | 139,464 | 124,184 | |||||||||
Restructuring and contract termination charges, net | $ (1,942) | $ 6,508 | $ 0 | $ 6,578 | $ (263) | $ 3,269 | $ 0 | $ 9,651 | 11,144 | 12,657 | 5,124 | |
Operating income from continuing operations | 115,683 | [1] | 80,202 | 88,064 | 39,935 | 93,583 | 78,038 | 74,183 | 49,811 | 323,884 | 295,615 | 294,582 |
Interest and other expense, net | 66,201 | (1,103) | 50,514 | |||||||||
Income from continuing operations before income taxes | 79,429 | [1] | 78,041 | 71,708 | 28,505 | 80,889 | 105,054 | 70,792 | 39,983 | 257,683 | 296,718 | 244,068 |
Provision for income taxes | 20,208 | 139,828 | 28,362 | |||||||||
Income from continuing operations | 71,322 | [1] | 75,445 | 64,673 | 26,035 | (38,444) | 96,546 | 62,726 | 36,062 | 237,475 | 156,890 | 215,706 |
Income from discontinued operations before income taxes | 0 | 650 | 22,229 | |||||||||
(Loss) gain on disposition of discontinued operations before income taxes | (859) | 179,615 | 619 | |||||||||
(Benefit from) provision for income taxes on discontinued operations and dispositions | (1,311) | 44,522 | 4,255 | |||||||||
Income from discontinued operations and dispositions | (30) | 1,103 | (610) | (11) | (2,673) | (5,468) | 141,343 | 2,541 | 452 | 135,743 | 18,593 | |
Net income | $ 71,292 | [1] | $ 76,548 | $ 64,063 | $ 26,024 | $ (41,117) | $ 91,078 | $ 204,069 | $ 38,603 | $ 237,927 | $ 292,633 | $ 234,299 |
Basic earnings per share: | ||||||||||||
Income from continuing operations | $ 0.64 | [1] | $ 0.68 | $ 0.59 | $ 0.24 | $ (0.35) | $ 0.88 | $ 0.57 | $ 0.33 | $ 2.15 | $ 1.43 | $ 1.97 |
Income from discontinued operations and dispositions | 0 | 0.01 | (0.01) | 0 | (0.02) | (0.05) | 1.29 | 0.02 | 0 | 1.24 | 0.17 | |
Net income | 0.64 | [1] | 0.69 | 0.58 | 0.24 | (0.37) | 0.83 | 1.86 | 0.35 | 2.15 | 2.67 | 2.14 |
Diluted earnings per share: | ||||||||||||
Income from continuing operations | 0.64 | [1] | 0.68 | 0.58 | 0.23 | (0.35) | 0.87 | 0.57 | 0.33 | 2.13 | 1.42 | 1.96 |
Income from discontinued operations and dispositions | 0 | 0.01 | (0.01) | 0 | (0.02) | (0.05) | 1.28 | 0.02 | 0 | 1.22 | 0.17 | |
Net income | $ 0.64 | [1] | $ 0.69 | $ 0.57 | $ 0.23 | $ (0.37) | $ 0.82 | $ 1.84 | $ 0.35 | $ 2.13 | $ 2.64 | $ 2.12 |
Product [Member] | ||||||||||||
Revenue | ||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 1,935,493 | $ 1,477,414 | $ 1,396,896 | |||||||||
Cost of Goods and Services Sold | 908,228 | 707,962 | 663,795 | |||||||||
Service [Member] | ||||||||||||
Revenue | ||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 842,503 | 779,568 | 718,621 | |||||||||
Cost of Goods and Services Sold | $ 528,829 | $ 475,266 | $ 437,361 | |||||||||
[1] | The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02 | $ 6,489 | $ 0 | $ 0 |
Net income | 237,927 | 292,633 | 234,299 |
Other comprehensive income (loss) | |||
Foreign currency translation adjustments, net of tax | (123,388) | 54,341 | (54,077) |
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02 | 6,489 | 0 | 0 |
Unrecognized prior service costs, net of tax | (77) | (77) | (860) |
Unrealized (losses) gains on securities, net of tax | (9) | 79 | 32 |
Other comprehensive (loss) income | (129,963) | 54,343 | (54,905) |
Comprehensive income | $ 107,964 | $ 346,976 | $ 179,394 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 163,111 | $ 202,134 |
Accounts receivable, net | 632,669 | 552,304 |
Inventories | 338,347 | 351,675 |
Other current assets | 100,507 | 93,842 |
Total current assets | 1,234,634 | 1,199,955 |
Property, plant and equipment, net | 318,590 | 298,066 |
Intangible assets, net | 1,199,667 | 1,346,940 |
Goodwill | 2,952,608 | 3,002,198 |
Other assets, net | 270,023 | 244,304 |
Total assets | 5,975,522 | 6,091,463 |
Current liabilities: | ||
Current portion of long-term debt | 14,856 | 217,306 |
Accounts payable | 220,949 | 222,093 |
Accrued restructuring and contract termination costs | 4,834 | 8,759 |
Accrued expenses and other current liabilities | 528,827 | 500,642 |
Current liabilities of discontinued operations | 2,165 | 2,102 |
Total current liabilities | 771,631 | 950,902 |
Long-term debt | 1,876,624 | 1,788,803 |
Long-term liabilities | 742,312 | 848,570 |
Total liabilities | 3,390,567 | 3,588,275 |
Commitments and contingencies (see Notes 15 and 18) | ||
Stockholders' equity: | ||
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | 0 | 0 |
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 110,597,000 and 110,361,000 shares at December 30, 2018 and December 31, 2017, respectively | 110,597 | 110,361 |
Capital in excess of par value | 48,772 | 58,828 |
Retained earnings | 2,602,067 | 2,380,517 |
Accumulated other comprehensive loss | (176,481) | (46,518) |
Total stockholders' equity | 2,584,955 | 2,503,188 |
Total liabilities and stockholders' equity | $ 5,975,522 | $ 6,091,463 |
Consolidated Balance Sheet Pare
Consolidated Balance Sheet Parenthetical - $ / shares | Dec. 30, 2018 | Dec. 31, 2017 |
Balance Sheet Parenthetical [Abstract] | ||
Preferred stock, par value | $ 1 | $ 1 |
Preferred stock, authorized | 1,000,000 | 1,000,000 |
Preferred stock, issued | 0 | 0 |
Preferred stock, outstanding | 0 | 0 |
Common stock, par value | $ 1 | $ 1 |
Common stock, authorized | 300,000,000 | 300,000,000 |
Common stock, issued | 110,597,000 | 110,361,000 |
Common stock, outstanding | 110,597,000 | 110,361,000 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) | Total | Common Stock Amount [Member] | Capital In Excess of Par Value [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] |
Beginning Balance at Jan. 03, 2016 | $ 2,110,441,000 | $ 112,034,000 | $ 52,932,000 | $ 1,991,431,000 | $ (45,956,000) |
Net income | 234,299,000 | ||||
Other comprehensive income (loss) | (54,905,000) | (54,905,000) | |||
Dividends | (30,629,000) | (30,629,000) | |||
Exercise of employee stock options and related income tax benefits | 14,418,000 | 576,000 | 13,842,000 | ||
Issuance of common stock for employee benefit plans | 2,463,000 | 50,000 | 2,413,000 | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 151,801,000 | 3,275,000 | 58,058,000 | 90,468,000 | |
Issuance of common stock for long-term incentive program | 10,425,000 | 232,000 | 10,193,000 | ||
Stock compensation | 4,631,000 | 0 | 4,631,000 | 0 | 0 |
Ending Balance at Jan. 01, 2017 | 2,153,570,000 | 109,617,000 | 26,130,000 | 2,118,684,000 | (100,861,000) |
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Info Retrospectively Adjusted | Accounting Standards Update 2016-09 [Member] | 14,228,000 | 0 | 177,000 | 14,051,000 | |
Net income | 292,633,000 | 0 | 292,633,000 | ||
Other comprehensive income (loss) | 54,343,000 | 54,343,000 | |||
Dividends | (30,800,000) | (30,800,000) | 0 | ||
Exercise of employee stock options and related income tax benefits | 18,004,000 | 578,000 | 17,426,000 | ||
Issuance of common stock for employee benefit plans | 2,467,000 | 37,000 | 2,430,000 | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 4,367,000 | 79,000 | 4,288,000 | ||
Issuance of common stock for long-term incentive program | 12,353,000 | 208,000 | 12,145,000 | ||
Stock compensation | 4,985,000 | 0 | 4,985,000 | 0 | 0 |
Ending Balance at Dec. 31, 2017 | 2,503,188,000 | 110,361,000 | 58,828,000 | 2,380,517,000 | (46,518,000) |
Net income | 237,927,000 | 237,927,000 | |||
Other comprehensive income (loss) | (129,963,000) | ||||
Dividends | (31,013,000) | (31,013,000) | |||
Exercise of employee stock options and related income tax benefits | 24,833,000 | 709,000 | 24,124,000 | ||
Issuance of common stock for employee benefit plans | 1,485,000 | 21,000 | 1,464,000 | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 57,393,000 | 717,000 | 56,676,000 | ||
Issuance of common stock for long-term incentive program | 15,873,000 | 223,000 | 15,650,000 | ||
Stock compensation | 5,382,000 | 0 | 5,382,000 | 0 | 0 |
Ending Balance at Dec. 30, 2018 | 2,584,955,000 | 110,597,000 | 48,772,000 | 2,602,067,000 | (176,481,000) |
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification | Accounting Standards Update 2016-16 [Member] | (2,062,000) | 0 | 0 | 0 | |
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification | Accounting Standards Update 2018-02 [Member] | 0 | 0 | 0 | $ 6,489,000 | (6,489,000) |
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax | (123,474,000) | (123,474,000) | |||
Cumulative Effect of New Accounting Principle in Period of Adoption | Accounting Standards Update 2014-09 [Member] | 10,209,000 | $ 0 | $ 0 | $ 0 | |
Cumulative Effect of New Accounting Principle in Period of Adoption | Accounting Standards Update 2018-02 [Member] | $ 6,500,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018USD ($) | Dec. 31, 2017USD ($) | Jan. 01, 2017USD ($) | |
Restricted Cash | $ 3,204 | $ 236 | $ 17,303 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 166,315 | 202,370 | 376,568 |
Operating activities: | |||
Net income | 237,927 | 292,633 | 234,299 |
Income from discontinued operations and dispositions, net of income taxes | (452) | (135,743) | (18,593) |
Income from continuing operations | 237,475 | 156,890 | 215,706 |
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations: | |||
Restructuring and contract termination charges, net | 11,144 | 12,657 | 5,124 |
Depreciation and amortization | 180,588 | 105,000 | 99,972 |
Stock-based compensation | 28,767 | 25,421 | 17,158 |
Pension and other postretirement expense (benefits) | 11,915 | (10,439) | 14,511 |
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | 14,639 | 2,162 | 16,183 |
Deferred taxes | (51,103) | 28,854 | (4,549) |
Deferred Income Tax Expense (Benefit), Continuing Operations, Discontinuing Operations | (51,103) | 28,854 | (6,526) |
Contingencies and Non-Cash Tax Matters | (671) | 182 | (291) |
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts | 3,341 | 2,592 | 2,137 |
(Gain) loss on disposition of businesses and assets, net | (12,844) | 309 | (5,562) |
Amortization of acquired inventory revaluation | 19,272 | 6,188 | 396 |
Gain on Sale of Investments | (557) | 0 | 0 |
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested: | |||
Accounts receivable, net | (94,512) | (36,633) | (18,960) |
Inventories, net | (30,183) | (17,923) | 6,752 |
Accounts payable | 8,900 | 34,331 | 30,716 |
Accrued expenses and other | (14,933) | (17,436) | (53,540) |
Net cash provided by operating activities of continuing operations | 311,238 | 292,155 | 323,776 |
Net cash (used in) provided by operating activities of discontinued operations | (200) | (3,702) | 26,839 |
Net cash provided by operating activities | 311,038 | 288,453 | 350,615 |
Investing activities: | |||
Capital expenditures | (93,253) | (39,089) | (31,702) |
Proceeds from Derivative Instrument, Investing Activities | 0 | 36,541 | 0 |
Payments to Acquire Investments | (7,019) | (10,783) | 0 |
Proceeds from Divestiture of Businesses | 38,027 | 1,100 | 21,000 |
Proceeds from surrender of life insurance policies | 72 | 45 | 44 |
Activity related to acquisitions, net of cash and cash equivalents acquired | (97,686) | (1,527,183) | (71,924) |
Net cash used in investing activities of continuing operations | (159,859) | (1,539,369) | (82,582) |
Net cash provided by (used in) investing activities of discontinued operations | 0 | 272,779 | (1,302) |
Net cash used in investing activities | (159,859) | (1,266,590) | (83,884) |
Financing activities: | |||
Payments on revolving credit facility | (1,264,000) | (235,965) | (902,507) |
Proceeds from revolving credit facility | 857,000 | 1,060,952 | 420,507 |
Proceeds from sale of senior debt | 369,340 | 0 | 546,190 |
Payments of debt financing costs | (2,634) | 0 | (7,868) |
Net payments on other credit facilities | (28,383) | (2,831) | (1,096) |
Settlement of cash flow hedges | (34,132) | (13,824) | (1,900) |
Payments for acquisition-related contingent consideration | (12,800) | (8,940) | (155) |
Excess tax benefit from exercise of common stock options | 0 | 0 | |
Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options | 24,833 | 18,004 | 14,418 |
Purchases of common stock | (57,445) | (3,834) | (151,801) |
Dividends paid | (31,009) | (30,793) | (30,799) |
Net cash provided by (used in) financing activities of continuing operations | (179,230) | 782,769 | (115,011) |
Net cash used in financing activities of discontinued operations | 0 | (533) | 0 |
Net cash (used in) provided by financing activities | (179,230) | 782,236 | (115,011) |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | (8,004) | 21,703 | (13,422) |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | (36,055) | (174,198) | 138,298 |
Cash and cash equivalents at beginning of year | 202,134 | 359,265 | |
Cash and cash equivalents at end of year | 163,111 | 202,134 | 359,265 |
Supplemental disclosures of cash flow information | |||
Interest | 56,451 | 35,780 | 30,718 |
Income taxes | $ 59,844 | $ 77,607 | $ 43,549 |
Nature of Operations and Accoun
Nature of Operations and Accounting Policies | 12 Months Ended |
Dec. 30, 2018 | |
Accounting Policies [Abstract] | |
Nature of Operations and Accounting Policies | Nature of Operations and Accounting Policies Nature of Operations: PerkinElmer, Inc. is a leading provider of products, services and solutions to the diagnostics, life sciences and applied markets. Through its advanced technologies and differentiated solutions, critical issues are addressed that help to improve lives and the world around us. The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. The Company has two operating segments: Discovery & Analytical Solutions and Diagnostics. The Company's Discovery & Analytical Solutions segment focuses on service and innovating for customers spanning the life sciences and applied markets. The Company's Diagnostics segment is targeted towards meeting the needs of clinically-oriented customers, especially within the growing areas of reproductive health, emerging market diagnostics and applied genomics. The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 30, 2018 (" fiscal year 2018 "), December 31, 2017 (" fiscal year 2017 ") and January 1, 2017 (" fiscal year 2016 ") included 52 weeks. The fiscal year ending December 29, 2019 will include 52 weeks. Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers. Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue. Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. When the Company determines during the period that previously undistributed earnings of certain international subsidiaries no longer meet the requirements of indefinite reinvestment, the Company recognizes the income tax expense in that period. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 8 below for additional details. The Company uses an individual unit of account approach for releasing the income tax effects of unrealized gains and losses from Accumulated Other Comprehensive Income ("AOCI"). Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed. Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented. Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive (loss) income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net. Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. The intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 14 below for additional details. Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 20 below. Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions. Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 6 below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use. Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance on capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). Specifically, ASU 2018-15 amends Intangibles-Goodwill and Other (Topic 350) to include in its scope implementation costs incurred in a hosting arrangement that is a service contract and clarifies that a customer should apply Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The provisions of this guidance are to be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14"). ASU 2018-14 adds, removes, and clarifies disclosure requirements related to defined benefit pension and other postretirement plans. ASU 2018-14 adds requirements for an entity to disclose the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans; and an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period . Further, ASU 2018-14 removes guidance that currently requires the following disclosures: the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year; the amount and timing of plan assets expected to be returned to the employer; information about (1) benefits covered by related-party insurance and annuity contracts and (2) significant transactions between the plan and related parties; and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. ASU 2018-14 also clarifies the guidance in Compensation-Retirement Benefits (Topic 715-20-50-3) on defined benefit plans to require disclosure of (1) the projected benefit obligation ("PBO") and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (2) the accumulated benefit obligation ("ABO") and fair value of plan assets for pension plans with ABOs in excess of plan assets. The provisions of this guidance are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-14 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). ASU 2018-13 adds, removes, and modifies certain disclosures related to fair value measurements. ASU 2018-13 adds requirements for an entity to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Further, ASU 2018-13 removes the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also modifies existing disclosure requirements related to measurement uncertainty. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In June 2018, the FASB issued Accounting Standards Update No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07") which supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-employees , and expands the scope of Topic 718 (which currently only includes share-based payments to employees) to also include share-based payments issued to non-employees for goods and services, except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, except for financing transactions, or awards issued to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers ("Topic 606"). The provisions of this guidance are to be applied using a modified retrospective approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified non-employee awards that have not been settled as of the adoption date and (2) equity-classified non-employee awards for which a measurement date has not been established. ASU 2018-07 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606. The Company early adopted the provisions of this guidance effective July 2, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flow. In March 2018, the FASB Issued Accounting Standards Update No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("ASU 2018-05"). ASU 2018-05 was issued to incorporate into Topic 740 recent SEC guidance related to the income tax accounting implications of the Tax Cut and Jobs Act (the "Tax Act"). The SEC issued Staff Accounting Bulletin No. 118 ("SAB 118") to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Act in the period of enactment. SAB 118 permits companies to disclose that some or all of the income tax effects from the Tax Act are incomplete by the due date of the financial statements, and if possible, disclose a reasonable estimate of such tax effects. ASU 2018-05 is effective immediately. The Company is applying the guidance in ASU 2018-05 when accounting for the enactment date effects of the Tax Act. At December 30, 2018 , the Company completed the accounting for all of the tax effects of the Tax Act using reasonable estimates of their effects based on currently available information. These estimates may be affected as additional clarification and implementation guidance becomes available. These changes could be material to the Company's income tax expense. See Note 8 for further disclosures. In February 2018, the FASB Issued Accounting Standards Update No. 2018-03, Technical Corrections and Improvements to Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2018-03") . ASU 2018-03 was issued to clarify certain aspects of guidance concerning the recognition of financial assets and liabilities established in Accounting Standards Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). This includes treatment for discontinuations and adjustments for equity securities without a readily determinable market value, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in a foreign currency, and transition guidance for equity securities without a readily determinable fair value. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years beginning after June 15, 2018. Early adoption is permitted for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, as long as the Company has adopted ASU 2016-01. The Company adopted the provisions of this guidance effective July 2, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In February 2018, the FASB Issued Accounting Standards Update No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02") . ASU 2018-02 provides entities with an option to reclassify stranded tax effects within AOCI to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act (or portion thereof) is recorded. ASU 2018-02 requires entities to disclose a description of the accounting policy for releasing income tax effects from AOCI; whether they elect to reclassify the stranded income tax effects from the Tax Act; and information about the other income tax effects that are reclassified. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and entities should apply the proposed amendments either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company adopted ASU 2018-02 on December 30, 2018. The adoption of the standard resulted in an increase in retained earnings at December 30, 2018 in the amount of $6.5 million , with a corresponding decrease in AOCI. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Impr |
Revenue (Notes)
Revenue (Notes) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Revenue [Abstract] | |||
Revenue from Contract with Customer [Text Block] | Revenue Nature of goods and services The following is a description of principal activities, by reportable segments, from which the Company generates its revenue. For more detailed information about the reportable segments, see Note 25. i. Discovery & Analytical Solutions The Discovery & Analytical Solutions ("DAS") segment of the Company principally generates revenue from sales of (a) instruments, consumables and services in the applied markets and (b) instruments, reagents, informatics, detection and imaging technologies, extended warranties, training and services in the life sciences market. Products and services may be sold separately or in bundled packages. The typical length of a contract for service is 12 to 36 months. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a subscription term with revenue recognized ratably over the contract period, and multi-year software licenses or software subscriptions that are invoiced annually with revenue recognized upfront. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Software licenses and subscriptions Customers may purchase perpetual or term licenses, or subscribe to licenses, which provide customers with the same functionality and differ mainly in the duration over which the customer benefits from the software. The Company sells its software subscriptions or software licenses with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software upfront at the point in time when the software is made available to the customer. For maintenance and consulting services, revenue is recognized ratably over the period in which the services are provided. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. Software subscriptions and maintenance service contracts are non-cancelable. Cloud services Cloud services, which allow customers to use hosted software over the contract period without taking possession of the software, are provided on either a subscription or consumption basis. Revenue related to cloud services provided on a subscription basis is recognized ratably over the contract period. Revenue related to cloud services provided on a consumption basis, such as the amount of storage used in a period, is recognized based on the customer utilization of such resources. Payment terms are generally net 30 days from signing of contract and contracts are non-cancelable. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Laboratory services and training The Company's service offerings include service contracts, field service, including related time and materials, and training. The Company recognizes revenue as the services are performed. Revenue for the service contracts is recognized over the contract period or at a point in time when the service is billable based on time and materials. The Company recognizes revenue as training is provided in service revenue. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. In general, customers can cancel the service contracts at any time with 30 to 90 days notice without significant penalty. ii. Diagnostics The Diagnostics segment of the Company principally generates revenue from sales of instruments, solutions, consumables, reagents, extended warranties and services in the diagnostics market. Products and services may be sold separately or in bundled packages. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a storage period with revenue recognized ratably over the contract period. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Solutions When the Company sells the instrument and reagents that work only on those instruments to a customer or distributor, the Company considers the instrument and reagents as separate performance obligations. The Company recognizes revenue when an instrument is sold to the customer upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Revenue from the sale of reagents is also recognized at the time of delivery or when title has transferred to the customer. Payment terms for instrument and reagent sales are usually net 30 days from invoice date. When the Company places the instrument at the customer's site and sells the reagents to a customer, the instrument and reagents are accounted for together as one performance obligation. The Company does not charge a fee for the use of the instrument and retains ownership of the placed instrument. The Company has a right to remove the instrument and replace it with another instrument at the customer's site at any time throughout the contract term. The Company recognizes revenue upon delivery of reagents, which is the point in time where the Company has performed its obligation to provide a screening solution to the customer. Payment terms are usually net 30 days from invoice date. Payment terms for certain contracts are based on equal installments over the duration of the contract. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Services The Company's service offerings include cord blood processing and storage, and training. The Company recognizes revenue for the cord blood processing and training as the services are performed in service revenue. Revenue for the storage contracts are recognized over the contract period. Storage is typically for a period of 1, 20, or 25 years or lifetime. Lifetime storage is recognized over a certain period that is based on the life expectancy estimate from Social Security data. For cord blood processing, customers pay the processing fee in full at the point of sale. The processing fee is non-refundable unless the cord blood is non-viable for storage. For storage, customers are required to pay the storage fees in full upfront. Storage fees are refundable to the customer on a pro-rated basis if the contract is canceled. Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments For the fiscal year ended December 30, 2018 Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 680,117 $ 385,005 $ 1,065,122 Europe 494,707 283,385 778,092 Asia 518,387 416,395 934,782 $ 1,693,211 $ 1,084,785 $ 2,777,996 Primary end-markets Diagnostics $ — $ 1,084,785 $ 1,084,785 Life sciences 934,690 — 934,690 Applied markets 758,521 — 758,521 $ 1,693,211 $ 1,084,785 $ 2,777,996 Timing of revenue recognition Products and services transferred at a point in time $ 1,199,255 $ 1,002,788 $ 2,202,043 Services transferred over time 493,956 81,997 575,953 $ 1,693,211 $ 1,084,785 $ 2,777,996 Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balance of contract assets as of December 30, 2018 and as of the date of adoption of ASC 606 were $31.9 million and $22.7 million , respectively. The amount of unbilled receivables recognized at the beginning of the period that were transferred to trade receivables during the fiscal year ended December 30, 2018 was $21.9 million . The increase in unbilled receivables during the fiscal year ended December 30, 2018 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $31.1 million . Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or long-term in "Long-term liabilities" in the consolidated balance sheet based on the timing of when the Company expects to recognize revenue. The balance of contract liabilities as of December 30, 2018 and as of the date of adoption of ASC 606 were $30.8 million and $29.0 million , respectively. The increase in contract liabilities during the fiscal year ended December 30, 2018 due to cash received, excluding amounts recognized as revenue during the period, was $23.6 million . The amount of revenue recognized during the fiscal year ended December 30, 2018 that was included in the contract liability balance at the beginning of the period was $21.8 million . Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheet. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities. Transaction price allocated to the remaining performance obligations The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized beyond one year in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders and noncancelable software subscriptions and cloud service contracts. | ||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 2,777,996 | $ 2,256,982 | $ 2,115,517 |
Transferred at Point in Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 2,202,043 | ||
Transferred over Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 575,953 | ||
Americas [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,065,122 | ||
Europe [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 778,092 | ||
Asia [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 934,782 | ||
Diagnostics [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,084,785 | ||
Life Sciences [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 934,690 | ||
Applied Markets [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 758,521 | ||
Discovery & Analytical Solutions [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,693,211 | 1,578,459 | 1,512,984 |
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,199,255 | ||
Discovery & Analytical Solutions [Member] | Transferred over Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 493,956 | ||
Discovery & Analytical Solutions [Member] | Americas [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 680,117 | ||
Discovery & Analytical Solutions [Member] | Europe [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 494,707 | ||
Discovery & Analytical Solutions [Member] | Asia [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 518,387 | ||
Discovery & Analytical Solutions [Member] | Diagnostics [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | ||
Discovery & Analytical Solutions [Member] | Life Sciences [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 934,690 | ||
Discovery & Analytical Solutions [Member] | Applied Markets [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 758,521 | ||
Diagnostics [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,084,785 | $ 678,523 | $ 602,533 |
Diagnostics [Member] | Transferred at Point in Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,002,788 | ||
Diagnostics [Member] | Transferred over Time [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 81,997 | ||
Diagnostics [Member] | Americas [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 385,005 | ||
Diagnostics [Member] | Europe [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 283,385 | ||
Diagnostics [Member] | Asia [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 416,395 | ||
Diagnostics [Member] | Diagnostics [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,084,785 | ||
Diagnostics [Member] | Life Sciences [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | ||
Diagnostics [Member] | Applied Markets [Member] | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 0 |
Business Combinations and Asset
Business Combinations and Asset Purchases | 12 Months Ended |
Dec. 30, 2018 | |
Business Combinations [Abstract] | |
Business Combinations and Asset Purchases | Business Combinations Acquisitions in fiscal year 2018 During fiscal year 2018, the Company completed the acquisition of four businesses for aggregate consideration of $106.0 million . The excess of the purchase price over the fair value of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.2 years . The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2018 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 520 Less: cash acquired (1,132 ) Total $ 104,892 Identifiable assets acquired and liabilities assumed: Current assets $ 6,522 Property, plant and equipment 1,166 Other assets 891 Identifiable intangible assets: Core technology 34,021 Trade names 1,070 Customer relationships 10,200 Goodwill 59,647 Deferred taxes (3,860 ) Debt assumed (461 ) Liabilities assumed (4,304 ) Total $ 104,892 Acquisitions in fiscal year 2017 Acquisition of EUROIMMUN Medizinische Labordiagnostika AG. During fiscal year 2017, the Company completed the acquisition of 99.98% of the outstanding stock of EUROIMMUN Medizinische Labordiagnostika AG (“EUROIMMUN”) for aggregate consideration of €1.2 billion (equivalent to $1.4 billion at December 19, 2017, the time of closing). The purchase price was funded by borrowings from the Company's senior unsecured revolving credit facility and senior unsecured term loan credit facility of $710.0 million and $200.0 million , respectively, and available cash on hand of $503.1 million . The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired. As a result of the acquisition, the Company recorded goodwill of $591.3 million , which is not tax deductible, and intangible assets of $907.4 million . The Company has reported the operations for this acquisition within the results of the Company's Diagnostics segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of this acquisition had a weighted average amortization period of 16.1 years . Other acquisitions in 2017. During fiscal year 2017, the Company also completed the acquisition of two other businesses for aggregate consideration of $142.0 million . The acquired businesses were Tulip Diagnostics Private Limited (“Tulip”), which was acquired for total consideration of $127.3 million in cash and one other business acquired for total consideration of $14.7 million in cash. At the acquisition date, the Company had a potential obligation to pay the former shareholders of Tulip up to INR 1.6 billion in additional consideration over a two year period, equivalent to $25.2 million , and is accounted for as compensation expense in the Company's financial statements over a two year period and is excluded from the purchase price allocation shown below. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations of Tulip within the results of the Company's Diagnostics segment and the other acquired business within the results of the Company's Discovery & Analytical Solutions segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.8 years . During fiscal year 2018, the Company paid the former shareholders of Tulip a portion of the additional consideration amounting to INR 716.3 million (equivalent to $11.3 million ). As of December 30, 2018 , the Company may have to pay the former shareholders of Tulip additional consideration of up to INR 803.6 million (currently equivalent to $11.4 million ) in the first quarter of fiscal year 2019. The total purchase price for the acquisitions in fiscal year 2017 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN 2017 Other (In thousands) Fair value of business combination: Cash payments $ 1,413,113 $ 140,861 Other liability — 1,273 Working capital and other adjustments — (93 ) Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,095 $ 139,602 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 109,859 11,356 Other assets 71,621 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 710,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 591,304 75,250 Deferred taxes (251,886 ) (15,735 ) Liabilities assumed (100,020 ) (8,328 ) Debt assumed (61,357 ) — Total $ 1,388,095 $ 139,602 EUROIMMUN's revenue and net loss for the period from the acquisition date to December 31, 2017 were $13.5 million and $1.0 million , respectively. The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: December 31, January 1, (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 2,562,580 $ 2,379,176 Income from continuing operations 143,459 156,210 Basic earnings per share: Income from continuing operations $ 1.31 $ 1.43 Diluted earnings per share: Income from continuing operations $ 1.29 $ 1.42 The unaudited pro forma information for fiscal years 2017 and 2016 have been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. The fiscal year 2017 unaudited pro forma income from continuing operations was adjusted to exclude approximately $9.8 million of acquisition-related transaction costs. The fiscal year 2016 pro forma income from continuing operations was adjusted to include these acquisition-related transaction costs and the nonrecurring expenses related to the fair value adjustments. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as fair value adjustment to inventory, increased interest expense on debt obtained to finance the transaction, and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities. Acquisitions in fiscal year 2016 During fiscal year 2016, the Company completed the acquisition of two businesses for total consideration of $72.3 million in cash. The acquired businesses were Bioo Scientific Corporation, which was acquired for total consideration of $63.5 million in cash and one other business acquired for total consideration of $8.8 million in cash. The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired. As a result of the acquisitions, the Company recorded goodwill of $43.1 million , which is not tax deductible, and intangible assets of $22.1 million . The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 9.4 years . The total purchase price for the acquisitions in fiscal year 2016 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2016 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 72,497 Working capital and other adjustments (261 ) Less: cash acquired (2,152 ) Total $ 70,084 Identifiable assets acquired and liabilities assumed: Current assets $ 7,153 Property, plant and equipment 7,542 Identifiable intangible assets: Core technology 6,600 Trade names 570 Customer relationships 14,900 Goodwill 43,072 Deferred taxes (7,768 ) Liabilities assumed (1,985 ) Total $ 70,084 The Company does not consider the acquisitions completed during fiscal years 2018, 2017 and 2016 , with the exception of the EUROIMMUN acquisition, to be material to its consolidated results of operations; therefore, the Company is only presenting pro forma financial information of operations for the EUROIMMUN acquisition. The aggregate revenue and the results of operations for the acquisitions completed during fiscal year 2018 for the period from their acquisition dates to December 30, 2018 were no t material. The aggregate revenue for the acquisitions, with the exception of EUROIMMUN, completed during fiscal year 2017 for the period from their acquisition dates to December 31, 2017 was $38.5 million and the results of operations were no t material. The aggregate revenue and results of operations for the acquisitions completed during fiscal year 2016 for the period from their respective acquisition dates to January 1, 2017 were minimal. The Company has also determined that the presentation of the results of operations for each of those acquisitions, from the date of acquisition, is impracticable due to the integration of the operations upon acquisition. As of December 30, 2018 , the allocations of purchase prices for acquisitions completed in fiscal years 2017 and 2016 were final. The preliminary allocations of the purchase prices for acquisitions completed in fiscal year 2018 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. During fiscal year 2018 , the Company obtained information relevant to determining the fair values of certain tangible and intangible assets acquired, and liabilities assumed, related to recent acquisitions and adjusted its purchase price allocations. Based on this information, for the EUROIMMUN acquisition, the Company recognized an increase in intangible assets of $10.0 million , an increase in other assets of $21.7 million , an increase in liabilities assumed of $12.3 million , a decrease in property and equipment of $20.1 million , a decrease in deferred tax liabilities of $23.6 million , and a decrease in goodwill of $23.5 million . Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. As of December 30, 2018 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $76.5 million . As of December 30, 2018 , the Company has recorded contingent consideration obligations of $69.7 million , of which $67.0 million was recorded in accrued expenses and other current liabilities, and $2.7 million was recorded in long-term liabilities. As of December 31, 2017 , the Company has recorded contingent consideration obligations of $65.3 million , of which $52.2 million was recorded in accrued expenses and other current liabilities, and $13.1 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 1.78 years from December 30, 2018 , and the remaining weighted average expected earnout period at December 30, 2018 was 5 months. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation. Total acquisition and divestiture-related costs (income) for fiscal years 2018, 2017 and 2016 were $15.8 million , $(8.5) million and $1.2 million , respectively. These amounts include $6.9 million of compensation expense and $0.7 million of net foreign exchange gain related to the foreign currency denominated stay bonus associated with the Tulip acquisition for fiscal year 2018 and $35.6 million of net foreign exchange gain related to the foreign currency forward contracts associated with the acquisition of EUROIMMUN and $14.9 million of compensation expense associated with the Tulip acquisition for fiscal year 2017. The acquisition-related interest expense amounted to $0.7 million and $0.3 million in fiscal years 2018 and 2017 , respectively. These acquisition and divestiture-related costs were expensed as incurred and recorded in selling, general and administrative expenses and interest and other (income) expense, net in the Company's consolidated statements of operations. |
Changes in Accounting Policies
Changes in Accounting Policies (Notes) | 12 Months Ended |
Dec. 30, 2018 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Changes in Accounting Policies Except for the changes described below, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements. The Company adopted ASC 606 with a date of the initial application of January 1, 2018. As a result, the Company has changed its accounting policy for revenue recognition as detailed below. The Company applied ASC 606 using the modified retrospective method only to contracts that are not completed contracts as of January 1, 2018, and the cumulative effect of initially applying ASC 606 is recognized as an adjustment to the beginning retained earnings. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 605. The details of the significant changes and quantitative impact of the changes are disclosed below. A. Sales of software subscriptions or sales of licenses and maintenance in bundled arrangements The Company previously recognized revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the undelivered items in the arrangement have value to the customer on a stand-alone basis and vendor-specific objective evidence ("VSOE") of fair value can be determined. If VSOE of fair value for the undelivered elements cannot be established, the Company deferred all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the undelivered element is maintenance, then the Company recognized the entire fee ratably over the maintenance period. Under ASC 606, the total consideration in the contract is allocated to all products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the list prices at which the Company sells the software license, software subscription, maintenance and/or consulting services. Accordingly, the Company now recognizes higher license revenue upfront and less service revenue over time. B. Sales of instruments The Company previously recognized revenue from sale of instruments when persuasive evidence of an arrangement existed, delivery had occurred, the price to the buyer was fixed or determinable, and collectability was reasonably assured. For certain sales of instruments that included customer-specified acceptance criteria, the Company previously recognized revenue after the acceptance criteria had been met. Under ASC 606, revenue is recognized when the Company satisfies a performance obligation by transferring control of the product to a customer. Accordingly, the Company now recognizes product revenue upon delivery or when title has transferred to the customer, as the Company believes acceptance is perfunctory. C. Sales commissions The Company previously recognized commission fees related to sales of products and services as selling expenses when they were incurred. Under ASC 606, the Company capitalizes those commission fees as costs of obtaining a contract, when they are incremental and, if they are expected to be recovered, the Company amortizes them consistently with the pattern of transfer of the product or service to which the asset relates. If the expected amortization period is one year or less, the commission fee is expensed when incurred. D. Impacts on financial statements The following tables summarize the impacts of ASC 606 adoption on the Company's consolidated financial statements for the fiscal year ended December 30, 2018 . Consolidated Balance Sheet As reported Adjustments Balances without adoption of ASC 606 (In thousands) Cash and cash equivalents $ 163,111 $ — $ 163,111 Accounts receivable, net 632,669 (16,264 ) 616,405 Inventories 338,347 9,773 348,120 Other current assets 100,507 (363 ) 100,144 Property, plant and equipment, net 318,590 — 318,590 Intangible assets, net 1,199,667 — 1,199,667 Goodwill 2,952,608 — 2,952,608 Other assets, net 270,023 — 270,023 Total assets $ 5,975,522 $ (6,854 ) $ 5,968,668 Current portion of long-term debt $ 14,856 $ — $ 14,856 Accounts payable 220,949 — 220,949 Accrued restructuring and contract termination charges 4,834 — 4,834 Accrued expenses and other current liabilities 528,827 19,173 548,000 Current liabilities of discontinued operations 2,165 — 2,165 Long-term debt 1,876,624 — 1,876,624 Long-term liabilities 742,312 — 742,312 Total liabilities 3,390,567 19,173 3,409,740 Commitments and contingencies Preferred stock — — — Common stock 110,597 — 110,597 Capital in excess of par value 48,772 — 48,772 Retained earnings 2,602,067 (26,027 ) 2,576,040 Accumulated other comprehensive loss (176,481 ) — (176,481 ) Total stockholders’ equity 2,584,955 (26,027 ) 2,558,928 Total liabilities and stockholders’ equity $ 5,975,522 $ (6,854 ) $ 5,968,668 Consolidated Statement of Operations As reported Adjustments Balances without adoption of ASC 606 (In thousands) Product revenue $ 1,935,493 $ (31,441 ) $ 1,904,052 Service revenue 842,503 — 842,503 Total revenue 2,777,996 (31,441 ) 2,746,555 Cost of product revenue 908,228 (10,290 ) 897,938 Cost of service revenue 528,829 — 528,829 Total cost of revenue 1,437,057 (10,290 ) 1,426,767 Selling, general and administrative expenses 811,913 329 812,242 Research and development expenses 193,998 — 193,998 Restructuring and contract termination charges, net 11,144 — 11,144 Operating income from continuing operations 323,884 (21,480 ) 302,404 Interest and other expense, net 66,201 — 66,201 Income from continuing operations before income taxes 257,683 (21,480 ) 236,203 Provision for income taxes 20,208 (5,662 ) 14,546 Income from continuing operations 237,475 (15,818 ) 221,657 Income from discontinued operations before income taxes — — — Loss on disposition of discontinued operations before income taxes (859 ) — (859 ) Benefit from income taxes on discontinued operations and dispositions (1,311 ) — (1,311 ) Gain from discontinued operations and dispositions 452 — 452 Net income $ 237,927 $ (15,818 ) $ 222,109 The adoption of ASC 606 increased comprehensive income by $15.8 million in the Company's consolidated statement of comprehensive income for the fiscal year ended December 30, 2018 . The adoption of ASC 606 had no impact on cash from or used in operating, investing, or financing activities in the Company's consolidated statement of cash flows as of and for the fiscal year ended December 30, 2018 . |
Discontinued Operations
Discontinued Operations | 12 Months Ended |
Dec. 30, 2018 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Discontinued Operations | Disposition of Businesses and Assets As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. When the discontinued operations represented a strategic shift that will have a major effect on the Company's operations and financial statements, the Company has accounted for these businesses as discontinued operations and accordingly, has presented the results of operations and related cash flows as discontinued operations. Any business deemed to be a discontinued operation prior to the adoption of Accounting Standards Update 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of An Entity, continues to be reported as a discontinued operation, and the results of operations and related cash flows are presented as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of December 30, 2018 and December 31, 2017 . The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: December 30, December 31, January 1, (In thousands) (Loss) gain on disposition of the Medical Imaging business $ (793 ) $ 179,615 $ — Gain on disposition of Technical Services business — — 1,753 Loss on disposition of Fluid Sciences Segment (66 ) — (1,134 ) (Loss) gain on disposition of discontinued operations before income taxes $ (859 ) $ 179,615 $ 619 On May 1, 2017 (the "Closing Date"), the Company completed the sale of its Medical Imaging business to Varex Imaging Corporation ("Varex") pursuant to the terms of the Master Purchase and Sale Agreement, dated December 21, 2016 (the “Agreement”), by and between the Company and Varian Medical Systems, Inc. ("Varian") and the subsequent Assignment and Assumption Agreement, dated January 27, 2017, between Varian and Varex, pursuant to which Varian assigned its rights under the Agreement to Varex. On the Closing Date, the Company received consideration of approximately $277.4 million for the sale of the Medical Imaging business. During fiscal year 2017, the Company paid Varex $4.2 million to settle a post-closing working capital adjustment. During fiscal year 2017, the Company recorded a pre-tax gain of $179.6 million and income tax expense of $43.1 million related to the sale of the Medical Imaging business in discontinued operations and dispositions. The corresponding tax liability was recorded within the other tax liabilities in the consolidated balance sheet, and the Company expects to utilize tax attributes to minimize the tax liability. Following the closing, the Company provided certain customary transitional services during a period of up to 12 months . Commercial transactions between the parties following the closing of the transaction were not significant. During the third quarter of fiscal year 2018, the Company completed the sale of substantially all of the assets and liabilities related to its multispectral imaging business for aggregate consideration of $37.3 million , recognizing a pre-tax gain of $13.0 million . The pre-tax gain is included in interest and other expense, net in the consolidated statement of operations. The multispectral imaging business was a component of the Company's DAS segment. The divestiture of the multispectral imaging business has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. During fiscal year 2017, the Company sold Suzhou PerkinElmer Medical Laboratory Co., Ltd. for aggregate consideration of $2.3 million , recognizing a pre-tax loss of $1.1 million . The pre-tax loss recognized in fiscal year 2017 is included in interest and other expense, net in the consolidated statement of operations. Suzhou PerkinElmer Medical Laboratory Co., Ltd. was a component of the Company's Diagnostics segment. The divestiture of Suzhou PerkinElmer Medical Laboratory Co., Ltd. has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. During fiscal year 2016, the Company sold PerkinElmer Labs, Inc. for cash consideration of $20.0 million , recognizing a pre-tax gain of $7.1 million . The sale generated a capital loss for tax purposes of $7.3 million , which resulted in an income tax benefit of $2.5 million that was recognized as a discrete benefit during the second quarter of 2016. During fiscal year 2017, the Company recognized an additional pre-tax gain of $1.1 million relating to the earn-out consideration received from the buyer. PerkinElmer Labs, Inc. was a component of the Company's Diagnostics segment. The pre-tax gain recognized in fiscal years 2017 and 2016 is included in interest and other expense, net in the consolidated statement of operations. The divestiture of PerkinElmer Labs, Inc. has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. In August 1999, the Company sold the assets of its Technical Service business. The Company recorded a pre-tax gain of $1.8 million in fiscal year 2016 for a contingency related to this business. This was recognized as a gain on disposition of discontinued operations before income taxes. The summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended: December 30, December 31, January 1, (In thousands) Revenue $ — $ 44,343 $ 146,217 Cost of revenue — 32,933 95,395 Selling, general and administrative expenses — 5,869 13,657 Research and development expenses — 4,891 14,368 Restructuring and contract termination charges, net — — 568 Income from discontinued operations before income taxes $ — $ 650 $ 22,229 The Company recorded a ( benefit from) provision for income taxes of $(1.3) million , $44.5 million and $4.3 million on discontinued operations and dispositions in fiscal years 2018, 2017 and 2016 , respectively. |
Restructuring and Contract Term
Restructuring and Contract Termination Charges, Net | 12 Months Ended |
Dec. 30, 2018 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Contract Termination Charges, Net | Restructuring and Contract Termination Charges, Net The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and its productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, as applicable, and are included as a component of income from continuing operations. The Company implemented a restructuring plan in each of the first, third and fourth quarters of fiscal year 2018 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q1 2018 Plan", "Q3 2018 Plan" and "Q4 2018 Plan", respectively). The Company implemented a restructuring plan in each of the fourth and third quarters of fiscal year 2017 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q4 2017 Plan and "Q3 2017 Plan", respectively). The Company implemented a restructuring plan in the first quarter of fiscal year 2017 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets (the "Q1 2017 Plan"). The Company implemented a restructuring plan in the third quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth product lines (the "Q3 2016 Plan"). The Company implemented a restructuring plan in the second quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth end markets (the "Q2 2016 Plan"). All other previous restructuring plans were workforce reductions or the closure of excess facility space principally intended to integrate the Company's businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with the Company's growth strategy (the "Previous Plans"). The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2018, 2017 and 2016 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Diagnostics Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Severance Excess Facility (In thousands, except headcount data) Q4 2018 Plan 1 $ — $ 348 $ — $ — $ 348 Q1 FY2019 — Q3 2018 Plan 61 618 1,146 — — 1,764 Q2 FY2019 — Q1 2018 Plan 47 902 5,096 — — 5,998 Q2 FY2019 — Q4 2017 Plan 29 255 1,680 — — 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,021 1,321 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 1,631 5,000 33 33 6,697 Q2 FY2018 Q2 FY2018 Q3 2016 Plan 22 41 1,779 — — 1,820 Q4 FY2017 — Q2 2016 Plan 72 561 4,106 — — 4,667 Q3 FY2017 — The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022 . The Company also has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded additional pre-tax charges of $5.0 million , $3.6 million and $0.1 million in the Discovery & Analytical Solutions segment during fiscal years 2018, 2017 and 2016 , respectively, and $0.5 million during fiscal year 2017 in the Diagnostics segment as a result of these contract terminations. At December 30, 2018 , the Company had $6.2 million recorded for accrued restructuring and contract termination charges, of which $4.8 million was recorded in short-term accrued restructuring and $1.4 million was recorded in long-term liabilities. At December 31, 2017 , the Company had $14.0 million recorded for accrued restructuring and contract termination charges, of which $8.8 million was recorded in short-term accrued restructuring, $2.3 million was recorded in long-term liabilities and $2.9 million was recorded in other reserves. The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during fiscal years 2018, 2017 and 2016 in continuing operations: Balance at January 3, 2016 2016 Charges and Changes in Estimates, Net 2016 Amounts Paid Balance at January 1, 2017 2017 Charges and Changes in Estimates, Net 2017 Amounts Paid Balance at December 31, 2017 2018 Charges and Changes in Estimates, Net 2018 Amounts Paid Balance at December 30, 2018 (In thousands) Severance: Q4 2018 Plan $ — $ — $ — $ — $ — $ — $ — $ 348 $ — $ 348 Q3 2018 Plan — — — — — — — 2,054 (639 ) 1,415 Q1 2018 Plan — — — — — — — 5,998 (4,389 ) 1,609 Q4 2017 Plan (1) — — — — 1,935 (16 ) 1,919 (381 ) (1,538 ) — Q3 2017 Plan (2) — — — — 2,342 (270 ) 2,072 (1,204 ) (868 ) — Q1 2017 Plan (3) — — — — 6,631 (4,133 ) 2,498 (983 ) (1,232 ) 283 Q3 2016 Plan — 1,820 (612 ) 1,208 (202 ) (1,006 ) — — — — Q2 2016 Plan — 4,667 (3,231 ) 1,436 (829 ) (607 ) — 232 (156 ) 76 Facility: Q1 2017 Plan — — — — 66 (33 ) 33 — (33 ) — Previous Plans 22,018 (1,451 ) (12,787 ) 7,780 (537 ) (2,844 ) 4,399 338 (2,425 ) 2,312 Restructuring 22,018 5,036 (16,630 ) 10,424 9,406 (8,909 ) 10,921 6,402 (11,280 ) 6,043 Contract Termination 132 88 (103 ) 117 3,251 (320 ) 3,048 4,742 (7,653 ) 137 Total Restructuring and Contract Termination $ 22,150 $ 5,124 $ (16,733 ) $ 10,541 $ 12,657 $ (9,229 ) $ 13,969 $ 11,144 $ (18,933 ) $ 6,180 ____________________________ (1) During fiscal year 2018 , the Company recognized pre-tax restructuring reversals of $0.2 million each in the Discovery & Analytical Solutions and Diagnostics segments, related to lower than expected costs associated with workforce reductions for the Q4 2017 Plan. (2) During fiscal year 2018 , the Company recognized pre-tax restructuring reversals of $0.8 million in the Discovery & Analytical Solutions segment and $0.4 million in the Diagnostics segment, related to lower than expected costs associated with workforce reductions for the Q3 2017 Plan. (3) During fiscal year 2018 , the Company recognized pre-tax restructuring reversals of $1.0 million in the Discovery & Analytical Solutions segment, related to lower than expected costs associated with workforce reductions for the Q1 2017 Plan. |
Interest and Other Expense (Inc
Interest and Other Expense (Income), Net | 12 Months Ended |
Dec. 30, 2018 | |
Other Income and Expenses [Abstract] | |
Interest and Other Expense (Income), Net | Interest and Other Expense, Net Interest and other expense, net, consisted of the following for the fiscal years ended: December 30, December 31, January 1, Interest income $ (1,141 ) $ (2,571 ) $ (702 ) Interest expense 66,976 43,940 41,528 (Gain) loss on disposition of businesses and assets, net (see Note 5) (12,844 ) 309 (5,562 ) Other expense (income), net 13,210 (42,781 ) 15,250 Total interest and other expense, net $ 66,201 $ (1,103 ) $ 50,514 Foreign currency transaction gains were $9.4 million , $29.2 million and $1.5 million in fiscal years 2018, 2017 and 2016 , respectively. Net losses (gains) from forward currency hedge contracts were $11.7 million , $(4.5) million and $5.4 million in fiscal years 2018, 2017 and 2016 , respectively. The other components of net periodic pension cost (credit) were $11.5 million , $(9.2) million and $11.5 million in fiscal years 2018, 2017 and 2016 , respectively. These amounts were included in other expense (income), net. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 30, 2018 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) Unrecognized tax benefits, beginning of year $ 30,308 $ 29,607 $ 28,143 Gross increases—tax positions in prior periods 6,931 749 1,514 Gross decreases—tax positions in prior periods (1,622 ) (828 ) (183 ) Gross increases—current-period tax positions — 2,346 3,547 Settlements (2,253 ) (324 ) — Lapse of statute of limitations (181 ) (1,371 ) (4,109 ) Foreign currency translation adjustments (174 ) 129 695 Unrecognized tax benefits, end of year $ 33,009 $ 30,308 $ 29,607 The Company classifies interest and penalties as a component of income tax expense. At December 30, 2018 and December 31, 2017 , the Company had accrued interest and penalties of $2.5 million and $1.9 million , respectively. During fiscal years 2018, 2017 and 2016 , the Company recognized a net expense (benefit) of $0.4 million , $(0.3) million and $(0.1) million , respectively, for interest and penalties in its total tax provision primarily due to settlements and statutes of limitations that had lapsed. At December 30, 2018 , the Company had gross tax effected unrecognized tax benefits of $33.0 million , of which $31.3 million , if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $2.3 million of its uncertain tax positions at December 30, 2018 , including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2010 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. On December 22, 2017, the President of the United States signed the Tax Act, which makes broad and complex changes to the U.S. Internal Revenue Code. Changes include, but are not limited to: (1) the lowering of the U.S. corporate tax rate from 35% to 21%; (2) the transition of U.S. international taxation from a worldwide tax system to a modified territorial system with a one-time transition tax on the deemed repatriation of cumulative foreign earnings as of December 31, 2017; (3) a new provision designed to tax global intangible low-taxed income (GILTI); (4) the creation of the base erosion anti-abuse tax (BEAT), which is effectively a new minimum tax; (5) the deduction for foreign-derived intangible income (FDII); (6) a new limitation on deductible interest expense; (7) the repeal of the domestic production activity deduction; and (8) limitations on the deductibility of certain executive compensation. ASU 2018-05 was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company is applying the guidance in ASU 2018-05 (see Note 1, Basis of Presentation ) when accounting for the enactment date effects of the Tax Act. The end of the measurement period for purposes of applying the provisions of ASU 2018-05 was December 22, 2018. As a result, the Company has completed the analysis based on legislative updates relating to the Tax Act currently available and has recorded the impact in tax expense from continuing operations as explained below. Remeasurement: The Company remeasured its future tax benefits and liabilities at the enacted tax rate of 21% and provided a provisional amount of $21.5 million during fiscal year 2017. During the fiscal year ended December 30, 2018 , the Company recognized a tax benefit of $0.3 million for the remeasurement of certain future tax liabilities and included these adjustments as a component of the provision for income tax from continuing operations. One-Time Transition Tax: The Tax Act requires the Company to pay a one-time transition tax on the unremitted earnings of foreign subsidiaries. Based on available information, the Company estimated the tax on the deemed repatriation of foreign earnings and recorded a tax expense of $85.0 million in continuing operations at December 31, 2017. During the fiscal year ended December 30, 2018 , the Company refined its calculations of the one-time transition tax based on newly issued guidance from the Internal Revenue Service and recorded a tax benefit of $4.6 million in continuing operations. GILTI, FDII, and other provisions: For fiscal year beginning in 2018, the Company is subject to several provisions of the Tax Act including computations under GILTI, FDII, and other provisions. Management has made a reasonable estimate of the impact of each provision of the Tax Act on the Company's effective tax rate for the fiscal year ended December 30, 2018 . Management will continue to refine the provisional estimates for the computations of the GILTI, FDII, and other provisions as additional clarification and implementation guidance becomes available. For the fiscal year ended December 30, 2018 , the Company has decided to adopt the period cost method and has not recorded any potential deferred tax effects related to GILTI and FDII in the financial statements. During fiscal year 2018 , the Company recorded net discrete income tax benefit of $8.1 million , of which $2.0 million was a result of the enactment of the Tax Act, along with an additional discrete benefit of $7.2 million related to the recognition of excess tax benefits on stock compensation partially offset by $1.1 million expense related to other tax matters. During fiscal years 2017 and 2016 , the Company recorded net discrete income tax expense of $98.6 million and income tax benefits of $9.6 million , respectively. The $98.6 million tax expense in fiscal year 2017 was primarily related to $106.5 million as a result of the Tax Act, partially offset by a discrete benefit of $5.1 million related to the recognition of excess tax benefits on stock compensation, while the $9.6 million of tax benefit in fiscal year 2016 was primarily related to the recognition of excess tax benefits on stock compensation, reversals of uncertain tax position reserves, and the resolution of other tax matters. The components of income from continuing operations before income taxes were as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) U.S. $ 32,627 $ 3,743 $ 39,689 Non-U.S. 225,056 292,975 204,379 Total $ 257,683 $ 296,718 $ 244,068 On a U.S. income tax basis, the Company has reported significant taxable income over the three year period ended December 30, 2018 . The Company has utilized tax attributes to minimize cash taxes paid on that taxable income. The components of the provision for income taxes on continuing operations were as follows: Current Expense Deferred Expense (Benefit) Total (In thousands) Fiscal year ended December 30, 2018 Federal $ 7,938 $ (5,250 ) $ 2,688 State 2,345 2,572 4,917 Non-U.S. 61,028 (48,425 ) 12,603 Total $ 71,311 $ (51,103 ) $ 20,208 Fiscal year ended December 31, 2017 Federal $ 62,003 $ 35,435 $ 97,438 State 3,332 (792 ) 2,540 Non-U.S. 45,639 (5,789 ) 39,850 Total $ 110,974 $ 28,854 $ 139,828 Fiscal year ended January 1, 2017 Federal $ 14 $ 2,994 $ 3,008 State 2,143 (575 ) 1,568 Non-U.S. 30,754 (6,968 ) 23,786 Total $ 32,911 $ (4,549 ) $ 28,362 The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) Continuing operations $ 20,208 $ 139,828 $ 28,362 Discontinued operations (1,311 ) 44,522 4,255 Total $ 18,897 $ 184,350 $ 32,617 A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) Tax at statutory rate $ 54,114 $ 103,851 $ 85,424 Non-U.S. rate differential, net (27,281 ) (65,836 ) (52,648 ) U.S. taxation of multinational operations 7,047 5,408 6,941 State income taxes, net 2,028 1,810 1,509 Prior year tax matters (6,034 ) (7,955 ) (9,621 ) Federal tax credits (3,738 ) (8,249 ) (7,189 ) Change in valuation allowance (759 ) 1,951 (2,755 ) Non-deductible acquisition expense — — 5,701 Impact of federal tax reform (2,025 ) 106,538 — Others, net (3,144 ) 2,310 1,000 Total $ 20,208 $ 139,828 $ 28,362 The variation in the Company's effective tax rate for each year is primarily a result of the recognition of earnings in foreign jurisdictions, predominantly Singapore, Finland and the Netherlands, which are taxed at rates lower than the U.S. federal statutory rate, resulting in a benefit from income taxes of $18.7 million in fiscal year 2018 , $55.9 million in fiscal year 2017 and $48.2 million in fiscal year 2016 . These amounts include $10.3 million in fiscal year 2018 , $10.1 million in fiscal year 2017 and $11.4 million in fiscal year 2016 of benefits derived from tax holidays in China and Singapore. The effect of these benefits derived from tax holidays on basic and diluted earnings per share for fiscal year 2018 was $0.09 and $0.09 , respectively, for fiscal year 2017 was $0.09 and $0.09 , respectively, and for fiscal year 2016 was $0.10 and $0.10 , respectively. The tax holiday in one of the Company's subsidiaries in China expired in 2017 and the tax holiday in one other subsidiary in China is scheduled to expire in fiscal year 2019 . The tax holiday in one of the Company's subsidiaries in Singapore is scheduled to expire in fiscal year 2023 . The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 30, 2018 and December 31, 2017 were as follows: December 30, December 31, (In thousands) Deferred tax assets: Inventory $ — $ 6,376 Reserves and accruals 39,487 26,657 Accrued compensation 21,709 17,333 Net operating loss and credit carryforwards 144,421 88,503 Accrued pension 31,146 34,682 Restructuring reserve 1,780 2,586 Deferred revenue 31,045 28,478 Unrealized foreign exchange loss — 10,910 Total deferred tax assets 269,588 215,525 Deferred tax liabilities: Inventory (278 ) — Postretirement health benefits (3,406 ) (3,391 ) Depreciation and amortization (309,958 ) (392,293 ) All other, net (1,879 ) (594 ) Total deferred tax liabilities (315,521 ) (396,278 ) Valuation allowance (102,087 ) (68,895 ) Net deferred tax liabilities $ (148,020 ) $ (249,648 ) The components of net deferred tax liabilities as of December 30, 2018 and December 31, 2017 were recognized in the consolidated balance sheets as follows: December 30, December 31, (In thousands) Other assets, net $ 79,312 $ 67,280 Long-term liabilities (227,332 ) (316,928 ) Total $ (148,020 ) $ (249,648 ) At December 30, 2018 , for income tax return purposes, the Company had U.S. federal net operating loss carryforwards of $38.3 million , state net operating loss carryforwards of $200.6 million , foreign net operating loss carryforwards of $515.5 million , state tax credit carryforwards of $6.8 million , general business tax credit carryforwards of $10.9 million , and foreign tax credit carryforwards of $0.1 million . These are subject to expiration in years ranging from 2019 to 2038 , and without expiration for certain foreign net operating loss carryforwards and certain state credit carryforwards. Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. The increase in the valuation allowance of $33.2 million in fiscal year 2018 is primarily due to an increase in tax attributes that the Company does not expect to realize for one of its non-U.S. subsidiaries. The components of net deferred tax (liabilities) assets as of December 30, 2018 and December 31, 2017 were as follows: December 30, December 31, (In thousands) U.S. $ 52,469 $ 44,974 Non-U.S. (200,489 ) (294,622 ) Total $ (148,020 ) $ (249,648 ) Historically, deferred income tax expense has not been provided on the cumulative undistributed earnings of the Company's international subsidiaries. During fiscal year 2018, the Company has determined that previously undistributed earnings of certain international subsidiaries of $1.0 billion no longer met the requirements of indefinite reinvestment and therefore recognized $2.9 million of income tax expense in fiscal year 2018. The Company’s intent is to continue to reinvest the remaining undistributed earnings of its international subsidiaries indefinitely. While federal income tax expense has been recognized as a result of the Tax Act, the Company has not provided any additional deferred taxes with respect to items such as foreign withholding taxes, state income tax or foreign exchange gain or loss. In addition, no additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax, or any additional outside basis difference inherent in these entities, as these amounts continue to be indefinitely reinvested in foreign operations. As of December 30, 2018 , the amount of foreign earnings that the Company has the intent and ability to keep invested outside the U.S. indefinitely and for which no additional incremental tax cost has been provided, other than the $80.4 million from the one-time transition tax on deemed repatriation, was approximately $652.1 million . It is not practicable for the Company to calculate the unrecognized deferred tax liability related to such incremental tax costs on those earnings. |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 30, 2018 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: December 30, December 31, January 1, (In thousands) Number of common shares—basic 110,561 109,857 109,478 Effect of dilutive securities: Stock options 761 708 640 Restricted stock awards 212 294 195 Number of common shares—diluted 111,534 110,859 110,313 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 349 287 458 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future. |
Accounts Receivable, Net
Accounts Receivable, Net | 12 Months Ended |
Dec. 30, 2018 | |
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] | |
Accounts Receivable, Net | Accounts Receivable, Net Accounts receivable were net of reserves for doubtful accounts of $30.6 million and $31.3 million as of December 30, 2018 and December 31, 2017 , respectively. |
Inventories, Net
Inventories, Net | 12 Months Ended |
Dec. 30, 2018 | |
Inventory Disclosure [Abstract] | |
Inventories, Net | Inventories Inventories as of December 30, 2018 and December 31, 2017 consisted of the following: December 30, December 31, (In thousands) Raw materials $ 119,115 $ 122,100 Work in progress 18,110 18,452 Finished goods 201,122 211,123 Total inventories $ 338,347 $ 351,675 |
Property, Plant and Equipment,
Property, Plant and Equipment, Net | 12 Months Ended |
Dec. 30, 2018 | |
Property, Plant and Equipment, Net [Abstract] | |
Property, Plant and Equipment, Net | Property, Plant and Equipment, Net Property, plant and equipment as of December 30, 2018 and December 31, 2017 , consisted of the following: December 30, December 31, (In thousands) At cost: Land $ 5,482 $ 5,624 Building and leasehold improvements 272,277 262,657 Machinery and equipment 402,424 362,638 Total property, plant and equipment 680,183 630,919 Accumulated depreciation (361,593 ) (332,853 ) Total property, plant and equipment, net $ 318,590 $ 298,066 Depreciation expense on property, plant and equipment for the fiscal years ended December 30, 2018 , December 31, 2017 and January 1, 2017 was $44.7 million , $31.3 million and $28.5 million , respectively. |
Marketable Securities and Inves
Marketable Securities and Investments | 12 Months Ended |
Dec. 30, 2018 | |
Marketable Securities [Abstract] | |
Marketable Securities and Investments | Marketable Securities and Investments Investments as of December 30, 2018 and December 31, 2017 consisted of the following: December 30, December 31, (In thousands) Marketable securities $ 2,447 $ 2,208 Cost method investments 16,783 10,783 $ 19,230 $ 12,991 Marketable securities. Marketable securities include equity and fixed-income securities held to meet obligations associated with the Company’s supplemental executive retirement plan and other deferred compensation plans. The Company has, accordingly, classified these securities as long-term. The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income (loss) in the statements of stockholders’ equity, were not material in fiscal years 2018 and 2017. The proceeds from the sales of securities and the related gains and losses are not material for any period presented. Marketable securities classified as available for sale as of December 30, 2018 and December 31, 2017 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) December 30, 2018 Equity securities $ 671 $ 1,037 $ — $ (366 ) Fixed-income securities 22 22 — — Other 1,754 1,817 — (63 ) $ 2,447 $ 2,876 $ — $ (429 ) December 31, 2017 Equity securities $ 811 $ 1,161 $ — $ (350 ) Fixed-income securities 22 22 — — Other 1,375 1,438 — (63 ) $ 2,208 $ 2,621 $ — $ (413 ) Cost method investments. The Company has equity interests in privately-held entities over which the Company neither has significant influence nor control and are accounted for using under the cost method. Under the cost method, the Company records the investment at cost and recognizes income for any dividends declared from distribution of investee’s earnings. The Company’s investments consist of (i) investments carried at fair value, including available-for-sale securities, and (ii) investments accounted for using the cost method of accounting. The Company regularly reviews its investments for impairment, including when the carrying value of an investment exceeds its market value. If the Company determines that an investment has sustained an other-than-temporary decline in its value, the investment is written down to its fair value by a charge to earnings that is included in Impairment of long-term investments and other assets. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the security in relation to its cost basis, (ii) the financial condition of the investee, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in the market value of the investment. For investments accounted for using the cost method of accounting, the Company evaluates information available (e.g., budgets, business plans, financial statements, etc.) in addition to quoted market prices, if any, in determining whether an other-than-temporary decline in value exists. Factors indicative of an other-than-temporary decline include recurring operating losses, credit defaults and subsequent rounds of financing at an amount below the cost basis of the Company’s investment. |
Goodwill and Intangible Assets,
Goodwill and Intangible Assets, Net | 12 Months Ended |
Dec. 30, 2018 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company performed its annual impairment testing for its reporting units as of January 1, 2018 , its annual impairment date for fiscal year 2018 . Non-amortizing intangibles are also subject to an annual impairment test. The Company consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible asset. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset. In addition, the Company evaluates the remaining useful life of our non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of our non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. This intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. The changes in the carrying amount of goodwill for fiscal years 2018 and 2017 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated Balance at January 1, 2017 $ 1,303,936 $ 944,030 $ 2,247,966 Foreign currency translation 37,646 29,091 66,737 Acquisitions, earnouts and other 2,653 684,842 687,495 Balance at December 31, 2017 1,344,235 1,657,963 3,002,198 Foreign currency translation (32,189 ) (35,289 ) (67,478 ) Acquisitions, earnouts and other 22,946 (5,058 ) 17,888 Balance at December 30, 2018 $ 1,334,992 $ 1,617,616 $ 2,952,608 Identifiable intangible asset balances at December 30, 2018 by category and by business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,030 $ 14,616 $ 42,646 Less: Accumulated amortization (25,978 ) (11,775 ) (37,753 ) Net patents 2,052 2,841 4,893 Trade names and trademarks 29,811 48,335 78,146 Less: Accumulated amortization (21,728 ) (12,073 ) (33,801 ) Net trade names and trademarks 8,083 36,262 44,345 Licenses 50,178 3,127 53,305 Less: Accumulated amortization (44,376 ) (1,174 ) (45,550 ) Net licenses 5,802 1,953 7,755 Core technology 240,734 300,177 540,911 Less: Accumulated amortization (189,033 ) (76,711 ) (265,744 ) Net core technology 51,701 223,466 275,167 Customer relationships 222,892 866,635 1,089,527 Less: Accumulated amortization (128,142 ) (165,822 ) (293,964 ) Net customer relationships 94,750 700,813 795,563 IPR&D — 1,360 1,360 Net amortizable intangible assets 162,388 966,695 1,129,083 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 232,972 $ 966,695 $ 1,199,667 Identifiable intangible asset balances at December 31, 2017 by category and business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,048 $ 11,911 $ 39,959 Less: Accumulated amortization (24,448 ) (10,637 ) (35,085 ) Net patents 3,600 1,274 4,874 Trade names and trademarks 29,950 51,024 80,974 Less: Accumulated amortization (20,022 ) (8,228 ) (28,250 ) Net trade names and trademarks 9,928 42,796 52,724 Licenses 43,061 10,239 53,300 Less: Accumulated amortization (34,620 ) (8,015 ) (42,635 ) Net licenses 8,441 2,224 10,665 Core technology 236,324 243,435 479,759 Less: Accumulated amortization (190,423 ) (59,920 ) (250,343 ) Net core technology 45,901 183,515 229,416 Customer relationships 233,573 907,938 1,141,511 Less: Accumulated amortization (116,696 ) (126,144 ) (242,840 ) Net customer relationships 116,877 781,794 898,671 IPR&D — 80,006 80,006 Net amortizable intangible assets 184,747 1,091,609 1,276,356 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 255,331 $ 1,091,609 $ 1,346,940 Total amortization expense related to definite-lived intangible assets was $135.9 million in fiscal year 2018 , $73.7 million in fiscal year 2017 and $71.5 million in fiscal year 2016 . Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $149.7 million in fiscal year 2019 , $152.0 million in fiscal year 2020 , $136.7 million in fiscal year 2021 , $126.6 million in fiscal year 2022 , and $109.1 million in fiscal year 2023 . The Company entered into a strategic agreement in fiscal year 2012 under which it acquired certain intangible assets and received a license to certain core technology for an analytics and data discovery platform, as well as the exclusive right to distribute the platform in certain scientific research and development markets. During fiscal year 2012, the Company paid $6.8 million for net intangible assets and $25.0 million for prepaid royalties. During fiscal year 2013, the Company extended the existing agreement for an additional year. In addition, the Company entered into a new agreement to expand the distribution rights to the clinical and other related markets and acquired additional intangible assets. During fiscal year 2013, the Company paid $7.0 million for net intangible assets and $40.3 million for prepaid royalties. During fiscal year 2016, the Company extended the existing agreement for an additional 3 years and expanded the distribution rights to the related markets. During fiscal year 2016, the Company paid $6.0 million for prepaid royalties related to the extension and new agreement. During the fiscal years 2017 and 2016 , the Company paid $5.1 million and $9.4 million , respectively, for additional prepaid royalties. As of December 30, 2018 , the Company recorded prepaid royalties of $65.0 million , of which $5.6 million was recorded in other current assets, and $59.4 million was recorded in other assets. The Company expenses royalties as revenue is recognized. These intangible assets are being amortized over their estimated useful lives. The Company has reported the amortization of these intangible assets within the results of the Company's Discovery & Analytical Solutions segment from the execution date. |
Debt
Debt | 12 Months Ended |
Dec. 30, 2018 | |
Debt Disclosure [Abstract] | |
Debt | Debt Senior Unsecured Revolving Credit Facility. The Company's senior unsecured revolving credit facility provides for $1.0 billion of revolving loans and has an initial maturity of August 11, 2021 . As of December 30, 2018 , undrawn letters of credit in the aggregate amount of $11.4 million were treated as issued and outstanding when calculating the borrowing availability under the senior unsecured revolving credit facility. As of December 30, 2018 , the Company had $570.6 million available for additional borrowing under the facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. The Eurocurrency margin as of December 30, 2018 was 110 basis points. The weighted average Eurocurrency interest rate as of December 30, 2018 was 2.51%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 3.61%, which was the interest applicable to the borrowings outstanding under the Eurocurrency rate as of December 30, 2018 . As of December 30, 2018 , the senior unsecured revolving credit facility had outstanding borrowings of $418.0 million , and $2.4 million of unamortized debt issuance costs. As of December 31, 2017 , the senior unsecured revolving credit facility had $625.0 million outstanding borrowings, and $3.3 million of unamortized debt issuance costs. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capital ratio that remains applicable for so long as the Company's debt is rated as investment grade. In the event that the Company's debt is not rated as investment grade, the debt-to-capital ratio covenant is replaced with a maximum consolidated leverage ratio covenant and a minimum consolidated interest coverage ratio covenant. Senior Unsecured Term Loan Credit Facility . The Company entered into a senior unsecured term loan credit facility on August 11, 2017 that provided for $200.0 million of term loans and had an initial maturity of twelve months from December 19, 2017, the date of the initial draw. The Company utilized the senior unsecured term loan facility for the acquisition of EUROIMMUN. The interest rates under the senior unsecured term loan credit facility were based on the Eurocurrency rate or the base rate at the time of the borrowing, plus a margin. The base rate was the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. In April 2018, the Company paid in full the outstanding balance of $200.0 million on the Company’s senior unsecured term loan credit facility, from the proceeds of the 0.6% senior unsecured notes due in 2021 that were issued in April 2018. 5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “November 2021 Notes”) in a registered public offering and received $493.6 million of net proceeds from the issuance. The November 2021 Notes were issued at 99.4% of the principal amount, which resulted in a discount of $3.1 million . As of December 30, 2018 , the November 2021 Notes had an aggregate carrying value of $497.4 million , net of $1.1 million of unamortized original issue discount and $1.6 million of unamortized debt issuance costs. As of December 31, 2017 , the November 2021 Notes had an aggregate carrying value of $496.6 million , net of $1.4 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs. The November 2021 Notes mature in November 2021 and bear interest at an annual rate of 5% . Interest on the November 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the November 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the November 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the November 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the November 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the November 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the November 2021 Notes) and a contemporaneous downgrade of the November 2021 Notes below investment grade, each holder of November 2021 Notes will have the right to require the Company to repurchase such holder's November 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest. 1.875% Senior Unsecured Notes due 2026. On July 19, 2016, the Company issued €500.0 million aggregate principal amount of senior unsecured notes due in 2026 (the “2026 Notes”) in a registered public offering and received approximately €492.3 million of net proceeds from the issuance. The 2026 Notes were issued at 99.118% of the principal amount, which resulted in a discount of €4.4 million . The 2026 Notes mature in July 2026 and bear interest at an annual rate of 1.875% . Interest on the 2026 Notes is payable annually on July 19th each year. The proceeds from the 2026 Notes were used to pay in full the outstanding balance of the Company's previous senior unsecured revolving credit facility. As of December 30, 2018 , the 2026 Notes had an aggregate carrying value of $564.5 million , net of $4.0 million of unamortized original issue discount and $3.8 million of unamortized debt issuance costs. As of December 31, 2017 , the 2026 Notes had an aggregate carrying value of $591.7 million , net of $4.7 million of unamortized original issue discount and $4.3 million of unamortized debt issuance costs. Prior to April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2026 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2026 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the 2026 Notes) plus 35 basis points; plus, in each case, accrued and unpaid interest. In addition, at any time on or after April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2026 Notes due to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2026 Notes) and a contemporaneous downgrade of the 2026 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the 2026 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest. 0.6% Senior Unsecured Notes due in 2021. On April 11, 2018, the Company issued €300.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “April 2021 Notes”) in a registered public offering and received approximately €298.7 million of net proceeds from the issuance. The April 2021 Notes were issued at 99.95% of the principal amount, which resulted in a discount of €0.2 million . As of December 30, 2018 , the April 2021 Notes had an aggregate carrying value of $341.3 million , net of $0.1 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs. The April 2021 Notes mature in April 2021 and bear interest at an annual rate of 0.6% . Interest on the April 2021 Notes is payable annually on April 9th each year. The proceeds from the April 2021 Notes were used to pay in full the outstanding balance of the Company’s senior unsecured term loan credit facility, and a portion of the outstanding senior unsecured revolving credit facility, and in each case the borrowings were incurred to pay a portion of the purchase price for the Company's acquisition of EUROIMMUN, which closed on December 19, 2017. Prior to the maturity date of the April 2021 Notes, the Company may redeem them in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the April 2021 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the April 2021 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the April 2021 Notes) plus 15 basis points; plus, in each case, accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the April 2021 Notes) and a contemporaneous downgrade of the April 2021 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the April 2021 Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest. Other Debt Facilities. The Company's other debt facilities include Euro-denominated bank loans with an aggregate carrying value of $32.1 million (or €28.0 million ) and $57.2 million (or €47.6 million ) as of December 30, 2018 and December 31, 2017 , respectively. These bank loans are primarily utilized for financing fixed assets and are repaid in monthly or quarterly installments with maturity dates extending to 2028. Of these bank loans, loans in the aggregate amount of $31.9 million bear fixed interest rates between 1.1% and 5.5% and a loan in the amount of $0.2 million bears a variable interest rate based on the Euribor rate plus a margin of 1.5% . An aggregate amount of $4.8 million of the bank loans are secured by mortgages on real property and the remaining $27.3 million are unsecured. Certain credit agreements for the unsecured bank loans include financial covenants which are based on an equity ratio or an equity ratio and minimum interest coverage ratio. In addition, the Company had other unsecured revolving credit facilities and a secured bank loan in the amount of $5.8 million and $0.3 million , respectively, as of December 30, 2018 and $2.7 million and $0.3 million , respectively, as of December 31, 2017 . The unsecured revolving debt facilities bear fixed interest rates between 2.3% and 17.6% . The secured bank loan of $0.3 million bears a fixed annual interest rate of 1.95% and is repaid in monthly installments until 2027. Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property, plant and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At December 30, 2018 , the Company had $34.5 million recorded for these financing lease obligations, of which $1.5 million was recorded as short-term debt and $33.0 million was recorded as long-term debt. At December 31, 2017 , the Company had $35.9 million recorded for these financing lease obligations, of which $1.4 million was recorded as short-term debt and $34.5 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other. Upon adoption of ASC 842, the Company will derecognize the impact of this build-to-suit arrangement. The following table summarizes the maturities of the Company’s indebtedness as of December 30, 2018 : Sr. Unsecured Revolving Credit Facility Maturing 2021 November 2021 Notes April 2021 Notes 2026 Notes Other Debt Facilities Financing Lease Obligations Total (In thousands) 2019 $ — $ — $ — $ — $ 13,324 $ 1,532 $ 14,856 2020 — — — — 8,527 1,597 10,124 2021 418,000 500,000 343,410 — 8,197 1,665 1,271,272 2022 — — — — 3,907 1,657 5,564 2023 — — — — 2,641 1,681 4,322 2024 and thereafter — — — 572,350 1,574 4,698 578,622 Total before unamortized discount and debt issuance costs and non-cash finance lease liabilities 418,000 500,000 343,410 572,350 38,170 12,830 1,884,760 Unamortized discount and debt issuance costs (2,401 ) (2,628 ) (2,133 ) (7,806 ) — — (14,968 ) Non-cash finance lease liabilities — — — — — 21,688 21,688 Total $ 415,599 $ 497,372 $ 341,277 $ 564,544 $ 38,170 $ 34,518 $ 1,891,480 |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 12 Months Ended |
Dec. 30, 2018 | |
Accounts Payable and Accrued Liabilities, Current [Abstract] | |
Accrued Expenses and Other Current Liabilities | Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities as of December 30, 2018 and December 31, 2017 consisted of the following: December 30, December 31, (In thousands) Payroll and incentives $ 86,549 $ 66,955 Employee benefits 44,060 37,354 Deferred revenue 155,064 159,923 Federal, non-U.S. and state income taxes 30,687 10,800 Other accrued operating expenses 212,467 225,610 Total accrued expenses and other current liabilities $ 528,827 $ 500,642 |
Employee Benefit Plans
Employee Benefit Plans | 12 Months Ended |
Dec. 31, 2017 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plans | Employee Benefit Plans Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $13.2 million in fiscal year 2018 , $12.5 million in fiscal year 2017 , and $12.8 million in fiscal year 2016 . Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan was closed to new hires effective January 31, 2001, and benefits for those employed by the Company’s former Life Sciences business were frozen as of that date. Plan benefits were frozen as of March 2003 for those employed by the Company’s former Analytical Instruments business and corporate employees. Plan benefits were frozen as of January 31, 2011 for all remaining employees that were still actively accruing in the plan. The plans provide benefits that are based on an employee’s years of service and compensation near retirement. Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended: December 30, December 31, January 1, (In thousands) Service and administrative costs $ 6,853 $ 4,951 $ 4,337 Interest cost 16,146 16,707 18,638 Expected return on plan assets (28,939 ) (26,401 ) (24,245 ) Actuarial loss (gain) 17,146 (7,085 ) 15,890 Amortization of prior service cost 375 (195 ) (210 ) Net periodic pension cost (credit) $ 11,581 $ (12,023 ) $ 14,410 The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1, Basis of Presentation . Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions. As discussed in Note 1, the Company adopted ASU 2017-07 on January 1, 2018. Actuarial gains and losses are now recognized in the line item "Interest and other expense, net" in the consolidated statements of operations. Actuarial gains and losses were presented within operating income prior to the adoption. As such, prior year amounts, including other components of periodic pension cost, have been reclassified to "Interest and other expense, net" in the Company's consolidated statements of operations due to the retrospective adoption of ASU 2017-07. The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 30, 2018 and December 31, 2017 . December 30, 2018 December 31, 2017 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 304,065 $ 283,310 $ 334,151 $ 308,713 Change in benefit obligations: Projected benefit obligations at beginning of year $ 343,410 $ 308,713 $ 279,522 $ 300,650 Service and administrative costs 4,528 2,325 2,201 2,750 Interest cost 5,484 10,662 4,870 11,836 Benefits paid and plan expenses (13,081 ) (19,709 ) (13,238 ) (20,032 ) Participants’ contributions 176 — 189 — Business acquisition 537 — 39,293 — Plan amendments 533 — — — Actuarial (gain) loss (13,141 ) (18,681 ) (1,486 ) 13,509 Effect of exchange rate changes (17,278 ) — 32,059 — Projected benefit obligations at end of year $ 311,168 $ 283,310 $ 343,410 $ 308,713 Change in plan assets: Fair value of plan assets at beginning of year $ 179,736 $ 253,427 $ 153,281 $ 243,817 Actual return on plan assets (5,653 ) (14,376 ) 15,866 29,642 Benefits paid and plan expenses (13,081 ) (19,709 ) (13,238 ) (20,032 ) Employer’s contributions 8,480 15,000 8,422 — Participants’ contributions 176 — 189 — Effect of exchange rate changes (10,495 ) — 15,216 — Fair value of plan assets at end of year $ 159,163 $ 234,342 $ 179,736 $ 253,427 Net liabilities recognized in the consolidated balance sheets $ (152,005 ) $ (48,968 ) $ (163,674 ) $ (55,286 ) Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 31,419 $ — $ 26,591 $ — Current liabilities (6,752 ) — (7,017 ) — Long-term liabilities (176,672 ) (48,968 ) (183,248 ) (55,286 ) Net liabilities recognized in the consolidated balance sheets $ (152,005 ) $ (48,968 ) $ (163,674 ) $ (55,286 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ (278 ) $ — $ (457 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 2.07 % 4.05 % 1.99 % 3.56 % Rate of compensation increase 3.48 % None 3.50 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: December 30, 2018 December 31, 2017 January 1, 2017 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 1.99 % 3.56 % 2.06 % 4.06 % 2.88 % 4.25 % Rate of compensation increase 3.50 % None 3.64 % None 3.26 % None Expected rate of return on assets 5.90 % 7.25 % 6.00 % 7.25 % 5.30 % 7.25 % The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: December 30, December 31, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 183,424 $ 190,265 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 180,560 $ 187,329 Fair value of plan assets — — Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 30, 2018 and December 31, 2017 , and target asset allocations for fiscal year 2019 are as follows: Target Allocation Percentage of Plan Assets at December 29, 2019 December 30, 2018 December 31, 2017 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 45-55% 35-50% 48 % 39 % 51 % 41 % Debt securities 45-55% 50-65% 51 % 61 % 49 % 59 % Other 0-5% 0-10% 1 % — % 0 % — % Total 100 % 100 % 100 % 100 % 100 % 100 % The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate. The Company's discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans. During fiscal year 2016, for the plans in the United States, the Society of Actuaries issued an updated projection scale, MP-2016, which reduced the life expectancy used to determine the projected benefit obligation. The Company adopted MP-2016 as of January 1, 2017. The adoption of the updated projection scale resulted in a $5.5 million decrease to the projected benefit obligation at January 1, 2017. The Company adopted a further updated projection scale, MP-2017, as of December 31, 2017. The adoption of MP-2017 resulted in a $2.6 million decrease to the projected benefit obligation at December 31, 2017. During fiscal year 2018, the Society of Actuaries issued MP-2018 mortality improvement rates to replace MP-2017 rates for use with the RP-2014 mortality table, which incorporates an additional year (2016) of U.S. population. The Company adopted MP-2018 as of December 30, 2018. The adoption of MP-2018 resulted in a $1.0 million decrease to the projected benefit obligation at December 30, 2018. The changes to the projected benefit obligations due to the adoption of the mortality base table and projection scale are included within "Actuarial loss (gain)" in the Change in Benefit Obligations for fiscal years 2018 and 2017 above. The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in large-cap and mid-cap companies located in the United States and abroad, and equity index funds. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds and venture capital funds that follow several different strategies. The fair values of the Company’s pension plan assets as of December 30, 2018 and December 31, 2017 by asset category, classified in the three levels of inputs described in Note 23 to the consolidated financial statements are as follows: Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,326 $ 6,326 $ — $ — Equity securities: U.S. large-cap 35,072 35,072 — — International large-cap value 24,175 24,175 — — U.S. small mid-cap 1,928 1,928 — — Emerging markets growth 11,993 11,993 — — Equity index funds 54,342 — 54,342 — Domestic real estate funds 1,353 1,353 — — Foreign real estate funds 22,196 — — 22,196 Commodity funds 886 886 — — Fixed income securities: Non-U.S. treasury securities 23,352 — 23,352 — Corporate and U.S. debt instruments 131,211 48,133 83,078 — Corporate bonds 24,848 — 24,848 — High yield bond funds 5,186 5,186 — — Other types of investments: Multi-strategy hedge funds 16,934 — — 16,934 Non-U.S. government index linked bonds 33,703 — 33,703 — Total assets measured at fair value $ 393,505 $ 135,052 $ 219,323 $ 39,130 Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 4,307 $ 4,307 $ — $ — Equity Securities: U.S. large-cap 30,008 30,008 — — International large-cap value 32,613 32,613 — — U.S. small-cap 2,104 2,104 — — Emerging markets growth 14,348 14,348 — — Equity index funds 90,838 — 90,838 — Domestic real estate funds 1,401 1,401 — — Commodity funds 7,387 7,387 — — Fixed income securities: Non-U.S. Treasury Securities 24,946 — 24,946 — Corporate and U.S. debt instruments 138,948 40,290 98,658 — Corporate bonds 27,571 — 27,571 — High yield bond funds 5,912 5,912 — — Other types of investments: Multi-strategy hedge funds 16,789 — — 16,789 Non-U.S. government index linked bonds 35,991 — 35,991 — Total assets measured at fair value $ 433,163 $ 138,370 $ 278,004 $ 16,789 Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 30, 2018 compared to December 31, 2017 . The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above. Equity Securities: Shares of registered investment companies that are publicly traded are categorized as Level 1 assets; they are valued at quoted market prices that represent the net asset value of the fund. These instruments have active markets. Equity index funds are mutual funds that are not publicly traded and are comprised primarily of underlying equity securities that are publicly traded on exchanges. Price quotes for the assets held by these funds are readily observable and available. Equity index funds are categorized as Level 2 assets. Fixed Income Securities: Fixed income mutual funds that are publicly traded are valued at quoted market prices that represent the net asset value of securities held by the fund and are categorized as Level 1 assets. Fixed income index funds that are not publicly traded are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments and are categorized as Level 2 assets. Individual fixed income bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used. Other Types of Investments: Non-U.S. government index link bond funds are not publicly traded and are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments. Underlying investments consist of bonds in which payment of income on the principal is related to a specific price index and are categorized as Level 2 assets. Hedge funds, private equity funds, foreign real estate funds and venture capital funds are valued at fair value by using the net asset values provided by the investment managers and are updated, if necessary, using analytical procedures, appraisals, public market data and/or inquiry of the investment managers. The net asset values are determined based upon the fair values of the underlying investments in the funds. These other investments invest primarily in readily available marketable securities and allocate gains, losses, and expense to the investor based on the ownership percentage as described in the fund agreements. They are categorized as Level 3 assets. The Company's policy is to recognize significant transfers between levels at the actual date of the event. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2018, 2017 and 2016 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Venture Capital Funds Foreign Real Estate Funds Multi-strategy Hedge Funds Total (In thousands) Balance at January 3, 2016 $ 1 $ — $ 23,415 $ 23,416 Realized losses (1 ) — — (1 ) Unrealized gains — — 375 375 Balance at January 1, 2017 — — 23,790 23,790 Sales — — (8,189 ) (8,189 ) Realized gains — — 1,542 1,542 Unrealized losses — — (354 ) (354 ) Balance at December 31, 2017 — — 16,789 16,789 Purchases — 22,196 — 22,196 Unrealized gains — — 145 145 Balance at December 30, 2018 $ — $ 22,196 $ 16,934 $ 39,130 With respect to plans outside of the United States, the Company expects to contribute $8.3 million in the aggregate during fiscal year 2019. During fiscal year 2018 , the Company contributed $8.5 million , in the aggregate, to pension plans outside of the United States and $15.0 million to its defined benefit pension plan in the United States for the plan year 2017. During fiscal year 2017, the Company made contributions of $8.4 million , in the aggregate, to plans outside of the United States. During fiscal year 2016, the Company contributed $9.6 million , in the aggregate, to plans outside of the United States. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2019 $ 11,313 $ 18,774 2020 11,654 18,948 2021 12,200 19,176 2022 12,267 19,353 2023 12,551 19,462 2024-2028 67,457 95,403 The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 30, 2018 and December 31, 2017 , the projected benefit obligations were $22.1 million and $23.7 million , respectively. Assets with a fair value of $1.8 million and $1.4 million , segregated in a trust (which is included in marketable securities and investments on the consolidated balance sheets), were available to meet this obligation as of December 30, 2018 and December 31, 2017 , respectively. Pension expenses and income for this plan netted to income of $0.3 million in fiscal year 2018 , expense of $3.2 million in fiscal year 2017 and expense of $1.6 million in fiscal year 2016 . Postretirement Medical Plans: The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. Net periodic postretirement medical benefit cost (credit) included the following components for the fiscal years ended: December 30, December 31, January 1, (In thousands) Service cost $ 106 $ 92 $ 101 Interest cost 120 125 142 Expected return on plan assets (1,254 ) (1,114 ) (1,035 ) Actuarial loss (gain) 1,621 (741 ) (539 ) Net periodic postretirement medical benefit cost (credit) $ 593 $ (1,638 ) $ (1,331 ) The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 30, 2018 and December 31, 2017 . December 30, December 31, (In thousands) Actuarial present value of benefit obligations: Retirees $ 688 $ 804 Active employees eligible to retire 408 379 Other active employees 2,317 1,948 Accumulated benefit obligations at beginning of year 3,413 3,131 Service cost 106 92 Interest cost 120 125 Benefits paid (117 ) (122 ) Actuarial (gain) loss (611 ) 187 Change in accumulated benefit obligations during the year (502 ) 282 Retirees 583 688 Active employees eligible to retire 362 408 Other active employees 1,966 2,317 Accumulated benefit obligations at end of year $ 2,911 $ 3,413 Change in plan assets: Fair value of plan assets at beginning of year $ 17,374 $ 15,453 Actual return on plan assets (993 ) 1,921 Benefits reimbursements paid (102 ) — Fair value of plan assets at end of year $ 16,279 $ 17,374 Net assets recognized in the consolidated balance sheets $ 13,368 $ 13,961 Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 13,368 $ 13,961 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 4.09 % 3.60 % Actuarial assumptions used to determine net cost during the year are as follows: December 30, December 31, January 1, Discount rate 3.60 % 4.11 % 4.34 % Expected rate of return on assets 7.25 % 7.25 % 7.25 % The Company maintains a master trust for plan assets related to the U.S. defined benefit plans and the U.S. postretirement medical plan. Accordingly, investment policies, target asset allocations and actual asset allocations are the same as those disclosed for the U.S. defined benefit plans. The fair values of the Company’s plan assets at December 30, 2018 and December 31, 2017 by asset category, classified in the three levels of inputs described in Note 23, are as follows: Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 390 $ 390 $ — $ — Equity securities: U.S. large-cap 2,436 2,436 — — International large-cap value 1,679 1,679 — — U.S. small mid-cap 134 134 — — Emerging markets growth 833 833 — — Domestic real estate funds 94 94 — — Commodity funds 62 62 — — Fixed income securities: Corporate debt instruments 9,115 3,344 5,771 — High yield bond funds 360 360 — — Other types of investments: Multi-strategy hedge funds 1,176 — — 1,176 Total assets measured at fair value $ 16,279 $ 9,332 $ 5,771 $ 1,176 Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 268 $ 268 $ — $ — Equity securities: U.S. large-cap 2,057 2,057 — — International large-cap value 2,236 2,236 — — U.S. small mid-cap 144 144 — — Emerging markets growth 984 984 — — Domestic real estate funds 96 96 — — Commodity funds 506 506 — — Fixed income securities: Corporate debt instruments 9,526 2,762 6,764 — High yield bond funds 406 406 — — Other types of investments: Multi-strategy hedge funds 1,151 — — 1,151 Total assets measured at fair value $ 17,374 $ 9,459 $ 6,764 $ 1,151 Valuation Techniques: Valuation techniques are the same as those disclosed for the U.S. defined benefit plans above. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2018, 2017 and 2016 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Multi-strategy Hedge Funds (In thousands) Balance at January 3, 2016 $ 1,374 Unrealized gains 134 Balance at January 1, 2017 1,508 Sales (562 ) Realized gains 229 Unrealized losses (24 ) Balance at December 31, 2017 1,151 Unrealized gains 25 Balance at December 30, 2018 $ 1,176 The Company does no t expect to make any contributions to the postretirement medical plan during fiscal year 2019 . The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2019 $ 136 2020 149 2021 168 2022 184 2023 194 2024-2028 1,050 Deferred Compensation Plans: During fiscal year 1998, the Company implemented a nonqualified deferred compensation plan that provides benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, or upon retirement or death. The plan was amended to eliminate deferral elections, with the exception of Company 401(k) excess contributions for eligible participants, for plan years beginning January 1, 2011. Benefit payments under the plan are funded by contributions from participants, and for certain participants, contributions by the Company. The obligations related to the deferred compensation plan totaled $1.1 million at December 30, 2018 and $1.0 million at December 31, 2017 . |
Contingencies
Contingencies | 12 Months Ended |
Dec. 30, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies | Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued $7.9 million and $9.4 million as of December 30, 2018 and December 31, 2017 , respectively, in accrued expenses and other current liabilities, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at December 30, 2018 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company. |
Warranty Reserves
Warranty Reserves | 12 Months Ended |
Dec. 30, 2018 | |
Product Warranties Disclosures [Abstract] | |
Warranty Reserves | Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the consolidated balance sheets. A summary of warranty reserve activity for the fiscal years ended December 30, 2018 , December 31, 2017 and January 1, 2017 is as follows: (In thousands) Balance at January 3, 2016 $ 9,843 Provision charged to income 14,901 Payments (14,749 ) Adjustments to previously provided warranties, net (850 ) Foreign currency translation and acquisitions (133 ) Balance at January 1, 2017 9,012 Provision charged to income 13,700 Payments (14,245 ) Adjustments to previously provided warranties, net (815 ) Foreign currency translation and acquisitions 1,398 Balance at December 31, 2017 9,050 Provision charged to income 13,545 Payments (13,775 ) Adjustments to previously provided warranties, net (157 ) Foreign currency translation and acquisitions (270 ) Balance at December 30, 2018 $ 8,393 |
Stock Plans
Stock Plans | 12 Months Ended |
Dec. 30, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Stock Plans | Stock Plans Stock-Based Compensation: In addition to the Company’s Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance restricted stock units, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued. The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2018, 2017 and 2016 : December 30, December 31, January 1, (In thousands) Cost of product and service revenue $ 1,466 $ 1,254 $ 1,031 Research and development expenses 1,359 1,389 902 Selling, general and administrative expenses 25,942 22,778 15,225 Total stock-based compensation expense $ 28,767 $ 25,421 $ 17,158 The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $13.6 million in fiscal year 2018 , $14.5 million in fiscal year 2017 and $10.5 million in fiscal year 2016 . Stock-based compensation costs capitalized as part of inventory were $0.3 million as of each of December 30, 2018 and December 31, 2017 . Stock Options: The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued. The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: December 30, December 31, January 1, Risk-free interest rate 3.0 % 2.0 % 1.7 % Expected dividend yield 0.4 % 0.4 % 0.6 % Expected lives 5 years 5 years 5 years Expected stock volatility 20.7 % 22.4 % 25.2 % The following table summarizes stock option activity for the fiscal year ended December 30, 2018 : December 30, 2018 Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 2,154 $ 42.77 Granted 364 77.84 Exercised (709 ) 35.02 Forfeited (44 ) 51.56 Outstanding at end of year 1,765 $ 52.91 Exercisable at end of year 965 $ 44.60 The aggregate intrinsic value for stock options outstanding at December 30, 2018 was $43.8 million with a weighted-average remaining contractual term of 4.2 years. The aggregate intrinsic value for stock options exercisable at December 30, 2018 was $31.6 million with a weighted-average remaining contractual term of 3.2 years. At December 30, 2018 , there were 1.8 million stock options that were vested, and expected to vest in the future, with an aggregate intrinsic value of $43.0 million and a weighted-average remaining contractual term of 4.2 years. The weighted-average per-share grant-date fair value of options granted during fiscal years 2018, 2017 and 2016 was $17.56 , $11.83 , and $10.20 , respectively. The total intrinsic value of options exercised during fiscal years 2018, 2017 and 2016 was $35.0 million , $17.6 million , and $16.6 million , respectively. Cash received from option exercises for fiscal years 2018, 2017 and 2016 was $24.8 million , $18.0 million , and $14.4 million , respectively. The total compensation expense recognized related to the Company’s outstanding options was $5.4 million in fiscal year 2018 , $4.7 million in fiscal year 2017 and $4.4 million in fiscal year 2016 . There was $6.7 million of total unrecognized compensation cost related to nonvested stock options granted as of December 30, 2018 . This cost is expected to be recognized over a weighted-average period of 1.8 years. Restricted Stock Awards: The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight line basis primarily in selling, general and administrative expenses over the vesting period, which is generally 3 years. These awards were granted under the Company’s 2009 Plan. Recipients of the restricted stock have the right to vote such shares and receive dividends. The following table summarizes restricted stock award activity for the fiscal year ended December 30, 2018 : December 30, 2018 Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 496 $ 50.30 Granted 214 76.00 Vested (206 ) 50.37 Forfeited (39 ) 55.73 Nonvested at end of year 465 $ 61.72 The fair value of restricted stock awards vested during fiscal years 2018, 2017 and 2016 was $10.4 million , $10.6 million , and $8.4 million , respectively. The total compensation expense recognized related to the restricted stock awards was $11.7 million in fiscal year 2018 , $10.3 million in fiscal year 2017 and $9.3 million in fiscal year 2016 . As of December 30, 2018 , there was $16.0 million of total unrecognized compensation cost, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.4 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 39,133 and 54,337 performance restricted stock units during fiscal years 2018 and 2017 , respectively, that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during fiscal years 2018 and 2017 was $80.31 and $52.78 , respectively. During fiscal year 2018 , 5,797 performance restricted stock units were forfeited. The total compensation expense recognized related to the performance restricted stock units was $3.2 million in fiscal year 2018 and $0.9 million in fiscal year 2017 . As of December 30, 2018 , there were 87,673 performance restricted stock units outstanding. Performance Units: The Company’s performance unit program provides a cash award based on the achievement of specific performance criteria. A target number of units are granted at the beginning of a three-year performance period. The number of units earned at the end of the performance period is determined by multiplying the number of units granted by a performance factor ranging from 0% to 200% . Awards are determined by multiplying the number of units earned by the stock price at the end of the performance period, and are paid in cash and accounted for as a liability based award. The compensation expense associated with these units is recognized over the period that the performance targets are expected to be achieved. The Company granted 37,281 performance units, 49,845 performance units, and 72,164 performance units during fiscal years 2018, 2017 and 2016 , respectively. The weighted-average per-share grant-date fair value of performance units granted during fiscal years 2018, 2017 and 2016 was $73.23 , $52.69 , and $42.79 , respectively. During fiscal year 2018 , no performance units were forfeited. During fiscal years 2017 and 2016 , 15,139 and 19,584 performance units were forfeited, respectively. The total compensation expense related to performance units was $7.7 million , $8.7 million , and $2.7 million for fiscal years 2018, 2017 and 2016 , respectively. As of December 30, 2018 , there were 144,151 performance units outstanding subject to forfeiture, with a corresponding liability of $14.0 million recorded in accrued expenses and long-term liabilities. Stock Awards: The Company’s stock award program provides an annual equity award to non-employee directors. For fiscal years 2018, 2017 and 2016 , the award equaled the number of shares of the Company’s common stock which has an aggregate fair market value of $100,000 on the date of the award. The stock award is prorated for non-employee directors who serve for only a portion of the year. The compensation expense associated with these stock awards is recognized when the stock award is granted. In fiscal years 2018, 2017 and 2016 , the Company awarded 11,088 shares, 12,006 shares, and 15,419 shares, respectively, to non-employee directors. The weighted-average per-share grant-date fair value of stock awards granted during fiscal years 2018, 2017 and 2016 was $72.17 , $63.14 , and $54.58 , respectively. The total compensation expense recognized related to these stock awards was $0.8 million in each of fiscal years 2018, 2017 and 2016 . Employee Stock Purchase Plan: In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Board voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2018 , the Company issued 21,321 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $69.57 per share. During fiscal year 2017 , the Company issued 36,769 shares under this plan at a weighted-average price of $67.09 per share. During fiscal year 2016 , the Company issued 49,578 shares under this plan at a weighted-average price of $49.67 per share. At December 30, 2018 there remains available for sale to employees an aggregate of 0.8 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Dec. 30, 2018 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity | Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, January 3, 2016 $ (46,846 ) $ 1,259 $ (369 ) $ (45,956 ) Current year change (54,077 ) (860 ) 32 (54,905 ) Balance, January 1, 2017 (100,923 ) 399 (337 ) (100,861 ) Current year change 54,341 (77 ) 79 54,343 Balance, December 31, 2017 (46,582 ) 322 (258 ) (46,518 ) Current year change (123,388 ) (77 ) (9 ) (123,474 ) Reclassification to retained earnings upon adoption of ASU 2018-02 (see Note 1) (6,489 ) — — (6,489 ) Balance, December 30, 2018 $ (176,459 ) $ 245 $ (267 ) $ (176,481 ) During fiscal years 2018, 2017 and 2016 , pre-tax expense of $0.1 million , $0.1 million , and $0.9 million , respectively, was reclassified from accumulated other comprehensive income into selling, general and administrative expenses as a component of net periodic pension cost. Stock Repurchases: On July 27, 2016, the Board of Directors (the "Board") authorized the Company to repurchase up to 8.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). On July 23, 2018, the Board authorized the Company to immediately terminate the Repurchase Program and further authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a new stock repurchase program (the "New Repurchase Program"). The New Repurchase Program will expire on July 23, 2020 unless terminated earlier by the Board and may be suspended or discontinued at any time. During fiscal year 2018, the Company had no stock repurchases under the Repurchase Program. No shares remain available for repurchase under the Repurchase Program due to its cancellation. During the fourth quarter of fiscal year 2018 , the Company repurchased 650,000 shares of common stock under the New Repurchase Program at an aggregate cost of $52.2 million . As of December 30, 2018 , $197.8 million remained available for aggregate repurchases of shares under the New Repurchase Program. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the fiscal year 2018 , the Company repurchased 66,506 shares of common stock for this purpose at an aggregate cost of $5.2 million . During fiscal year 2017 , the Company repurchased 78,644 shares of common stock for this purpose at an aggregate cost of $4.4 million . During fiscal year 2016 , the Company repurchased 75,198 shares of common stock for this purpose at an aggregate cost of $3.6 million . The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2018 and 2017 . At December 30, 2018 , the Company had accrued $7.7 million for a dividend declared on October 24, 2018 for the fourth quarter of fiscal year 2018 that was paid in February 2019 . On January 24, 2019 , the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2019 that will be payable in May 2019 . In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources. |
Derivatives And Hedging Activit
Derivatives And Hedging Activities | 12 Months Ended |
Dec. 30, 2018 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivatives and Hedging Activities | Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 70% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months , have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statements of cash flows. Principal hedged currencies include the British Pound, Euro, Swedish Krona, Chinese Yuan and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $223.3 million at December 30, 2018 , $212.1 million at December 31, 2017 , and $137.5 million at January 1, 2017 , and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2018, 2017 and 2016 . In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s consolidated statements of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements, included combined Euro notional amounts of €37.3 million and combined U.S. Dollar notional amounts of $5.7 million as of December 30, 2018 , combined Euro notional amounts of €57.2 million and combined U.S. Dollar notional amounts of $1.3 billion as of December 31, 2017 , and combined Euro notional amounts of €58.6 million , combined U.S. Dollar notional amounts of $8.7 million and combined Swedish Krona notional amounts of kr969.5 million as of January 1, 2017 . The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the fiscal years 2018 and 2017 . The Company paid $34.1 million and $13.8 million during the fiscal years 2018 and 2017 , respectively, from the settlement of these hedges. During fiscal year 2018, the Company entered into a series of foreign currency forward contracts with a notional amount of €298.7 million to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. The foreign currency forward contracts were settled during the second quarter of 2018 and the Company recorded a net realized foreign exchange loss in AOCI of $2.6 million for the fiscal year ended December 30, 2018 . During fiscal year 2016, the Company designated the 2026 Notes to hedge its investments in certain foreign subsidiaries. In January 2018, the Company removed the hedging relationship of its 2026 Notes and investments in certain foreign subsidiaries and recognized $2.1 million of unrealized foreign exchange gain in AOCI. In April 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 30, 2018 , the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €216.0 million . The unrealized foreign exchange gain recorded in AOCI related to the net investment hedge was $9.3 million for the fiscal year ended December 30, 2018 . During fiscal year 2018 , the Company designated the April 2021 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from the April 2021 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 30, 2018 , the total notional amount of the April 2021 Notes that was designated to hedge investments in foreign subsidiaries was €298.7 million . The unrealized foreign exchange gain recorded in AOCI related to the net investment hedge was $27.5 million for the fiscal year ended December 30, 2018 . The Company does no t expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive (loss) income into interest and other expense, net within the next twelve months. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 30, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 30, 2018 . The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2018 and 2017 . The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 30, 2018 and December 31, 2017 classified in one of the three classifications described above: Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,447 $ 2,447 $ — $ — Foreign exchange derivative assets 750 — 750 — Foreign exchange derivative liabilities (594 ) — (594 ) — Contingent consideration (69,661 ) — — (69,661 ) Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,208 $ 2,208 $ — $ — Foreign exchange derivative assets 1,431 — 1,431 — Foreign exchange derivative liabilities, net (23,638 ) — (23,638 ) — Contingent consideration (65,328 ) — — (65,328 ) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both December 30, 2018 and December 31, 2017 , none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. During fiscal year 2015, the Company acquired all the shares of Vanadis. Under the terms of the acquisition, the initial purchase consideration was $32.0 million , net of cash and the Company will be obligated to make potential future milestone payments, based on completion of a proof of concept, regulatory approvals and product sales, of up to $93.0 million ranging from 2016 to 2019. The key assumptions used to determine the fair value of the contingent consideration included projected milestone dates of 2016 to 2019 , discount rates ranging from 3.1% to 11.3% , conditional probabilities of success of each individual milestone ranging from 85% to 95% and cumulative probabilities of success for each individual milestone ranging from 53% to 90% . The fair value of the contingent consideration as of the acquisition date was estimated at $56.9 million . During fiscal year 2018 , the Company updated the fair value of the contingent consideration and recorded a liability of $63.2 million as of December 30, 2018 . The key assumptions used to determine the fair value of the contingent consideration as of December 30, 2018 included projected milestone dates in 2019 , discount rates ranging from 3.7% to 6.8% , conditional probabilities of success of each individual milestone ranging from 95% to 100% and cumulative probabilities of success for each individual milestone ranging from 89.3% to 100% . A significant delay in the product development (including projected regulatory milestone) achievement date in isolation could result in a significantly lower fair value measurement; a significant acceleration in the product development (including projected regulatory milestone) achievement date in isolation would not have a material impact on the fair value measurement; a significant change in the discount rate in isolation would not have a material impact on the fair value measurement; and a significant change in the probabilities of success in isolation could result in a significant change in fair value measurement. During the fiscal year 2018 , the Company recorded a contingent consideration obligation relating to other acquisitions with an estimated fair value of $6.5 million and the Company paid $16.5 million of contingent consideration to the former shareholders of Vanadis, of which $12.8 million was included in financing activities and $3.7 million was included in operating activities in the consolidated statements of cash flows. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the consolidated statements of operations. As of December 30, 2018 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $76.5 million . The expected maximum earnout period for acquisitions with open contingency period does not exceed 1.78 years from the December 30, 2018 , and the remaining weighted average expected earnout period at December 30, 2018 was 5 months. A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at January 3, 2016 $ (57,350 ) Additions — Amounts paid and foreign currency translation 332 Reclassified to other current liabilities for milestone achieved 10,000 Change in fair value (included within selling, general and administrative expenses) (16,183 ) Balance at January 1, 2017 (63,201 ) Additions — Amounts paid and foreign currency translation 34 Change in fair value (included within selling, general and administrative expenses) (2,161 ) Balance at December 31, 2017 (65,328 ) Additions (6,200 ) Amounts paid and foreign currency translation 16,507 Change in fair value (included within selling, general and administrative expenses) (14,640 ) Balance at December 30, 2018 $ (69,661 ) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. As of December 30, 2018 , the Company’s senior unsecured revolving credit facility, which provides for $1.0 billion of revolving loans, had a carrying value of $415.6 million , net of $2.4 million of unamortized debt issuance costs. As of December 31, 2017 , the Company's senior unsecured revolving credit facility had a carrying value of $621.7 million , net of $3.3 million of unamortized debt issuance costs. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2018 . Consequently, the carrying value approximates fair value and were classified as Level 2. The Company's November 2021 Notes, with a face value of $500.0 million , had an aggregate carrying value of $497.4 million , net of $1.1 million of unamortized original issue discount and $1.6 million of unamortized debt issuance costs as of December 30, 2018 . The November 2021 Notes had an aggregate carrying value of $496.6 million , net of $1.4 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs as of December 31, 2017 . The November 2021 Notes had a fair value of $516.1 million and $536.6 million as of December 30, 2018 and December 31, 2017 , respectively. The fair value of the November 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's 2026 Notes, with a face value of €500.0 million , had an aggregate carrying value of $564.5 million , net of $4.0 million of unamortized original issue discount and $3.8 million of unamortized debt issuance costs as of December 30, 2018 . The 2026 Notes had an aggregate carrying value of $591.7 million , net of $4.7 million of unamortized original issue discount and $4.3 million of unamortized debt issuance costs as of December 31, 2017 . The 2026 Notes had a fair value of €496.1 million and €508.9 million as of December 30, 2018 and December 31, 2017 , respectively. The fair value of the 2026 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's April 2021 Notes, with a face value of €300.0 million , had an aggregate carrying value of $341.3 million , net of $0.1 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs as of December 30, 2018 . The April 2021 Notes had a fair value of €300.5 million as of December 30, 2018 . The fair value of the April 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company’s other debt facilities that were assumed from the EUROIMMUN acquisition had an aggregate carrying value of $38.2 million and $60.2 million as of December 30, 2018 and December 31, 2017 , respectively. As of December 30, 2018 , these consisted of bank loans in the aggregate amount of $38.0 million bearing fixed interest rates between 1.1% and 17.6% and a bank loan in the amount of $0.2 million bearing a variable interest rate based on the Euribor rate plus a margin of 1.5% . The Company had no change in credit standing during fiscal year 2018 . Consequently, the carrying value approximates fair value. As of December 30, 2018 , the April 2021 Notes, November 2021 Notes, 2026 Notes and other debt facilities were classified as Level 2. The Company's financing lease obligations had an aggregate carrying value of $34.5 million and $35.9 million as of December 30, 2018 and December 31, 2017 , respectively. The non-cash finance lease liabilities due to build-to-suit accounting amounted to $21.7 million as of each of the year ended December 30, 2018 and December 31, 2017 . The remaining carrying amounts of the Company's financing lease obligations approximated their fair value as there has been minimal change in the Company's incremental borrowing rate. As of December 30, 2018 , there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks. |
Leases
Leases | 12 Months Ended |
Dec. 30, 2018 | |
Leases [Abstract] | |
Leases | Leases The Company leases certain property and equipment under operating leases. Rental expense charged to continuing operations for fiscal years 2018, 2017 and 2016 amounted to $62.3 million , $54.0 million , and $52.0 million , respectively. Minimum rental commitments under noncancelable operating leases are as follows: $56.4 million in fiscal year 2019 , $46.6 million in fiscal year 2020 , $33.5 million in fiscal year 2021 , $22.1 million in fiscal year 2022 , $15.6 million in fiscal year 2023 and $67.6 million in fiscal year 2024 and thereafter . On August 22, 2013 , the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million . Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and at the transaction date the Company had deferred $26.5 million of gains which are being amortized in operating expenses over the initial lease term of 15 years . The Company amortized $1.8 million of the deferred gains related to the lease during each of the fiscal years 2018, 2017 and 2016 . The deferred gains remaining to be amortized were $17.0 million at December 30, 2018 , of which $1.8 million was recorded in accrued expenses and other current liabilities, and $15.3 million was recorded in long-term liabilities. The deferred gains remaining to be amortized were $18.8 million at December 31, 2017 , of which $1.8 million was recorded in accrued expenses and other current liabilities, and $17.0 million was recorded in long-term liabilities. Upon adoption of ASC 842, the Company will recognize the unamortized deferred gains in retained earnings. |
Industry Segment and Geographic
Industry Segment and Geographic Area Information | 12 Months Ended |
Dec. 30, 2018 | |
Segment Reporting [Abstract] | |
Industry Segment Information | Industry Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: December 30, December 31, January 1, (In thousands) Discovery & Analytical Solutions Product revenue $ 1,010,899 $ 941,328 $ 934,098 Service revenue 682,312 637,131 578,886 Total revenue 1,693,211 1,578,459 1,512,984 Operating income from continuing operations (1) 230,481 205,259 196,508 Diagnostics Product revenue 924,594 536,086 462,798 Service revenue 160,191 142,437 139,735 Total revenue 1,084,785 678,523 602,533 Operating income from continuing operations (2) 153,196 146,862 147,996 Corporate Operating loss from continuing operations (59,793 ) (56,506 ) (49,922 ) Continuing Operations Product revenue 1,935,493 1,477,414 1,396,896 Service revenue 842,503 779,568 718,621 Total revenue 2,777,996 2,256,982 2,115,517 Operating income from continuing operations 323,884 295,615 294,582 Interest and other expense, net (see Note 7) 66,201 (1,103 ) 50,514 Income from continuing operations before income taxes $ 257,683 $ 296,718 $ 244,068 ____________________________ (1) Legal costs for significant litigation matters in the Company's Discovery & Analytical Solutions segment were $5.3 million for fiscal year 2018 and $2.7 million for fiscal year 2017. (2) Legal costs for a significant litigation matter in the Company's Diagnostics segment were $0.2 million for fiscal year 2018 . Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 30, 2018 : Depreciation and Amortization Expense Capital Expenditures December 30, December 31, January 1, December 30, December 31, January 1, (In thousands) (In thousands) Discovery & Analytical Solutions $ 70,362 $ 72,590 $ 72,484 $ 34,852 $ 26,200 $ 21,486 Diagnostics 107,434 31,204 25,339 54,737 11,262 8,556 Corporate 2,792 1,206 2,149 3,664 1,627 1,660 Continuing operations $ 180,588 $ 105,000 $ 99,972 $ 93,253 $ 39,089 $ 31,702 Discontinued operations $ — $ 929 $ 6,266 $ — $ 182 $ 1,302 Total Assets December 30, December 31, January 1, (In thousands) Discovery & Analytical Solutions $ 2,567,054 $ 2,611,737 $ 2,612,757 Diagnostics 3,358,964 3,447,437 1,505,381 Corporate 49,504 32,289 31,171 Current and long-term assets of discontinued operations — — 127,374 Total assets $ 5,975,522 $ 6,091,463 $ 4,276,683 The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 30, 2018 and net long-lived assets based on physical location as of December 30, 2018 and December 31, 2017 : Revenue December 30, December 31, January 1, (In thousands) U.S. $ 906,398 $ 837,018 $ 842,364 International: China 559,865 374,931 336,728 United Kingdom 72,124 65,164 65,904 Germany 142,411 91,669 89,839 India 92,327 84,812 43,891 Italy 95,908 77,477 70,948 France 97,990 80,153 71,104 Japan 79,238 76,322 65,980 Other international 731,735 569,436 528,759 Total international 1,871,598 1,419,964 1,273,153 Total sales $ 2,777,996 $ 2,256,982 $ 2,115,517 Net Long-Lived Assets December 30, December 31, January 1, (In thousands) U.S. $ 201,649 $ 210,116 $ 182,186 International: Germany 99,181 88,249 1,292 China 61,261 64,815 36,458 United Kingdom 33,429 28,028 14,638 India 14,636 14,820 2,020 Finland 16,211 14,764 12,295 Italy 11,324 10,334 3,398 Singapore 14,942 9,240 6,820 Brazil 8,237 7,963 1,452 Netherlands 3,750 4,281 4,162 Sweden 3,038 3,869 2,645 Other international 22,653 19,565 7,684 Total international 288,662 265,928 92,864 Total net long-lived assets $ 490,311 $ 476,044 $ 275,050 |
Quarterly Financial Information
Quarterly Financial Information (Unaudited) | 12 Months Ended |
Dec. 30, 2018 | |
Quarterly Financial Information Disclosure [Abstract] | |
Quarterly Financial Information (Unaudited) | Quarterly Financial Information (Unaudited) Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) December 30, 2018 Revenue $ 643,972 $ 703,362 $ 674,313 $ 756,349 $ 2,777,996 Gross profit 292,222 340,140 332,327 376,250 1,340,939 Restructuring and contract termination charges, net 6,578 — 6,508 (1,942 ) 11,144 Operating income from continuing operations 39,935 88,064 80,202 115,683 323,884 Income from continuing operations before income taxes 28,505 71,708 78,041 79,429 257,683 Income from continuing operations 26,035 64,673 75,445 71,322 237,475 Loss (income) from discontinued operations and dispositions (11 ) (610 ) 1,103 (30 ) 452 Net income 26,024 64,063 76,548 71,292 237,927 Basic earnings per share: Income from continuing operations $ 0.24 $ 0.59 $ 0.68 $ 0.64 $ 2.15 Income (loss) from discontinued operations and dispositions — (0.01 ) 0.01 — — Net income 0.24 0.58 0.69 0.64 2.15 Diluted earnings per share: Income from continuing operations $ 0.23 $ 0.58 $ 0.68 $ 0.64 $ 2.13 Income (loss) from discontinued operations and dispositions — (0.01 ) 0.01 — — Net income 0.23 0.57 0.69 0.64 2.13 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 December 31, 2017 Revenue $ 514,115 $ 546,962 $ 554,275 $ 641,630 $ 2,256,982 Gross profit 239,756 257,602 268,967 307,429 1,073,754 Restructuring and contract termination charges, net 9,651 — 3,269 (263 ) 12,657 Operating income from continuing operations 49,811 74,183 78,038 93,583 295,615 Income from continuing operations before income taxes 39,983 70,792 105,054 80,889 296,718 Income (loss) from continuing operations 36,062 62,726 96,546 (38,444 ) 156,890 Income (loss) from discontinued operations and dispositions 2,541 141,343 (5,468 ) (2,673 ) 135,743 Net income (loss) 38,603 204,069 91,078 (41,117 ) 292,633 Basic earnings per share: Income (loss) from continuing operations $ 0.33 $ 0.57 $ 0.88 $ (0.35 ) $ 1.43 Income (loss) from discontinued operations and dispositions 0.02 1.29 (0.05 ) (0.02 ) 1.24 Net income (loss) 0.35 1.86 0.83 (0.37 ) 2.67 Diluted earnings per share: Income (loss) continuing operations $ 0.33 $ 0.57 $ 0.87 $ (0.35 ) $ 1.42 Income (loss) from discontinued operations and dispositions 0.02 1.28 (0.05 ) (0.02 ) 1.22 Net income (loss) 0.35 1.84 0.82 (0.37 ) 2.64 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. |
Nature of Operations and Acco_2
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies) | 12 Months Ended |
Dec. 30, 2018 | |
Accounting Policies [Abstract] | |
Consolidation [Policy Text Block] | The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. |
Segment Reporting [Policy Text Block] | |
Fiscal Periods [Policy Text Block] | The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 30, 2018 (" fiscal year 2018 "), December 31, 2017 (" fiscal year 2017 ") and January 1, 2017 (" fiscal year 2016 ") included 52 weeks. |
Accounting Policies and Estimates [Policy Text Block] | Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. |
Revenue Recognition [Policy Text Block] | Revenue Recognition: The Company adopted ASC 606 with a date of the initial application of January 1, 2018. As a result, the Company has changed its accounting policy for revenue recognition as detailed below. The Company applied ASC 606 using the modified retrospective method only to contracts that are not completed contracts as of January 1, 2018, and the cumulative effect of initially applying ASC 606 is recognized as an adjustment to the beginning retained earnings. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 605. The details of the significant changes and quantitative impact of the changes are disclosed below. A. Sales of software subscriptions or sales of licenses and maintenance in bundled arrangements The Company previously recognized revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the undelivered items in the arrangement have value to the customer on a stand-alone basis and vendor-specific objective evidence ("VSOE") of fair value can be determined. If VSOE of fair value for the undelivered elements cannot be established, the Company deferred all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the undelivered element is maintenance, then the Company recognized the entire fee ratably over the maintenance period. Under ASC 606, the total consideration in the contract is allocated to all products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the list prices at which the Company sells the software license, software subscription, maintenance and/or consulting services. Accordingly, the Company now recognizes higher license revenue upfront and less service revenue over time. B. Sales of instruments The Company previously recognized revenue from sale of instruments when persuasive evidence of an arrangement existed, delivery had occurred, the price to the buyer was fixed or determinable, and collectability was reasonably assured. For certain sales of instruments that included customer-specified acceptance criteria, the Company previously recognized revenue after the acceptance criteria had been met. Under ASC 606, revenue is recognized when the Company satisfies a performance obligation by transferring control of the product to a customer. Accordingly, the Company now recognizes product revenue upon delivery or when title has transferred to the customer, as the Company believes acceptance is perfunctory. C. Sales commissions The Company previously recognized commission fees related to sales of products and services as selling expenses when they were incurred. Under ASC 606, the Company capitalizes those commission fees as costs of obtaining a contract, when they are incremental and, if they are expected to be recovered, the Company amortizes them consistently with the pattern of transfer of the product or service to which the asset relates. If the expected amortization period is one year or less, the commission fee is expensed when incurred. |
Warranty Costs [Policy Text Block] | Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. |
Shipping and Handling Costs [Policy Text Block] | Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. |
Inventories [Policy Text Block] | Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. |
Income Taxes [Policy Text Block] | Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. When the Company determines during the period that previously undistributed earnings of certain international subsidiaries no longer meet the requirements of indefinite reinvestment, the Company recognizes the income tax expense in that period. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 8 below for additional details. |
Property, Plant and Equipment [Policy Text Block] | Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed. |
Asset Retirement Obligations [Policy Text Block] | Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented. |
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block] | Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. |
Translation of Foreign Currencies [Policy Text Block] | Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive (loss) income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net |
Business Combinations [Policy Text Block] | Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. |
Goodwill and Other Intangible Assets [Policy Text Block] | Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. The intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 14 below for additional details. |
Stock-Based Compensation [Policy Text Block] | Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 20 below. |
Marketable Securities and Investments [Policy Text Block] | Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions. |
Cash Flows [Policy Text Block] | Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. |
Environmental Matters [Policy Text Block] | Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. |
Research and Development Expense, Policy [Policy Text Block] | Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. |
Restructuring Charges [Policy Text Block] | Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 6 below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use. |
New Accounting Pronouncement or Change in Accounting Principle, Description | Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. |
Derivative Instruments and Hedging [Policy Text Block] | Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. |
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance on capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). Specifically, ASU 2018-15 amends Intangibles-Goodwill and Other (Topic 350) to include in its scope implementation costs incurred in a hosting arrangement that is a service contract and clarifies that a customer should apply Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The provisions of this guidance are to be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14"). ASU 2018-14 adds, removes, and clarifies disclosure requirements related to defined benefit pension and other postretirement plans. ASU 2018-14 adds requirements for an entity to disclose the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans; and an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period . Further, ASU 2018-14 removes guidance that currently requires the following disclosures: the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year; the amount and timing of plan assets expected to be returned to the employer; information about (1) benefits covered by related-party insurance and annuity contracts and (2) significant transactions between the plan and related parties; and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. ASU 2018-14 also clarifies the guidance in Compensation-Retirement Benefits (Topic 715-20-50-3) on defined benefit plans to require disclosure of (1) the projected benefit obligation ("PBO") and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (2) the accumulated benefit obligation ("ABO") and fair value of plan assets for pension plans with ABOs in excess of plan assets. The provisions of this guidance are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-14 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). ASU 2018-13 adds, removes, and modifies certain disclosures related to fair value measurements. ASU 2018-13 adds requirements for an entity to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Further, ASU 2018-13 removes the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also modifies existing disclosure requirements related to measurement uncertainty. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In June 2018, the FASB issued Accounting Standards Update No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07") which supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-employees , and expands the scope of Topic 718 (which currently only includes share-based payments to employees) to also include share-based payments issued to non-employees for goods and services, except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, except for financing transactions, or awards issued to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers ("Topic 606"). The provisions of this guidance are to be applied using a modified retrospective approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified non-employee awards that have not been settled as of the adoption date and (2) equity-classified non-employee awards for which a measurement date has not been established. ASU 2018-07 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606. The Company early adopted the provisions of this guidance effective July 2, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flow. In March 2018, the FASB Issued Accounting Standards Update No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("ASU 2018-05"). ASU 2018-05 was issued to incorporate into Topic 740 recent SEC guidance related to the income tax accounting implications of the Tax Cut and Jobs Act (the "Tax Act"). The SEC issued Staff Accounting Bulletin No. 118 ("SAB 118") to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Act in the period of enactment. SAB 118 permits companies to disclose that some or all of the income tax effects from the Tax Act are incomplete by the due date of the financial statements, and if possible, disclose a reasonable estimate of such tax effects. ASU 2018-05 is effective immediately. The Company is applying the guidance in ASU 2018-05 when accounting for the enactment date effects of the Tax Act. At December 30, 2018 , the Company completed the accounting for all of the tax effects of the Tax Act using reasonable estimates of their effects based on currently available information. These estimates may be affected as additional clarification and implementation guidance becomes available. These changes could be material to the Company's income tax expense. See Note 8 for further disclosures. In February 2018, the FASB Issued Accounting Standards Update No. 2018-03, Technical Corrections and Improvements to Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2018-03") . ASU 2018-03 was issued to clarify certain aspects of guidance concerning the recognition of financial assets and liabilities established in Accounting Standards Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). This includes treatment for discontinuations and adjustments for equity securities without a readily determinable market value, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in a foreign currency, and transition guidance for equity securities without a readily determinable fair value. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years beginning after June 15, 2018. Early adoption is permitted for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, as long as the Company has adopted ASU 2016-01. The Company adopted the provisions of this guidance effective July 2, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In February 2018, the FASB Issued Accounting Standards Update No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02") . ASU 2018-02 provides entities with an option to reclassify stranded tax effects within AOCI to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act (or portion thereof) is recorded. ASU 2018-02 requires entities to disclose a description of the accounting policy for releasing income tax effects from AOCI; whether they elect to reclassify the stranded income tax effects from the Tax Act; and information about the other income tax effects that are reclassified. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and entities should apply the proposed amendments either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company adopted ASU 2018-02 on December 30, 2018. The adoption of the standard resulted in an increase in retained earnings at December 30, 2018 in the amount of $6.5 million , with a corresponding decrease in AOCI. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12") , which amends the hedge accounting recognition and presentation requirements in Topic 815. ASU 2017-12 makes targeted changes to the existing hedge accounting model to better align an entity’s financial reporting for hedging relationships with the entity’s risk management activities, and to reduce the complexity of, and simplify the application of, the hedge accounting model. Specifically, ASU 2017-12 expands the types of transactions eligible for hedge accounting, eliminates the requirement to separately measure and present hedge ineffectiveness, simplifies the way assessments of hedge ineffectiveness may be performed, relaxes the documentation requirements for entering into hedging positions, provides targeted improvements to fair value hedges of interest rate risk, and permits an entity to exclude the change in the fair value of cross-currency basis spreads in currency swaps from the assessment of hedge effectiveness. The standard also requires entities to provide new disclosures about the impact fair value and cash flow hedges have on their income statements and about cumulative basis adjustments arising from fair value hedges. The provisions of this guidance are to be applied using a modified retrospective approach to existing hedging relationships as of the adoption date. However, the transition provisions allow for certain elections at the date of adoption and entities may choose to apply any of the provided elections. ASU 2017-12 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company early adopted the provisions of this guidance effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting ("ASU 2017-09") , which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. If an entity modifies its awards and concludes that it is not required to apply modification accounting under the standard, it must still consider whether the modification affects its application of other guidance. Additionally, if a significant modification does not result in incremental compensation cost, entities are required to disclose the “lack of” incremental compensation cost resulting from such significant modification. The standard also removes the guidance in Topic 718 stating that modification accounting is not required when an entity adds an antidilution provision as long as that modification is not made in contemplation of an equity restructuring. The provisions of this guidance are to be applied on a prospective basis to awards modified on or after the effective date. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In March 2017, the FASB issued Accounting Standards Update No. 2017-07, Compensation - Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost ("ASU 2017-07") , which amends the requirements in Topic 715 related to the income statement presentation of the components of net periodic benefit cost for an entity’s sponsored defined benefit pension and other postretirement plans. ASU 2017-07 requires entities to (1) disaggregate the current-service-cost component from the other components of net benefit cost (the “other components”) and present it with other current employee compensation costs in their income statements and (2) present the other components elsewhere in their income statements and outside of income from operations, and disclose the income statement lines that contain the other components if they are not presented on appropriately described separate lines. Additionally, the standard requires that only the service-cost component of net benefit cost is eligible for capitalization (e.g., as part of inventory or property, plant, and equipment). The change in income statement presentation requires retrospective application, while the change in capitalized benefit cost is to be applied prospectively. ASU 2017-07 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The standard provides a practical expedient that permits entities to use the components of cost disclosed in prior years as a basis for the retrospective application of the new income statement presentation. Entities need to disclose the use of the practical expedient. The Company adopted ASU 2017-07 effective January 1, 2018 using a retrospective approach for each period presented. For the fiscal years 2017 and 2016, $(9.2) million and $11.5 million , respectively, of net periodic pension (credit) cost previously presented within operating income has been presented outside of operating income in the line item "Interest and other expense, net" in the consolidated statements of operations due to the retrospective adoption of ASU 2017-07. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business ("ASU 2017-01"), which amends Topic 805 to provide a screen to determine when a set of assets and liabilities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the standard (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace missing elements. The standard provides a framework to assist entities in evaluating whether both an input and a substantive process are present. The standard also provides a framework that includes two sets of criteria to consider that depend on whether a set has outputs and a more stringent criteria for sets without outputs. Lastly, the standard narrows the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606, Revenue from Contracts with Customers . The provisions of this guidance are to be applied prospectively. ASU 2017-01 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted in limited circumstances. The Company adopted ASU 2017-01 effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash ("ASU 2016-18"), which amends Topic 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The provisions of this guidance are to be applied using a retrospective transition method to each period presented. ASU 2016-18 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company adopted ASU 2016-18 effective January 1, 2018. For the fiscal years 2017 and 2016, $17.2 million and $(17.0) million , respectively, of changes in restricted cash balances that were previously presented within investing activities in the consolidated statements of cash flows have been excluded from the cash flows used in investing activities and the effect of exchange rate changes increased by $0.2 million in fiscal year 2017, due to the retrospective adoption of ASU 2016-18. Restricted cash amounting to $17.3 million and $0.2 million at January 1, 2017 and December 31, 2017, respectively, have been included with the cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the consolidated statement of cash flows for the fiscal year ended December 31, 2017. Restricted cash amounting to $0.3 million and $17.3 million at January 3, 2016 and January 1, 2017, respectively, have been included with the cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the consolidated statement of cash flows for the fiscal year ended January 1, 2017. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In October 2016, the FASB issued Accounting Standards Update No. 2016-16, Income Taxes (Topic 740), Intra-entity Transfer of Assets Other than Inventory ("ASU 2016-16"). ASU 2016-16 removes the prohibition in Topic 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The standard requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The provisions of this guidance are to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company adopted ASU 2016-16 on January 1, 2018. The adoption of the standard resulted in a decrease in the retained earnings at January 1, 2018 of approximately $2.1 million with corresponding increase in deferred tax assets of $10.7 million and decrease in prepaid taxes of $12.8 million related to prior years’ intra-entity transfers of assets other than inventory. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230 and other topics. The provisions of this guidance are to be applied using a retrospective transition method to each period presented, and if it is impracticable to apply the amendments retrospectively for some of the issues, ASU 2016-15 allows the amendments for those issues to be applied prospectively as of the earliest date practicable. ASU 2016-15 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company adopted ASU 2016-15 effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease of assets will primarily depend on its classification as a finance or operating lease. ASU 2016-02 also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. ASU 2016-02 is to be applied using a modified retrospective approach. Subsequent to the issuance of ASU 2016-02, in July 2018, the FASB issued Accounting Standards Update No. 2018-10, Codification Improvements to Topic 842, Leases ("ASU 2018-10") and Accounting Standards Update No. 2018-11, Leases (Topic 842): Targeted Improvements ("ASU 2018-11"). The amendments in ASU 2018-10 clarify, correct or remove inconsistencies in the guidance provided under ASU 2016-02 related to sixteen specific issues identified. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard. Under the new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity's reporting for the comparative periods presented in the financial statements in the period of adoption will continue to be in accordance with ASC 840, Leases ("ASC 840" ). An entity that elects this additional (and optional) transition method must provide the required disclosures under ASC 840 for all periods that continue to be in accordance with ASC 840. ASU 2018-11 also provides lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if certain criteria are met. The effective date and transition requirements for these two standards are the same as the effective date and transition requirements of ASU 2016-02. The standards were effective for the Company beginning on December 31, 2018. The Company did not early adopt these standards and adopted these standards using the optional transition method. The Company elected to apply the modified retrospective approach, and applied the new leases standard at December 31, 2018, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. As a lessee, the most significant impact of the standards relates to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. In addition, the Company had deferred gains from a sale-leaseback transaction that are being amortized in operating expenses over the lease term and the lease is accounted for as an operating lease under ASC 840. Under the new standards, the Company will recognize the deferred gains from the sale as a cumulative-effect adjustment in retained earnings at December 31, 2018. The Company will also derecognize the impact of its build-to-suit arrangement in which the Company was the deemed owner during the construction period, for which the construction is complete and the lease commenced before the initial date of adoption. The adoption of the standards will result in an increase in retained earnings at December 31, 2018 of approximately $19.1 million for the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standards will result in recognition of right-of-use assets of approximately $190.7 million and lease liabilities of approximately $137.7 million , primarily related to the facilities operating leases, a decrease in property and equipment of approximately $31.9 million and an increase in deferred tax liabilities of $2.1 million for the tax impact of the cumulative adjustments. The adoption will have no impact to cash from or used in operating, investing or financing activities in the Company's consolidated statement of cash flows at December 31, 2018. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). Under this new guidance, an entity should use a five-step process to recognize revenue, depicting the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also r |
Revenue (Tables)
Revenue (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Disaggregation of Revenue [Line Items] | |
Disaggregation of Revenue [Table Text Block] | In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments For the fiscal year ended December 30, 2018 Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 680,117 $ 385,005 $ 1,065,122 Europe 494,707 283,385 778,092 Asia 518,387 416,395 934,782 $ 1,693,211 $ 1,084,785 $ 2,777,996 Primary end-markets Diagnostics $ — $ 1,084,785 $ 1,084,785 Life sciences 934,690 — 934,690 Applied markets 758,521 — 758,521 $ 1,693,211 $ 1,084,785 $ 2,777,996 Timing of revenue recognition Products and services transferred at a point in time $ 1,199,255 $ 1,002,788 $ 2,202,043 Services transferred over time 493,956 81,997 575,953 $ 1,693,211 $ 1,084,785 $ 2,777,996 |
Business Combinations and Ass_2
Business Combinations and Asset Purchases (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Business Acquisition [Line Items] | |
Business Acquisition, Pro Forma Information [Table Text Block] | The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: December 31, January 1, (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 2,562,580 $ 2,379,176 Income from continuing operations 143,459 156,210 Basic earnings per share: Income from continuing operations $ 1.31 $ 1.43 Diluted earnings per share: Income from continuing operations $ 1.29 $ 1.42 |
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed | The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2018 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 520 Less: cash acquired (1,132 ) Total $ 104,892 Identifiable assets acquired and liabilities assumed: Current assets $ 6,522 Property, plant and equipment 1,166 Other assets 891 Identifiable intangible assets: Core technology 34,021 Trade names 1,070 Customer relationships 10,200 Goodwill 59,647 Deferred taxes (3,860 ) Debt assumed (461 ) Liabilities assumed (4,304 ) Total $ 104,892 The total purchase price for the acquisitions in fiscal year 2016 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2016 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 72,497 Working capital and other adjustments (261 ) Less: cash acquired (2,152 ) Total $ 70,084 Identifiable assets acquired and liabilities assumed: Current assets $ 7,153 Property, plant and equipment 7,542 Identifiable intangible assets: Core technology 6,600 Trade names 570 Customer relationships 14,900 Goodwill 43,072 Deferred taxes (7,768 ) Liabilities assumed (1,985 ) Total $ 70,084 The total purchase price for the acquisitions in fiscal year 2017 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN 2017 Other (In thousands) Fair value of business combination: Cash payments $ 1,413,113 $ 140,861 Other liability — 1,273 Working capital and other adjustments — (93 ) Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,095 $ 139,602 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 109,859 11,356 Other assets 71,621 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 710,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 591,304 75,250 Deferred taxes (251,886 ) (15,735 ) Liabilities assumed (100,020 ) (8,328 ) Debt assumed (61,357 ) — Total $ 1,388,095 $ 139,602 |
Changes in Accounting Policie_2
Changes in Accounting Policies (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Accounting Policies [Abstract] | |
Schedule of Prospective Adoption of New Accounting Pronouncements [Table Text Block] | Impacts on financial statements The following tables summarize the impacts of ASC 606 adoption on the Company's consolidated financial statements for the fiscal year ended December 30, 2018 . Consolidated Balance Sheet As reported Adjustments Balances without adoption of ASC 606 (In thousands) Cash and cash equivalents $ 163,111 $ — $ 163,111 Accounts receivable, net 632,669 (16,264 ) 616,405 Inventories 338,347 9,773 348,120 Other current assets 100,507 (363 ) 100,144 Property, plant and equipment, net 318,590 — 318,590 Intangible assets, net 1,199,667 — 1,199,667 Goodwill 2,952,608 — 2,952,608 Other assets, net 270,023 — 270,023 Total assets $ 5,975,522 $ (6,854 ) $ 5,968,668 Current portion of long-term debt $ 14,856 $ — $ 14,856 Accounts payable 220,949 — 220,949 Accrued restructuring and contract termination charges 4,834 — 4,834 Accrued expenses and other current liabilities 528,827 19,173 548,000 Current liabilities of discontinued operations 2,165 — 2,165 Long-term debt 1,876,624 — 1,876,624 Long-term liabilities 742,312 — 742,312 Total liabilities 3,390,567 19,173 3,409,740 Commitments and contingencies Preferred stock — — — Common stock 110,597 — 110,597 Capital in excess of par value 48,772 — 48,772 Retained earnings 2,602,067 (26,027 ) 2,576,040 Accumulated other comprehensive loss (176,481 ) — (176,481 ) Total stockholders’ equity 2,584,955 (26,027 ) 2,558,928 Total liabilities and stockholders’ equity $ 5,975,522 $ (6,854 ) $ 5,968,668 Consolidated Statement of Operations As reported Adjustments Balances without adoption of ASC 606 (In thousands) Product revenue $ 1,935,493 $ (31,441 ) $ 1,904,052 Service revenue 842,503 — 842,503 Total revenue 2,777,996 (31,441 ) 2,746,555 Cost of product revenue 908,228 (10,290 ) 897,938 Cost of service revenue 528,829 — 528,829 Total cost of revenue 1,437,057 (10,290 ) 1,426,767 Selling, general and administrative expenses 811,913 329 812,242 Research and development expenses 193,998 — 193,998 Restructuring and contract termination charges, net 11,144 — 11,144 Operating income from continuing operations 323,884 (21,480 ) 302,404 Interest and other expense, net 66,201 — 66,201 Income from continuing operations before income taxes 257,683 (21,480 ) 236,203 Provision for income taxes 20,208 (5,662 ) 14,546 Income from continuing operations 237,475 (15,818 ) 221,657 Income from discontinued operations before income taxes — — — Loss on disposition of discontinued operations before income taxes (859 ) — (859 ) Benefit from income taxes on discontinued operations and dispositions (1,311 ) — (1,311 ) Gain from discontinued operations and dispositions 452 — 452 Net income $ 237,927 $ (15,818 ) $ 222,109 The adoption of ASC 606 increased comprehensive income by $15.8 million in the Company's consolidated statement of comprehensive income for the fiscal year ended December 30, 2018 . The adoption of ASC 606 had no impact on cash from or used in operating, investing, or financing activities in the Company's consolidated statement of cash flows as of and for the fiscal year ended December 30, 2018 . |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | The summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended: December 30, December 31, January 1, (In thousands) Revenue $ — $ 44,343 $ 146,217 Cost of revenue — 32,933 95,395 Selling, general and administrative expenses — 5,869 13,657 Research and development expenses — 4,891 14,368 Restructuring and contract termination charges, net — — 568 Income from discontinued operations before income taxes $ — $ 650 $ 22,229 |
Schedule of Gains and Losses on Disposition of Discontinued Operations [Table Text Block] | The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: December 30, December 31, January 1, (In thousands) (Loss) gain on disposition of the Medical Imaging business $ (793 ) $ 179,615 $ — Gain on disposition of Technical Services business — — 1,753 Loss on disposition of Fluid Sciences Segment (66 ) — (1,134 ) (Loss) gain on disposition of discontinued operations before income taxes $ (859 ) $ 179,615 $ 619 |
Restructuring and Contract Te_2
Restructuring and Contract Terminaiton Charges, Net (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Related Costs [Table Text Block] | The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2018, 2017 and 2016 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Diagnostics Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Severance Excess Facility (In thousands, except headcount data) Q4 2018 Plan 1 $ — $ 348 $ — $ — $ 348 Q1 FY2019 — Q3 2018 Plan 61 618 1,146 — — 1,764 Q2 FY2019 — Q1 2018 Plan 47 902 5,096 — — 5,998 Q2 FY2019 — Q4 2017 Plan 29 255 1,680 — — 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,021 1,321 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 1,631 5,000 33 33 6,697 Q2 FY2018 Q2 FY2018 Q3 2016 Plan 22 41 1,779 — — 1,820 Q4 FY2017 — Q2 2016 Plan 72 561 4,106 — — 4,667 Q3 FY2017 — |
Schedule of Restructuring Reserve by Type of Cost [Table Text Block] | The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during fiscal years 2018, 2017 and 2016 in continuing operations: Balance at January 3, 2016 2016 Charges and Changes in Estimates, Net 2016 Amounts Paid Balance at January 1, 2017 2017 Charges and Changes in Estimates, Net 2017 Amounts Paid Balance at December 31, 2017 2018 Charges and Changes in Estimates, Net 2018 Amounts Paid Balance at December 30, 2018 (In thousands) Severance: Q4 2018 Plan $ — $ — $ — $ — $ — $ — $ — $ 348 $ — $ 348 Q3 2018 Plan — — — — — — — 2,054 (639 ) 1,415 Q1 2018 Plan — — — — — — — 5,998 (4,389 ) 1,609 Q4 2017 Plan (1) — — — — 1,935 (16 ) 1,919 (381 ) (1,538 ) — Q3 2017 Plan (2) — — — — 2,342 (270 ) 2,072 (1,204 ) (868 ) — Q1 2017 Plan (3) — — — — 6,631 (4,133 ) 2,498 (983 ) (1,232 ) 283 Q3 2016 Plan — 1,820 (612 ) 1,208 (202 ) (1,006 ) — — — — Q2 2016 Plan — 4,667 (3,231 ) 1,436 (829 ) (607 ) — 232 (156 ) 76 Facility: Q1 2017 Plan — — — — 66 (33 ) 33 — (33 ) — Previous Plans 22,018 (1,451 ) (12,787 ) 7,780 (537 ) (2,844 ) 4,399 338 (2,425 ) 2,312 Restructuring 22,018 5,036 (16,630 ) 10,424 9,406 (8,909 ) 10,921 6,402 (11,280 ) 6,043 Contract Termination 132 88 (103 ) 117 3,251 (320 ) 3,048 4,742 (7,653 ) 137 Total Restructuring and Contract Termination $ 22,150 $ 5,124 $ (16,733 ) $ 10,541 $ 12,657 $ (9,229 ) $ 13,969 $ 11,144 $ (18,933 ) $ 6,180 ____________________________ (1) During fiscal year 2018 , the Company recognized pre-tax restructuring reversals of $0.2 million each in the Discovery & Analytical Solutions and Diagnostics segments, related to lower than expected costs associated with workforce reductions for the Q4 2017 Plan. (2) During fiscal year 2018 , the Company recognized pre-tax restructuring reversals of $0.8 million in the Discovery & Analytical Solutions segment and $0.4 million in the Diagnostics segment, related to lower than expected costs associated with workforce reductions for the Q3 2017 Plan. (3) During fiscal year 2018 , the Company recognized pre-tax restructuring reversals of $1.0 million in the Discovery & Analytical Solutions segment, related to lower than expected costs associated with workforce reductions for the Q1 2017 Plan. |
Interest and Other Expense (I_2
Interest and Other Expense (Income), Net (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Other Income and Expenses [Abstract] | |
Interest and Other Expense (Income), Net | Interest and other expense, net, consisted of the following for the fiscal years ended: December 30, December 31, January 1, Interest income $ (1,141 ) $ (2,571 ) $ (702 ) Interest expense 66,976 43,940 41,528 (Gain) loss on disposition of businesses and assets, net (see Note 5) (12,844 ) 309 (5,562 ) Other expense (income), net 13,210 (42,781 ) 15,250 Total interest and other expense, net $ 66,201 $ (1,103 ) $ 50,514 |
Income Taxes (Tables)
Income Taxes (Tables) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 30, 2018 | Dec. 31, 2017 | |
Income Tax Disclosure [Abstract] | ||
Summary of Income Tax Contingencies [Table Text Block] | The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) Unrecognized tax benefits, beginning of year $ 30,308 $ 29,607 $ 28,143 Gross increases—tax positions in prior periods 6,931 749 1,514 Gross decreases—tax positions in prior periods (1,622 ) (828 ) (183 ) Gross increases—current-period tax positions — 2,346 3,547 Settlements (2,253 ) (324 ) — Lapse of statute of limitations (181 ) (1,371 ) (4,109 ) Foreign currency translation adjustments (174 ) 129 695 Unrecognized tax benefits, end of year $ 33,009 $ 30,308 $ 29,607 | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | The components of income from continuing operations before income taxes were as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) U.S. $ 32,627 $ 3,743 $ 39,689 Non-U.S. 225,056 292,975 204,379 Total $ 257,683 $ 296,718 $ 244,068 | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | The components of the provision for income taxes on continuing operations were as follows: Current Expense Deferred Expense (Benefit) Total (In thousands) Fiscal year ended December 30, 2018 Federal $ 7,938 $ (5,250 ) $ 2,688 State 2,345 2,572 4,917 Non-U.S. 61,028 (48,425 ) 12,603 Total $ 71,311 $ (51,103 ) $ 20,208 Fiscal year ended December 31, 2017 Federal $ 62,003 $ 35,435 $ 97,438 State 3,332 (792 ) 2,540 Non-U.S. 45,639 (5,789 ) 39,850 Total $ 110,974 $ 28,854 $ 139,828 Fiscal year ended January 1, 2017 Federal $ 14 $ 2,994 $ 3,008 State 2,143 (575 ) 1,568 Non-U.S. 30,754 (6,968 ) 23,786 Total $ 32,911 $ (4,549 ) $ 28,362 | |
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block] | The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) Continuing operations $ 20,208 $ 139,828 $ 28,362 Discontinued operations (1,311 ) 44,522 4,255 Total $ 18,897 $ 184,350 $ 32,617 | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: December 30, December 31, January 1, (In thousands) Tax at statutory rate $ 54,114 $ 103,851 $ 85,424 Non-U.S. rate differential, net (27,281 ) (65,836 ) (52,648 ) U.S. taxation of multinational operations 7,047 5,408 6,941 State income taxes, net 2,028 1,810 1,509 Prior year tax matters (6,034 ) (7,955 ) (9,621 ) Federal tax credits (3,738 ) (8,249 ) (7,189 ) Change in valuation allowance (759 ) 1,951 (2,755 ) Non-deductible acquisition expense — — 5,701 Impact of federal tax reform (2,025 ) 106,538 — Others, net (3,144 ) 2,310 1,000 Total $ 20,208 $ 139,828 $ 28,362 | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 30, 2018 and December 31, 2017 were as follows: December 30, December 31, (In thousands) Deferred tax assets: Inventory $ — $ 6,376 Reserves and accruals 39,487 26,657 Accrued compensation 21,709 17,333 Net operating loss and credit carryforwards 144,421 88,503 Accrued pension 31,146 34,682 Restructuring reserve 1,780 2,586 Deferred revenue 31,045 28,478 Unrealized foreign exchange loss — 10,910 Total deferred tax assets 269,588 215,525 Deferred tax liabilities: Inventory (278 ) — Postretirement health benefits (3,406 ) (3,391 ) Depreciation and amortization (309,958 ) (392,293 ) All other, net (1,879 ) (594 ) Total deferred tax liabilities (315,521 ) (396,278 ) Valuation allowance (102,087 ) (68,895 ) Net deferred tax liabilities $ (148,020 ) $ (249,648 ) | |
Schedule of Deferred Income Taxes, Domestic and Foreign [Table Text Block] | The components of net deferred tax (liabilities) assets as of December 30, 2018 and December 31, 2017 were as follows: December 30, December 31, (In thousands) U.S. $ 52,469 $ 44,974 Non-U.S. (200,489 ) (294,622 ) Total $ (148,020 ) $ (249,648 ) | |
Components of net deferred tax asset recognized [Table Text Block] | The components of net deferred tax liabilities as of December 30, 2018 and December 31, 2017 were recognized in the consolidated balance sheets as follows: December 30, December 31, (In thousands) Other assets, net $ 79,312 $ 67,280 Long-term liabilities (227,332 ) (316,928 ) Total $ (148,020 ) $ (249,648 ) | |
Deferred tax assets, other assets, net | $ 79,312 | $ 67,280 |
Deferred tax liabilities, Long-term liabilities | (227,332) | (316,928) |
Deferred Tax Liabilities, Net | $ (148,020) | $ (249,648) |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Earnings Per Share [Abstract] | |
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations | The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: December 30, December 31, January 1, (In thousands) Number of common shares—basic 110,561 109,857 109,478 Effect of dilutive securities: Stock options 761 708 640 Restricted stock awards 212 294 195 Number of common shares—diluted 111,534 110,859 110,313 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 349 287 458 |
Inventories, Net (Tables)
Inventories, Net (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Inventory Disclosure [Abstract] | |
Schedule of Net Inventories | Inventories as of December 30, 2018 and December 31, 2017 consisted of the following: December 30, December 31, (In thousands) Raw materials $ 119,115 $ 122,100 Work in progress 18,110 18,452 Finished goods 201,122 211,123 Total inventories $ 338,347 $ 351,675 |
Property, Plant and Equipment_2
Property, Plant and Equipment, Net (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Property, Plant and Equipment, Net [Abstract] | |
Property, Plant and Equipment [Table Text Block] | Property, plant and equipment as of December 30, 2018 and December 31, 2017 , consisted of the following: December 30, December 31, (In thousands) At cost: Land $ 5,482 $ 5,624 Building and leasehold improvements 272,277 262,657 Machinery and equipment 402,424 362,638 Total property, plant and equipment 680,183 630,919 Accumulated depreciation (361,593 ) (332,853 ) Total property, plant and equipment, net $ 318,590 $ 298,066 |
Marketable Securities and Inv_2
Marketable Securities and Investments (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Marketable Securities [Abstract] | |
Schedule of Investments, Noncurrent [Table Text Block] | Investments as of December 30, 2018 and December 31, 2017 consisted of the following: December 30, December 31, (In thousands) Marketable securities $ 2,447 $ 2,208 Cost method investments 16,783 10,783 $ 19,230 $ 12,991 |
Available-for-sale Securities [Table Text Block] | Marketable securities classified as available for sale as of December 30, 2018 and December 31, 2017 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) December 30, 2018 Equity securities $ 671 $ 1,037 $ — $ (366 ) Fixed-income securities 22 22 — — Other 1,754 1,817 — (63 ) $ 2,447 $ 2,876 $ — $ (429 ) December 31, 2017 Equity securities $ 811 $ 1,161 $ — $ (350 ) Fixed-income securities 22 22 — — Other 1,375 1,438 — (63 ) $ 2,208 $ 2,621 $ — $ (413 ) |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets, Net (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Changes in the Carrying Amount of Goodwill | The changes in the carrying amount of goodwill for fiscal years 2018 and 2017 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated Balance at January 1, 2017 $ 1,303,936 $ 944,030 $ 2,247,966 Foreign currency translation 37,646 29,091 66,737 Acquisitions, earnouts and other 2,653 684,842 687,495 Balance at December 31, 2017 1,344,235 1,657,963 3,002,198 Foreign currency translation (32,189 ) (35,289 ) (67,478 ) Acquisitions, earnouts and other 22,946 (5,058 ) 17,888 Balance at December 30, 2018 $ 1,334,992 $ 1,617,616 $ 2,952,608 |
Identifiable Intangible Asset Balances | Identifiable intangible asset balances at December 30, 2018 by category and by business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,030 $ 14,616 $ 42,646 Less: Accumulated amortization (25,978 ) (11,775 ) (37,753 ) Net patents 2,052 2,841 4,893 Trade names and trademarks 29,811 48,335 78,146 Less: Accumulated amortization (21,728 ) (12,073 ) (33,801 ) Net trade names and trademarks 8,083 36,262 44,345 Licenses 50,178 3,127 53,305 Less: Accumulated amortization (44,376 ) (1,174 ) (45,550 ) Net licenses 5,802 1,953 7,755 Core technology 240,734 300,177 540,911 Less: Accumulated amortization (189,033 ) (76,711 ) (265,744 ) Net core technology 51,701 223,466 275,167 Customer relationships 222,892 866,635 1,089,527 Less: Accumulated amortization (128,142 ) (165,822 ) (293,964 ) Net customer relationships 94,750 700,813 795,563 IPR&D — 1,360 1,360 Net amortizable intangible assets 162,388 966,695 1,129,083 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 232,972 $ 966,695 $ 1,199,667 Identifiable intangible asset balances at December 31, 2017 by category and business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,048 $ 11,911 $ 39,959 Less: Accumulated amortization (24,448 ) (10,637 ) (35,085 ) Net patents 3,600 1,274 4,874 Trade names and trademarks 29,950 51,024 80,974 Less: Accumulated amortization (20,022 ) (8,228 ) (28,250 ) Net trade names and trademarks 9,928 42,796 52,724 Licenses 43,061 10,239 53,300 Less: Accumulated amortization (34,620 ) (8,015 ) (42,635 ) Net licenses 8,441 2,224 10,665 Core technology 236,324 243,435 479,759 Less: Accumulated amortization (190,423 ) (59,920 ) (250,343 ) Net core technology 45,901 183,515 229,416 Customer relationships 233,573 907,938 1,141,511 Less: Accumulated amortization (116,696 ) (126,144 ) (242,840 ) Net customer relationships 116,877 781,794 898,671 IPR&D — 80,006 80,006 Net amortizable intangible assets 184,747 1,091,609 1,276,356 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 255,331 $ 1,091,609 $ 1,346,940 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Debt Disclosure [Abstract] | |
Schedule of Maturities of Long-term Debt [Table Text Block] | The following table summarizes the maturities of the Company’s indebtedness as of December 30, 2018 : Sr. Unsecured Revolving Credit Facility Maturing 2021 November 2021 Notes April 2021 Notes 2026 Notes Other Debt Facilities Financing Lease Obligations Total (In thousands) 2019 $ — $ — $ — $ — $ 13,324 $ 1,532 $ 14,856 2020 — — — — 8,527 1,597 10,124 2021 418,000 500,000 343,410 — 8,197 1,665 1,271,272 2022 — — — — 3,907 1,657 5,564 2023 — — — — 2,641 1,681 4,322 2024 and thereafter — — — 572,350 1,574 4,698 578,622 Total before unamortized discount and debt issuance costs and non-cash finance lease liabilities 418,000 500,000 343,410 572,350 38,170 12,830 1,884,760 Unamortized discount and debt issuance costs (2,401 ) (2,628 ) (2,133 ) (7,806 ) — — (14,968 ) Non-cash finance lease liabilities — — — — — 21,688 21,688 Total $ 415,599 $ 497,372 $ 341,277 $ 564,544 $ 38,170 $ 34,518 $ 1,891,480 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Accounts Payable and Accrued Liabilities, Current [Abstract] | |
Schedule of Accrued Liabilities [Table Text Block] | Accrued expenses and other current liabilities as of December 30, 2018 and December 31, 2017 consisted of the following: December 30, December 31, (In thousands) Payroll and incentives $ 86,549 $ 66,955 Employee benefits 44,060 37,354 Deferred revenue 155,064 159,923 Federal, non-U.S. and state income taxes 30,687 10,800 Other accrued operating expenses 212,467 225,610 Total accrued expenses and other current liabilities $ 528,827 $ 500,642 |
Employee Benefit Plans (Tables)
Employee Benefit Plans (Tables) | 12 Months Ended | |
Dec. 30, 2018 | Dec. 31, 2017 | |
Pension Plans, Defined Benefit | ||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||
Components of Net Periodic Benefit Cost (Credit) | Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended: December 30, December 31, January 1, (In thousands) Service and administrative costs $ 6,853 $ 4,951 $ 4,337 Interest cost 16,146 16,707 18,638 Expected return on plan assets (28,939 ) (26,401 ) (24,245 ) Actuarial loss (gain) 17,146 (7,085 ) 15,890 Amortization of prior service cost 375 (195 ) (210 ) Net periodic pension cost (credit) $ 11,581 $ (12,023 ) $ 14,410 | |
Schedule of Net Funded Status | The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 30, 2018 and December 31, 2017 . December 30, 2018 December 31, 2017 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 304,065 $ 283,310 $ 334,151 $ 308,713 Change in benefit obligations: Projected benefit obligations at beginning of year $ 343,410 $ 308,713 $ 279,522 $ 300,650 Service and administrative costs 4,528 2,325 2,201 2,750 Interest cost 5,484 10,662 4,870 11,836 Benefits paid and plan expenses (13,081 ) (19,709 ) (13,238 ) (20,032 ) Participants’ contributions 176 — 189 — Business acquisition 537 — 39,293 — Plan amendments 533 — — — Actuarial (gain) loss (13,141 ) (18,681 ) (1,486 ) 13,509 Effect of exchange rate changes (17,278 ) — 32,059 — Projected benefit obligations at end of year $ 311,168 $ 283,310 $ 343,410 $ 308,713 Change in plan assets: Fair value of plan assets at beginning of year $ 179,736 $ 253,427 $ 153,281 $ 243,817 Actual return on plan assets (5,653 ) (14,376 ) 15,866 29,642 Benefits paid and plan expenses (13,081 ) (19,709 ) (13,238 ) (20,032 ) Employer’s contributions 8,480 15,000 8,422 — Participants’ contributions 176 — 189 — Effect of exchange rate changes (10,495 ) — 15,216 — Fair value of plan assets at end of year $ 159,163 $ 234,342 $ 179,736 $ 253,427 Net liabilities recognized in the consolidated balance sheets $ (152,005 ) $ (48,968 ) $ (163,674 ) $ (55,286 ) Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 31,419 $ — $ 26,591 $ — Current liabilities (6,752 ) — (7,017 ) — Long-term liabilities (176,672 ) (48,968 ) (183,248 ) (55,286 ) Net liabilities recognized in the consolidated balance sheets $ (152,005 ) $ (48,968 ) $ (163,674 ) $ (55,286 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ (278 ) $ — $ (457 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 2.07 % 4.05 % 1.99 % 3.56 % Rate of compensation increase 3.48 % None 3.50 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: December 30, 2018 December 31, 2017 January 1, 2017 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 1.99 % 3.56 % 2.06 % 4.06 % 2.88 % 4.25 % Rate of compensation increase 3.50 % None 3.64 % None 3.26 % None Expected rate of return on assets 5.90 % 7.25 % 6.00 % 7.25 % 5.30 % 7.25 % | |
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] | The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: December 30, December 31, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 183,424 $ 190,265 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 180,560 $ 187,329 Fair value of plan assets — — | |
Schedule of Allocation of Plan Assets | Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 30, 2018 and December 31, 2017 , and target asset allocations for fiscal year 2019 are as follows: Target Allocation Percentage of Plan Assets at December 29, 2019 December 30, 2018 December 31, 2017 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 45-55% 35-50% 48 % 39 % 51 % 41 % Debt securities 45-55% 50-65% 51 % 61 % 49 % 59 % Other 0-5% 0-10% 1 % — % 0 % — % Total 100 % 100 % 100 % 100 % 100 % 100 % | |
Schedule of Changes in Fair Value of Plan Assets | The fair values of the Company’s pension plan assets as of December 30, 2018 and December 31, 2017 by asset category, classified in the three levels of inputs described in Note 23 to the consolidated financial statements are as follows: Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,326 $ 6,326 $ — $ — Equity securities: U.S. large-cap 35,072 35,072 — — International large-cap value 24,175 24,175 — — U.S. small mid-cap 1,928 1,928 — — Emerging markets growth 11,993 11,993 — — Equity index funds 54,342 — 54,342 — Domestic real estate funds 1,353 1,353 — — Foreign real estate funds 22,196 — — 22,196 Commodity funds 886 886 — — Fixed income securities: Non-U.S. treasury securities 23,352 — 23,352 — Corporate and U.S. debt instruments 131,211 48,133 83,078 — Corporate bonds 24,848 — 24,848 — High yield bond funds 5,186 5,186 — — Other types of investments: Multi-strategy hedge funds 16,934 — — 16,934 Non-U.S. government index linked bonds 33,703 — 33,703 — Total assets measured at fair value $ 393,505 $ 135,052 $ 219,323 $ 39,130 Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 4,307 $ 4,307 $ — $ — Equity Securities: U.S. large-cap 30,008 30,008 — — International large-cap value 32,613 32,613 — — U.S. small-cap 2,104 2,104 — — Emerging markets growth 14,348 14,348 — — Equity index funds 90,838 — 90,838 — Domestic real estate funds 1,401 1,401 — — Commodity funds 7,387 7,387 — — Fixed income securities: Non-U.S. Treasury Securities 24,946 — 24,946 — Corporate and U.S. debt instruments 138,948 40,290 98,658 — Corporate bonds 27,571 — 27,571 — High yield bond funds 5,912 5,912 — — Other types of investments: Multi-strategy hedge funds 16,789 — — 16,789 Non-U.S. government index linked bonds 35,991 — 35,991 — Total assets measured at fair value $ 433,163 $ 138,370 $ 278,004 $ 16,789 | |
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets | A reconciliation of the beginning and ending Level 3 assets for fiscal years 2018, 2017 and 2016 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Venture Capital Funds Foreign Real Estate Funds Multi-strategy Hedge Funds Total (In thousands) Balance at January 3, 2016 $ 1 $ — $ 23,415 $ 23,416 Realized losses (1 ) — — (1 ) Unrealized gains — — 375 375 Balance at January 1, 2017 — — 23,790 23,790 Sales — — (8,189 ) (8,189 ) Realized gains — — 1,542 1,542 Unrealized losses — — (354 ) (354 ) Balance at December 31, 2017 — — 16,789 16,789 Purchases — 22,196 — 22,196 Unrealized gains — — 145 145 Balance at December 30, 2018 $ — $ 22,196 $ 16,934 $ 39,130 | |
Schedule of Expected Benefit Payments | The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2019 $ 11,313 $ 18,774 2020 11,654 18,948 2021 12,200 19,176 2022 12,267 19,353 2023 12,551 19,462 2024-2028 67,457 95,403 | |
Other Postretirement Benefit Plans, Defined Benefit [Member] | ||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||
Components of Net Periodic Benefit Cost (Credit) | Net periodic postretirement medical benefit cost (credit) included the following components for the fiscal years ended: December 30, December 31, January 1, (In thousands) Service cost $ 106 $ 92 $ 101 Interest cost 120 125 142 Expected return on plan assets (1,254 ) (1,114 ) (1,035 ) Actuarial loss (gain) 1,621 (741 ) (539 ) Net periodic postretirement medical benefit cost (credit) $ 593 $ (1,638 ) $ (1,331 ) | |
Schedule of Net Funded Status | The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 30, 2018 and December 31, 2017 . December 30, December 31, (In thousands) Actuarial present value of benefit obligations: Retirees $ 688 $ 804 Active employees eligible to retire 408 379 Other active employees 2,317 1,948 Accumulated benefit obligations at beginning of year 3,413 3,131 Service cost 106 92 Interest cost 120 125 Benefits paid (117 ) (122 ) Actuarial (gain) loss (611 ) 187 Change in accumulated benefit obligations during the year (502 ) 282 Retirees 583 688 Active employees eligible to retire 362 408 Other active employees 1,966 2,317 Accumulated benefit obligations at end of year $ 2,911 $ 3,413 Change in plan assets: Fair value of plan assets at beginning of year $ 17,374 $ 15,453 Actual return on plan assets (993 ) 1,921 Benefits reimbursements paid (102 ) — Fair value of plan assets at end of year $ 16,279 $ 17,374 Net assets recognized in the consolidated balance sheets $ 13,368 $ 13,961 Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 13,368 $ 13,961 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 4.09 % 3.60 % Actuarial assumptions used to determine net cost during the year are as follows: December 30, December 31, January 1, Discount rate 3.60 % 4.11 % 4.34 % Expected rate of return on assets 7.25 % 7.25 % 7.25 % | |
Schedule of Changes in Fair Value of Plan Assets | The fair values of the Company’s plan assets at December 30, 2018 and December 31, 2017 by asset category, classified in the three levels of inputs described in Note 23, are as follows: Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 390 $ 390 $ — $ — Equity securities: U.S. large-cap 2,436 2,436 — — International large-cap value 1,679 1,679 — — U.S. small mid-cap 134 134 — — Emerging markets growth 833 833 — — Domestic real estate funds 94 94 — — Commodity funds 62 62 — — Fixed income securities: Corporate debt instruments 9,115 3,344 5,771 — High yield bond funds 360 360 — — Other types of investments: Multi-strategy hedge funds 1,176 — — 1,176 Total assets measured at fair value $ 16,279 $ 9,332 $ 5,771 $ 1,176 Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 268 $ 268 $ — $ — Equity securities: U.S. large-cap 2,057 2,057 — — International large-cap value 2,236 2,236 — — U.S. small mid-cap 144 144 — — Emerging markets growth 984 984 — — Domestic real estate funds 96 96 — — Commodity funds 506 506 — — Fixed income securities: Corporate debt instruments 9,526 2,762 6,764 — High yield bond funds 406 406 — — Other types of investments: Multi-strategy hedge funds 1,151 — — 1,151 Total assets measured at fair value $ 17,374 $ 9,459 $ 6,764 $ 1,151 | |
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets | A reconciliation of the beginning and ending Level 3 assets for fiscal years 2018, 2017 and 2016 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Multi-strategy Hedge Funds (In thousands) Balance at January 3, 2016 $ 1,374 Unrealized gains 134 Balance at January 1, 2017 1,508 Sales (562 ) Realized gains 229 Unrealized losses (24 ) Balance at December 31, 2017 1,151 Unrealized gains 25 Balance at December 30, 2018 $ 1,176 | |
Schedule of Expected Benefit Payments | The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2019 $ 136 2020 149 2021 168 2022 184 2023 194 2024-2028 1,050 |
Warranty Reserves (Tables)
Warranty Reserves (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Product Warranties Disclosures [Abstract] | |
Warranty Reserve Activity | A summary of warranty reserve activity for the fiscal years ended December 30, 2018 , December 31, 2017 and January 1, 2017 is as follows: (In thousands) Balance at January 3, 2016 $ 9,843 Provision charged to income 14,901 Payments (14,749 ) Adjustments to previously provided warranties, net (850 ) Foreign currency translation and acquisitions (133 ) Balance at January 1, 2017 9,012 Provision charged to income 13,700 Payments (14,245 ) Adjustments to previously provided warranties, net (815 ) Foreign currency translation and acquisitions 1,398 Balance at December 31, 2017 9,050 Provision charged to income 13,545 Payments (13,775 ) Adjustments to previously provided warranties, net (157 ) Foreign currency translation and acquisitions (270 ) Balance at December 30, 2018 $ 8,393 |
Stock Plans (Tables)
Stock Plans (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Summary of Total Compensation Recognized Related to Outstanding Equity Awards | The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2018, 2017 and 2016 : December 30, December 31, January 1, (In thousands) Cost of product and service revenue $ 1,466 $ 1,254 $ 1,031 Research and development expenses 1,359 1,389 902 Selling, general and administrative expenses 25,942 22,778 15,225 Total stock-based compensation expense $ 28,767 $ 25,421 $ 17,158 |
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model | The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: December 30, December 31, January 1, Risk-free interest rate 3.0 % 2.0 % 1.7 % Expected dividend yield 0.4 % 0.4 % 0.6 % Expected lives 5 years 5 years 5 years Expected stock volatility 20.7 % 22.4 % 25.2 % |
Summary of Stock Option Activity | The following table summarizes stock option activity for the fiscal year ended December 30, 2018 : December 30, 2018 Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 2,154 $ 42.77 Granted 364 77.84 Exercised (709 ) 35.02 Forfeited (44 ) 51.56 Outstanding at end of year 1,765 $ 52.91 Exercisable at end of year 965 $ 44.60 |
Summary of Restricted Stock Award Activity | The following table summarizes restricted stock award activity for the fiscal year ended December 30, 2018 : December 30, 2018 Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 496 $ 50.30 Granted 214 76.00 Vested (206 ) 50.37 Forfeited (39 ) 55.73 Nonvested at end of year 465 $ 61.72 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Stockholders' Equity Note [Abstract] | |
Components of Accumulated Other Comprehensive Loss | The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, January 3, 2016 $ (46,846 ) $ 1,259 $ (369 ) $ (45,956 ) Current year change (54,077 ) (860 ) 32 (54,905 ) Balance, January 1, 2017 (100,923 ) 399 (337 ) (100,861 ) Current year change 54,341 (77 ) 79 54,343 Balance, December 31, 2017 (46,582 ) 322 (258 ) (46,518 ) Current year change (123,388 ) (77 ) (9 ) (123,474 ) Reclassification to retained earnings upon adoption of ASU 2018-02 (see Note 1) (6,489 ) — — (6,489 ) Balance, December 30, 2018 $ (176,459 ) $ 245 $ (267 ) $ (176,481 ) |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Fair Value Disclosures [Abstract] | |
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis | The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 30, 2018 and December 31, 2017 classified in one of the three classifications described above: Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,447 $ 2,447 $ — $ — Foreign exchange derivative assets 750 — 750 — Foreign exchange derivative liabilities (594 ) — (594 ) — Contingent consideration (69,661 ) — — (69,661 ) Fair Value Measurements at December 31, 2017 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,208 $ 2,208 $ — $ — Foreign exchange derivative assets 1,431 — 1,431 — Foreign exchange derivative liabilities, net (23,638 ) — (23,638 ) — Contingent consideration (65,328 ) — — (65,328 ) |
Reconciliation of Beginning and Ending Level 3 Net Liabilities | A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at January 3, 2016 $ (57,350 ) Additions — Amounts paid and foreign currency translation 332 Reclassified to other current liabilities for milestone achieved 10,000 Change in fair value (included within selling, general and administrative expenses) (16,183 ) Balance at January 1, 2017 (63,201 ) Additions — Amounts paid and foreign currency translation 34 Change in fair value (included within selling, general and administrative expenses) (2,161 ) Balance at December 31, 2017 (65,328 ) Additions (6,200 ) Amounts paid and foreign currency translation 16,507 Change in fair value (included within selling, general and administrative expenses) (14,640 ) Balance at December 30, 2018 $ (69,661 ) |
Industry Segment and Geograph_2
Industry Segment and Geographic Area Information (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Segment Reporting [Abstract] | |
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations | Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: December 30, December 31, January 1, (In thousands) Discovery & Analytical Solutions Product revenue $ 1,010,899 $ 941,328 $ 934,098 Service revenue 682,312 637,131 578,886 Total revenue 1,693,211 1,578,459 1,512,984 Operating income from continuing operations (1) 230,481 205,259 196,508 Diagnostics Product revenue 924,594 536,086 462,798 Service revenue 160,191 142,437 139,735 Total revenue 1,084,785 678,523 602,533 Operating income from continuing operations (2) 153,196 146,862 147,996 Corporate Operating loss from continuing operations (59,793 ) (56,506 ) (49,922 ) Continuing Operations Product revenue 1,935,493 1,477,414 1,396,896 Service revenue 842,503 779,568 718,621 Total revenue 2,777,996 2,256,982 2,115,517 Operating income from continuing operations 323,884 295,615 294,582 Interest and other expense, net (see Note 7) 66,201 (1,103 ) 50,514 Income from continuing operations before income taxes $ 257,683 $ 296,718 $ 244,068 ____________________________ (1) Legal costs for significant litigation matters in the Company's Discovery & Analytical Solutions segment were $5.3 million for fiscal year 2018 and $2.7 million for fiscal year 2017. (2) Legal costs for a significant litigation matter in the Company's Diagnostics segment were $0.2 million for fiscal year 2018 . |
Schedule of Depreciation, Amortization and Capital Expenditures | Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 30, 2018 : Depreciation and Amortization Expense Capital Expenditures December 30, December 31, January 1, December 30, December 31, January 1, (In thousands) (In thousands) Discovery & Analytical Solutions $ 70,362 $ 72,590 $ 72,484 $ 34,852 $ 26,200 $ 21,486 Diagnostics 107,434 31,204 25,339 54,737 11,262 8,556 Corporate 2,792 1,206 2,149 3,664 1,627 1,660 Continuing operations $ 180,588 $ 105,000 $ 99,972 $ 93,253 $ 39,089 $ 31,702 Discontinued operations $ — $ 929 $ 6,266 $ — $ 182 $ 1,302 |
Schedule of Total Assets by Segment | Total Assets December 30, December 31, January 1, (In thousands) Discovery & Analytical Solutions $ 2,567,054 $ 2,611,737 $ 2,612,757 Diagnostics 3,358,964 3,447,437 1,505,381 Corporate 49,504 32,289 31,171 Current and long-term assets of discontinued operations — — 127,374 Total assets $ 5,975,522 $ 6,091,463 $ 4,276,683 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 30, 2018 and net long-lived assets based on physical location as of December 30, 2018 and December 31, 2017 : Revenue December 30, December 31, January 1, (In thousands) U.S. $ 906,398 $ 837,018 $ 842,364 International: China 559,865 374,931 336,728 United Kingdom 72,124 65,164 65,904 Germany 142,411 91,669 89,839 India 92,327 84,812 43,891 Italy 95,908 77,477 70,948 France 97,990 80,153 71,104 Japan 79,238 76,322 65,980 Other international 731,735 569,436 528,759 Total international 1,871,598 1,419,964 1,273,153 Total sales $ 2,777,996 $ 2,256,982 $ 2,115,517 Net Long-Lived Assets December 30, December 31, January 1, (In thousands) U.S. $ 201,649 $ 210,116 $ 182,186 International: Germany 99,181 88,249 1,292 China 61,261 64,815 36,458 United Kingdom 33,429 28,028 14,638 India 14,636 14,820 2,020 Finland 16,211 14,764 12,295 Italy 11,324 10,334 3,398 Singapore 14,942 9,240 6,820 Brazil 8,237 7,963 1,452 Netherlands 3,750 4,281 4,162 Sweden 3,038 3,869 2,645 Other international 22,653 19,565 7,684 Total international 288,662 265,928 92,864 Total net long-lived assets $ 490,311 $ 476,044 $ 275,050 |
Quarterly Financial Informati_2
Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended |
Dec. 30, 2018 | |
Quarterly Financial Information Disclosure [Abstract] | |
Schedule of Quarterly Financial Information | Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) December 30, 2018 Revenue $ 643,972 $ 703,362 $ 674,313 $ 756,349 $ 2,777,996 Gross profit 292,222 340,140 332,327 376,250 1,340,939 Restructuring and contract termination charges, net 6,578 — 6,508 (1,942 ) 11,144 Operating income from continuing operations 39,935 88,064 80,202 115,683 323,884 Income from continuing operations before income taxes 28,505 71,708 78,041 79,429 257,683 Income from continuing operations 26,035 64,673 75,445 71,322 237,475 Loss (income) from discontinued operations and dispositions (11 ) (610 ) 1,103 (30 ) 452 Net income 26,024 64,063 76,548 71,292 237,927 Basic earnings per share: Income from continuing operations $ 0.24 $ 0.59 $ 0.68 $ 0.64 $ 2.15 Income (loss) from discontinued operations and dispositions — (0.01 ) 0.01 — — Net income 0.24 0.58 0.69 0.64 2.15 Diluted earnings per share: Income from continuing operations $ 0.23 $ 0.58 $ 0.68 $ 0.64 $ 2.13 Income (loss) from discontinued operations and dispositions — (0.01 ) 0.01 — — Net income 0.23 0.57 0.69 0.64 2.13 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 December 31, 2017 Revenue $ 514,115 $ 546,962 $ 554,275 $ 641,630 $ 2,256,982 Gross profit 239,756 257,602 268,967 307,429 1,073,754 Restructuring and contract termination charges, net 9,651 — 3,269 (263 ) 12,657 Operating income from continuing operations 49,811 74,183 78,038 93,583 295,615 Income from continuing operations before income taxes 39,983 70,792 105,054 80,889 296,718 Income (loss) from continuing operations 36,062 62,726 96,546 (38,444 ) 156,890 Income (loss) from discontinued operations and dispositions 2,541 141,343 (5,468 ) (2,673 ) 135,743 Net income (loss) 38,603 204,069 91,078 (41,117 ) 292,633 Basic earnings per share: Income (loss) from continuing operations $ 0.33 $ 0.57 $ 0.88 $ (0.35 ) $ 1.43 Income (loss) from discontinued operations and dispositions 0.02 1.29 (0.05 ) (0.02 ) 1.24 Net income (loss) 0.35 1.86 0.83 (0.37 ) 2.67 Diluted earnings per share: Income (loss) continuing operations $ 0.33 $ 0.57 $ 0.87 $ (0.35 ) $ 1.42 Income (loss) from discontinued operations and dispositions 0.02 1.28 (0.05 ) (0.02 ) 1.22 Net income (loss) 0.35 1.84 0.82 (0.37 ) 2.64 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. |
Nature of Operations and Acco_3
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details) | 12 Months Ended | ||||||
Dec. 29, 2019 | Dec. 30, 2018USD ($)plansegments | Dec. 31, 2017USD ($) | Jan. 01, 2017USD ($) | Dec. 31, 2018USD ($) | Jan. 01, 2018USD ($) | Jan. 03, 2016USD ($) | |
Number of Stock-based Compensation Plans | plan | 1 | ||||||
Number of Operating Segments | segments | 2 | ||||||
Operating Cycle | 52 | ||||||
License and services revenue as a percentage of total revenue | 4.15% | 4.50% | |||||
Defined Benefit Plan, Other Cost (Credit) | $ 11,500,000 | $ (9,200,000) | $ 11,500,000 | ||||
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | (8,004,000) | 21,703,000 | (13,422,000) | ||||
Restricted Cash | 3,204,000 | 236,000 | 17,303,000 | ||||
Accounting Standards Update 2018-02 [Member] | |||||||
Cumulative Effect of New Accounting Principle in Period of Adoption | 6,500,000 | ||||||
Accounting Standards Update 2017-07 [Member] | |||||||
Defined Benefit Plan, Other Cost (Credit) | (9,200,000) | 11,500,000 | |||||
Accounting Standards Update 2016-18 [Member] | |||||||
Increase (Decrease) in Restricted Cash | (17,218,000) | 16,959,000 | |||||
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 200,000 | ||||||
Restricted Cash | $ 236,000 | $ 17,303,000 | $ 338,000 | ||||
Accounting Standards Update 2016-16 [Member] | |||||||
Cumulative Effect of New Accounting Principle in Period of Adoption | $ 2,100,000 | ||||||
Impact of New Accounting Principles, Deferred Tax Assets | 10,700,000 | ||||||
Impact of New Accounting Principles, Prepaid Taxes | (12,800,000) | ||||||
Accounting Standards Update 2016-02 [Member] | |||||||
Cumulative Effect of New Accounting Principle in Period of Adoption | $ (19,100,000) | ||||||
Impact of New Accounting Principle, Right-of-use Asset | 190,700,000 | ||||||
Impact of New Accounting Principle, Lease Liabilities | (137,700,000) | ||||||
Impact of New Accounting Principle, Property and Equipment | (31,900,000) | ||||||
Tax Impact of Cumulative Adjustments, Deferred Tax Liabilities | $ (2,100,000) | ||||||
Accounting Standards Update 2014-09 [Member] | |||||||
Cumulative Effect of New Accounting Principle in Period of Adoption | $ 10,209,000 | 10,200,000 | |||||
Tax impact of Cumulative Adjustments, Deferred Income Tax | 3,000,000 | ||||||
Impact of New Accounting Principle, Deferred Revenue | (11,500,000) | ||||||
Accounting Standards Update 2014-09 [Member] | |||||||
Impact of New Accounting Principle, Cash Flows | $ 0 | ||||||
Minimum [Member] | Building [Member] | |||||||
Property, Plant and Equipment, Useful Life, Maximum | 10 years | ||||||
Minimum [Member] | Tools, Dies and Molds [Member] | |||||||
Property, Plant and Equipment, Useful Life, Maximum | 3 years | ||||||
Maximum [Member] | Building [Member] | |||||||
Property, Plant and Equipment, Useful Life, Maximum | 40 years | ||||||
Maximum [Member] | Machinery and Equipment [Member] | |||||||
Property, Plant and Equipment, Useful Life, Maximum | 8 years | ||||||
Scenario, Forecast [Member] | |||||||
Operating Cycle | 52 |
Revenue (Details)
Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 01, 2018 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 2,777,996 | $ 2,256,982 | $ 2,115,517 | |
Contract with Customer, Asset and Liability [Abstract] | ||||
Contract with Customer, Asset, Net, Current | 31,900 | $ 22,700 | ||
Contract with Customer, Liability, Current | 30,800 | $ 29,000 | ||
Contract with Customer, Liability, Revenue Recognized | (21,800) | |||
Increase (Decrease) in Unbilled Receivables | 31,100 | |||
Unbilled Receivables Transferred To Accounts Receivables | (21,900) | |||
Contract with Customer, Liability, Increase (Decrease) | 23,600 | |||
Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 2,202,043 | |||
Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 575,953 | |||
Americas [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,065,122 | |||
Europe [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 778,092 | |||
Asia [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 934,782 | |||
Discovery & Analytical Solutions [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,693,211 | 1,578,459 | 1,512,984 | |
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,199,255 | |||
Discovery & Analytical Solutions [Member] | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 493,956 | |||
Discovery & Analytical Solutions [Member] | Americas [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 680,117 | |||
Discovery & Analytical Solutions [Member] | Europe [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 494,707 | |||
Discovery & Analytical Solutions [Member] | Asia [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 518,387 | |||
Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,084,785 | $ 678,523 | $ 602,533 | |
Diagnostics [Member] | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,002,788 | |||
Diagnostics [Member] | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 81,997 | |||
Diagnostics [Member] | Americas [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 385,005 | |||
Diagnostics [Member] | Europe [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 283,385 | |||
Diagnostics [Member] | Asia [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 416,395 | |||
Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,084,785 | |||
Diagnostics [Member] | Discovery & Analytical Solutions [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | |||
Diagnostics [Member] | Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,084,785 | |||
Life Sciences [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 934,690 | |||
Life Sciences [Member] | Discovery & Analytical Solutions [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 934,690 | |||
Life Sciences [Member] | Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | |||
Applied Markets [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 758,521 | |||
Applied Markets [Member] | Discovery & Analytical Solutions [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 758,521 | |||
Applied Markets [Member] | Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 0 |
Business Combinations and Ass_3
Business Combinations and Asset Purchases (Narrative) (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 | |
Business Acquisition [Line Items] | ||||||||||||
Revenue | $ 756,349,000 | $ 674,313,000 | $ 703,362,000 | $ 643,972,000 | $ 641,630,000 | $ 554,275,000 | $ 546,962,000 | $ 514,115,000 | $ 2,777,996,000 | $ 2,256,982,000 | ||
Business Combination, Contingent Consideration, Liability, Current | (67,000,000) | (52,200,000) | (67,000,000) | (52,200,000) | ||||||||
Business Combination, Contingent Consideration, Liability, Noncurrent | 2,700,000 | 13,100,000 | 2,700,000 | 13,100,000 | ||||||||
Business Combination, Contingent Consideration, Liability, Total | 69,661,000 | 65,300,000 | $ 69,661,000 | 65,300,000 | ||||||||
Business Combination, Contingent Consideration Arrangements, Maximum Period | 1 year 9 months 11 days | |||||||||||
Business Combination, Contingent Consideration Arrangements, Description | Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). The expected maximum earnout period for an acquisition with open contingency period do not exceed 1.75 years from the acquisition date, and the remaining weighted average expected earnout period at December 31, 2017 was 11 months. | |||||||||||
Goodwill | 2,952,608,000 | $ 3,002,198,000 | $ 2,952,608,000 | 3,002,198,000 | $ 2,247,966,000 | |||||||
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions | 1 year | |||||||||||
Business Combination, Contingent Consideration Arrangements, Weighted Average Period | 5 years | |||||||||||
Business Combination, Acquisition Related Costs | $ 15,800,000 | (8,500,000) | 1,200,000 | |||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 76,500,000 | 76,500,000 | ||||||||||
Foreign Currency Transaction Gain (Loss), before Tax | 9,400,000 | 29,200,000 | 1,500,000 | |||||||||
Interest Expense | 66,976,000 | $ 43,940,000 | 41,528,000 | |||||||||
Fiscal Year 2018 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 6,522,000 | 6,522,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (461,000) | (461,000) | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 1,166,000 | 1,166,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 891,000 | 891,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 104,892,000 | 104,892,000 | ||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 95,950,000 | |||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 3,354,000 | |||||||||||
Weighted average amortization period (in years) | 11 years 2 months | |||||||||||
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value | $ (6,200,000) | |||||||||||
Goodwill | 59,647,000 | 59,647,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (3,860,000) | (3,860,000) | ||||||||||
Working capital and other adjustments | 520,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (4,304,000) | (4,304,000) | ||||||||||
Cash Acquired | (1,132,000) | |||||||||||
Business Combination, Consideration Transferred | 104,892,000 | |||||||||||
Interest Expense | 710,000 | |||||||||||
Tulip Diagnostics Private Limited [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Weighted average amortization period (in years) | 11 years 9 months | |||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 127,280,000 | |||||||||||
Compensation Expense, Excluding Cost of Good and Service Sold | (6,900,000) | $ (14,900,000) | ||||||||||
Foreign Currency Transaction Gain (Loss), before Tax | 700,000 | |||||||||||
EUROIMMUM [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 99.98% | 99.98% | ||||||||||
Business Acquisition, Pro Forma Revenue | $ 2,562,580,000 | 2,379,176,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | $ 121,174,000 | 121,174,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (100,020,000) | (100,020,000) | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 109,859,000 | 109,859,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 71,621,000 | 71,621,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 1,388,095,000 | 1,388,095,000 | ||||||||||
Intangible Assets, Gross (Excluding Goodwill) | 907,400,000 | 907,400,000 | ||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 1,413,113,000 | |||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 0 | |||||||||||
Weighted average amortization period (in years) | 16 years 1 month | |||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | $ 13,500,000 | |||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | (1,000,000) | |||||||||||
Business Acquisition, Transaction Costs | 9,800,000 | 9,800,000 | ||||||||||
Goodwill | 591,304,000 | 591,304,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (251,886,000) | (251,886,000) | ||||||||||
Working capital and other adjustments | 0 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (61,357,000) | (61,357,000) | ||||||||||
Cash Acquired | (25,018,000) | |||||||||||
Business Combination, Consideration Transferred | 1,388,095,000 | |||||||||||
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax | $ 143,459,000 | $ 156,210,000 | ||||||||||
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ 1.31 | $ 1.43 | ||||||||||
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ 1.29 | $ 1.42 | ||||||||||
Foreign Currency Transaction Gain (Loss), before Tax | 35,600,000 | |||||||||||
Business Combination, Increase (Decrease) in Liabilities Assumed | 12,300,000 | |||||||||||
Business Combination, Increase (Decrease) in Deferred Tax Liabilities | (23,605,000) | |||||||||||
Goodwill, Purchase Accounting Adjustments | (23,505,000) | |||||||||||
Business Combination, Increase (Decrease) in Other Assets | 21,677,000 | |||||||||||
Business Combination, Increase (Decrease) in Property and Equipment | (20,100,000) | |||||||||||
Business Combination, Increase (Decrease) in Intangible Assets | 10,000,000 | |||||||||||
Fiscal Year 2017 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 142,041,000 | |||||||||||
Interest Expense | 259,000 | |||||||||||
Fiscal Year 2017 Other Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Aggregate Revenue from Immaterial Acquisitions | 38,500,000 | |||||||||||
Operating Income (Loss) From Immaterial Acquisitions | 0 | 0 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 16,268,000 | 16,268,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (8,328,000) | (8,328,000) | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 11,356,000 | 11,356,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 1,691,000 | 1,691,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 139,602,000 | 139,602,000 | ||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 140,861,000 | |||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | 1,273,000 | |||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 14,700,000 | |||||||||||
Goodwill | 75,250,000 | 75,250,000 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (15,735,000) | (15,735,000) | ||||||||||
Working capital and other adjustments | (93,000) | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | 0 | 0 | ||||||||||
Cash Acquired | (2,439,000) | |||||||||||
Business Combination, Consideration Transferred | 139,602,000 | |||||||||||
2016 Acquisitions (excluding Bioo) [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 8,800,000 | |||||||||||
Fiscal Year 2016 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 7,153,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (1,985,000) | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 7,542,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 70,084,000 | |||||||||||
Intangible Assets, Gross (Excluding Goodwill) | 22,100,000 | |||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | $ 72,497,000 | |||||||||||
Weighted average amortization period (in years) | 9 years 5 months | |||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 72,300,000 | |||||||||||
Goodwill | 43,072,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (7,768,000) | |||||||||||
Working capital and other adjustments | (261,000) | |||||||||||
Cash Acquired | (2,152,000) | |||||||||||
Business Combination, Consideration Transferred | 70,084,000 | |||||||||||
Bioo Scientific Corporation [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 63,500,000 | |||||||||||
Vanadis Diagnostics AB [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value | (63,200,000) | $ 56,878,000 | ||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 93,000,000 | |||||||||||
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 34,021,000 | 34,021,000 | ||||||||||
Core Technology [Member] | EUROIMMUM [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 160,000,000 | 160,000,000 | ||||||||||
Core Technology [Member] | Fiscal Year 2017 Other Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 12,400,000 | 12,400,000 | ||||||||||
Core Technology [Member] | Fiscal Year 2016 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 6,600,000 | |||||||||||
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 1,070,000 | 1,070,000 | ||||||||||
Trade Names [Member] | EUROIMMUM [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 36,000,000 | 36,000,000 | ||||||||||
Trade Names [Member] | Fiscal Year 2017 Other Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 3,000,000 | 3,000,000 | ||||||||||
Trade Names [Member] | Fiscal Year 2016 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 570,000 | |||||||||||
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 10,200,000 | 10,200,000 | ||||||||||
Customer Relationships [Member] | EUROIMMUM [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 710,000,000 | 710,000,000 | ||||||||||
Customer Relationships [Member] | Fiscal Year 2017 Other Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 43,700,000 | 43,700,000 | ||||||||||
Customer Relationships [Member] | Fiscal Year 2016 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 14,900,000 | |||||||||||
In Process Research and Development [Member] | EUROIMMUM [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 1,400,000 | 1,400,000 | ||||||||||
In Process Research and Development [Member] | Fiscal Year 2017 Other Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 0 | 0 | ||||||||||
Diagnostics [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Goodwill | 1,617,616,000 | 1,657,963,000 | 1,617,616,000 | 1,657,963,000 | 944,030,000 | |||||||
Discovery & Analytical Solutions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Goodwill | 1,334,992,000 | 1,344,235,000 | 1,334,992,000 | 1,344,235,000 | $ 1,303,936,000 | |||||||
Euro Member Countries, Euro | EUROIMMUM [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 1,200,000,000 | |||||||||||
United States of America, Dollars | Fiscal Year 2018 Acquisitions [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 106,024,000 | |||||||||||
United States of America, Dollars | Tulip Diagnostics Private Limited [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 25,200,000 | 25,200,000 | ||||||||||
Business Combination, Payment of Stay Bonus | 11,254,000 | |||||||||||
Business Combination, Remaining Stay Bonus To Be Paid | 11,400,000 | 11,400,000 | ||||||||||
United States of America, Dollars | EUROIMMUM [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 1,413,113,000 | |||||||||||
United States of America, Dollars | EUROIMMUM [Member] | Term Loan Credit Facility, 12 Months Maturity [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 200,000,000 | |||||||||||
United States of America, Dollars | EUROIMMUM [Member] | Line of Credit, Maturing August 11, 2021 [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 710,000,000 | |||||||||||
United States of America, Dollars | EUROIMMUM [Member] | Cash and Cash Equivalents [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 503,113,000 | |||||||||||
India, Rupees | Tulip Diagnostics Private Limited [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 1,600,000,000 | $ 1,600,000,000 | ||||||||||
Business Combination, Payment of Stay Bonus | 716,286,000 | |||||||||||
Business Combination, Remaining Stay Bonus To Be Paid | $ 803,600,000 | $ 803,600,000 |
Business Combinations and Ass_4
Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($) | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Business Acquisition [Line Items] | |||
Goodwill | $ 2,952,608,000 | $ 3,002,198,000 | $ 2,247,966,000 |
Fiscal Year 2018 Acquisitions [Member] | |||
Business Acquisition [Line Items] | |||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 95,950,000 | ||
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value | 6,200,000 | ||
Working capital and other adjustments | 520,000 | ||
Less: cash acquired | 1,132,000 | ||
Business Combination, Consideration Transferred | 104,892,000 | ||
Current assets | 6,522,000 | ||
Property, plant and equipment | 1,166,000 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 891,000 | ||
Goodwill | 59,647,000 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (3,860,000) | ||
Liabilities assumed | (461,000) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (4,304,000) | ||
Total | 104,892,000 | ||
Business Combination, Consideration Transferred, Liabilities Incurred | 3,354,000 | ||
EUROIMMUM [Member] | |||
Business Acquisition [Line Items] | |||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 1,413,113,000 | ||
Working capital and other adjustments | 0 | ||
Less: cash acquired | 25,018,000 | ||
Business Combination, Consideration Transferred | 1,388,095,000 | ||
Current assets | 121,174,000 | ||
Property, plant and equipment | 109,859,000 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 71,621,000 | ||
Goodwill | 591,304,000 | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (251,886,000) | ||
Liabilities assumed | (100,020,000) | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (61,357,000) | ||
Total | 1,388,095,000 | ||
Business Combination, Consideration Transferred, Liabilities Incurred | 0 | ||
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 34,021,000 | ||
Core Technology [Member] | EUROIMMUM [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 160,000,000 | ||
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 1,070,000 | ||
Trade Names [Member] | EUROIMMUM [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 36,000,000 | ||
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 10,200,000 | ||
Customer Relationships [Member] | EUROIMMUM [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 710,000,000 | ||
In Process Research and Development [Member] | EUROIMMUM [Member] | |||
Business Acquisition [Line Items] | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 1,400,000 | ||
Diagnostics [Member] | |||
Business Acquisition [Line Items] | |||
Goodwill | 1,617,616,000 | 1,657,963,000 | 944,030,000 |
Discovery & Analytical Solutions [Member] | |||
Business Acquisition [Line Items] | |||
Goodwill | $ 1,334,992,000 | $ 1,344,235,000 | $ 1,303,936,000 |
Changes in Accounting Policie_3
Changes in Accounting Policies (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||
Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ (2,777,996) | $ (2,256,982) | $ (2,115,517) | ||||||||||
Cost of Goods and Services Sold | (1,437,057) | ||||||||||||
Selling, general and administrative expenses | 811,913 | 626,018 | 590,471 | ||||||||||
Research and development expenses | 193,998 | 139,464 | 124,184 | ||||||||||
Restructuring and contract termination charges, net | $ (1,942) | $ 6,508 | $ 0 | $ 6,578 | $ (263) | $ 3,269 | $ 0 | $ 9,651 | 11,144 | 12,657 | 5,124 | ||
Interest and other expense, net | 66,201 | (1,103) | 50,514 | ||||||||||
Restructuring and contract termination charges, net | (11,144) | (12,657) | (5,124) | ||||||||||
Operating income from continuing operations | 115,683 | [1] | 80,202 | 88,064 | 39,935 | 93,583 | 78,038 | 74,183 | 49,811 | 323,884 | 295,615 | 294,582 | |
Nonoperating Income (Expense) | 66,201 | (1,103) | 50,514 | ||||||||||
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | 79,429 | [1] | 78,041 | 71,708 | 28,505 | 80,889 | 105,054 | 70,792 | 39,983 | 257,683 | 296,718 | 244,068 | |
Provision for income taxes | 20,208 | 139,828 | 28,362 | ||||||||||
Income from discontinued operations before income taxes | 0 | 650 | 22,229 | ||||||||||
Operating income from continuing operations | 71,322 | [1] | 75,445 | 64,673 | 26,035 | (38,444) | 96,546 | 62,726 | 36,062 | 237,475 | 156,890 | 215,706 | |
(Loss) gain on disposition of discontinued operations before income taxes | (859) | 179,615 | 619 | ||||||||||
Cash and cash equivalents | 163,111 | 202,134 | 163,111 | 202,134 | 359,265 | ||||||||
Accounts receivable, net | (632,669) | (552,304) | (632,669) | (552,304) | |||||||||
Inventories | 338,347 | 351,675 | 338,347 | 351,675 | |||||||||
Other current assets | (100,507) | (93,842) | (100,507) | (93,842) | |||||||||
Property, plant and equipment, net | 318,590 | 298,066 | 318,590 | 298,066 | |||||||||
Intangible assets, net | 1,199,667 | 1,346,940 | 1,199,667 | 1,346,940 | |||||||||
Goodwill | 2,952,608 | 3,002,198 | 2,952,608 | 3,002,198 | 2,247,966 | ||||||||
Other assets, net | 270,023 | 244,304 | 270,023 | 244,304 | |||||||||
Current portion of long-term debt | 14,856 | 217,306 | 14,856 | 217,306 | |||||||||
Assets | (5,975,522) | (6,091,463) | (5,975,522) | (6,091,463) | |||||||||
Accounts payable | 220,949 | 222,093 | 220,949 | 222,093 | |||||||||
Accrued restructuring and contract termination costs | 4,834 | 8,759 | 4,834 | 8,759 | |||||||||
Accrued expenses and other current liabilities | 528,827 | 500,642 | 528,827 | 500,642 | |||||||||
Current liabilities of discontinued operations | 2,165 | 2,102 | 2,165 | 2,102 | |||||||||
Long-term debt | 1,876,624 | 1,788,803 | 1,876,624 | 1,788,803 | |||||||||
Long-term liabilities | 742,312 | 848,570 | 742,312 | 848,570 | |||||||||
Liabilities | 3,390,567 | 3,588,275 | 3,390,567 | 3,588,275 | |||||||||
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | 0 | 0 | 0 | 0 | |||||||||
Common Stock, Value, Issued | 110,597 | 110,361 | 110,597 | 110,361 | |||||||||
Capital in excess of par value | 48,772 | 58,828 | 48,772 | 58,828 | |||||||||
Retained earnings | 2,602,067 | 2,380,517 | 2,602,067 | 2,380,517 | |||||||||
Accumulated other comprehensive loss | (176,481) | (46,518) | (176,481) | (46,518) | (100,861) | $ (45,956) | |||||||
Stockholders' Equity Attributable to Parent | 2,584,955 | 2,503,188 | 2,584,955 | 2,503,188 | 2,153,570 | $ 2,110,441 | |||||||
Liabilities and Equity | (5,975,522) | (6,091,463) | (5,975,522) | (6,091,463) | |||||||||
Net income | 71,292 | [1] | 76,548 | 64,063 | 26,024 | (41,117) | 91,078 | 204,069 | 38,603 | 237,927 | 292,633 | 234,299 | |
Provision For Income Taxes On Discontinued Operations And Dispositions | 1,311 | (44,522) | (4,255) | ||||||||||
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | (30) | $ 1,103 | $ (610) | $ (11) | $ (2,673) | $ (5,468) | $ 141,343 | $ 2,541 | 452 | 135,743 | 18,593 | ||
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | (31,441) | ||||||||||||
Cost of Revenue | (10,290) | ||||||||||||
Selling, general and administrative expenses | 329 | ||||||||||||
Research and development expenses | 0 | ||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Operating income from continuing operations | (21,480) | ||||||||||||
Nonoperating Income (Expense) | 0 | ||||||||||||
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | (21,480) | ||||||||||||
Provision for income taxes | (5,662) | ||||||||||||
Operating income from continuing operations | (15,818) | ||||||||||||
Income from discontinued operations before income taxes | 0 | ||||||||||||
(Loss) gain on disposition of discontinued operations before income taxes | 0 | ||||||||||||
Cash and cash equivalents | 0 | 0 | |||||||||||
Accounts receivable, net | (16,264) | (16,264) | |||||||||||
Inventories | 9,773 | 9,773 | |||||||||||
Other current assets | (363) | (363) | |||||||||||
Property, plant and equipment, net | 0 | 0 | |||||||||||
Intangible assets, net | 0 | 0 | |||||||||||
Goodwill | 0 | 0 | |||||||||||
Other assets, net | 0 | 0 | |||||||||||
Assets | (6,854) | (6,854) | |||||||||||
Current portion of long-term debt | 0 | 0 | |||||||||||
Accounts payable | 0 | 0 | |||||||||||
Accrued restructuring and contract termination costs | 0 | 0 | |||||||||||
Accrued expenses and other current liabilities | 19,173 | 19,173 | |||||||||||
Current liabilities of discontinued operations | 0 | 0 | |||||||||||
Long-term debt | 0 | 0 | |||||||||||
Long-term liabilities | 0 | 0 | |||||||||||
Liabilities | 19,173 | 19,173 | |||||||||||
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | 0 | 0 | |||||||||||
Common Stock, Value, Issued | 0 | 0 | |||||||||||
Capital in excess of par value | 0 | 0 | |||||||||||
Retained earnings | (26,027) | (26,027) | |||||||||||
Accumulated other comprehensive loss | 0 | 0 | |||||||||||
Stockholders' Equity Attributable to Parent | (26,027) | (26,027) | |||||||||||
Liabilities and Equity | (6,854) | (6,854) | |||||||||||
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | 0 | ||||||||||||
Net income | (15,818) | ||||||||||||
Provision For Income Taxes On Discontinued Operations And Dispositions | 0 | ||||||||||||
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | (2,746,555) | ||||||||||||
Cost of Revenue | (1,426,767) | ||||||||||||
Selling, general and administrative expenses | 812,242 | ||||||||||||
Research and development expenses | 193,998 | ||||||||||||
Restructuring and contract termination charges, net | 11,144 | ||||||||||||
Operating income from continuing operations | 302,404 | ||||||||||||
Nonoperating Income (Expense) | 66,201 | ||||||||||||
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | 236,203 | ||||||||||||
Provision for income taxes | 14,546 | ||||||||||||
Operating income from continuing operations | 221,657 | ||||||||||||
Income from discontinued operations before income taxes | 0 | ||||||||||||
(Loss) gain on disposition of discontinued operations before income taxes | (859) | ||||||||||||
Cash and cash equivalents | 163,111 | 163,111 | |||||||||||
Accounts receivable, net | (616,405) | (616,405) | |||||||||||
Inventories | 348,120 | 348,120 | |||||||||||
Other current assets | (100,144) | (100,144) | |||||||||||
Property, plant and equipment, net | 318,590 | 318,590 | |||||||||||
Intangible assets, net | 1,199,667 | 1,199,667 | |||||||||||
Goodwill | 2,952,608 | 2,952,608 | |||||||||||
Other assets, net | 270,023 | 270,023 | |||||||||||
Assets | (5,968,668) | (5,968,668) | |||||||||||
Current portion of long-term debt | 14,856 | 14,856 | |||||||||||
Accounts payable | 220,949 | 220,949 | |||||||||||
Accrued restructuring and contract termination costs | 4,834 | 4,834 | |||||||||||
Accrued expenses and other current liabilities | 548,000 | 548,000 | |||||||||||
Current liabilities of discontinued operations | 2,165 | 2,165 | |||||||||||
Long-term debt | 1,876,624 | 1,876,624 | |||||||||||
Long-term liabilities | 742,312 | 742,312 | |||||||||||
Liabilities | 3,409,740 | 3,409,740 | |||||||||||
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | 0 | 0 | |||||||||||
Common Stock, Value, Issued | 110,597 | 110,597 | |||||||||||
Capital in excess of par value | 48,772 | 48,772 | |||||||||||
Retained earnings | 2,576,040 | 2,576,040 | |||||||||||
Accumulated other comprehensive loss | (176,481) | (176,481) | |||||||||||
Stockholders' Equity Attributable to Parent | 2,558,928 | 2,558,928 | |||||||||||
Liabilities and Equity | $ (5,968,668) | (5,968,668) | |||||||||||
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | 452 | ||||||||||||
Net income | 222,109 | ||||||||||||
Provision For Income Taxes On Discontinued Operations And Dispositions | (1,311) | ||||||||||||
Accounting Standards Update 2014-09 [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Impact of New Accounting Principle, Comprehensive income | 15,800 | ||||||||||||
Product [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | (1,935,493) | (1,477,414) | (1,396,896) | ||||||||||
Cost of Goods and Services Sold | (908,228) | (707,962) | (663,795) | ||||||||||
Product [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | (31,441) | ||||||||||||
Cost of Goods and Services Sold | (10,290) | ||||||||||||
Product [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | (1,904,052) | ||||||||||||
Cost of Goods and Services Sold | (897,938) | ||||||||||||
Service [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | (842,503) | (779,568) | (718,621) | ||||||||||
Cost of Goods and Services Sold | (528,829) | $ (475,266) | $ (437,361) | ||||||||||
Service [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | ||||||||||||
Cost of Goods and Services Sold | 0 | ||||||||||||
Service [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member] | |||||||||||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | (842,503) | ||||||||||||
Cost of Goods and Services Sold | $ (528,829) | ||||||||||||
[1] | The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy |
Discontinued Operations Narrati
Discontinued Operations Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
(Loss) gain on disposition of discontinued operations before income taxes | $ (859) | $ 179,615 | $ 619 |
(Benefit from) provision for income taxes on discontinued operations and dispositions | (1,311) | 44,522 | 4,255 |
Disposal Group, Including Discontinued Operation, Liabilities, Current | 2,165 | 2,102 | |
Technical Services Business [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
(Loss) gain on disposition of discontinued operations before income taxes | 0 | 0 | 1,753 |
Fluid Sciences Segment [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
(Loss) gain on disposition of discontinued operations before income taxes | (66) | 0 | (1,134) |
PerkinElmer Labs, Inc. [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
(Loss) gain on disposition of discontinued operations before income taxes | 7,114 | ||
Disposal Group, Including Discontinued Operation, Consideration | $ 20,000 | ||
Gain (Loss) on Disposition of Business | $ 1,100 | ||
Capital loss on disposition of a business | 7,300 | ||
Tax effect of disposition of a business | 2,500 | ||
Medical Imaging Business [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Discontinued Operation, Period of Continuing Involvement after Disposal | 12 months | ||
(Loss) gain on disposition of discontinued operations before income taxes | (793) | $ 179,615 | $ 0 |
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation | 43,131 | ||
Disposal Group, Including Discontinued Operation, Consideration | 277,400 | ||
Disposal Group, Including Discontinued Operation, Working Capital Adjustment | 4,200 | ||
Suzhou PerkinElmer Medical Laboratory Co. Ltd [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
(Loss) gain on disposition of discontinued operations before income taxes | (1,108) | ||
Disposal Group, Including Discontinued Operation, Consideration | $ 2,300 | ||
Multispectral Imaging Business [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
(Loss) gain on disposition of discontinued operations before income taxes | 13,031 | ||
Disposal Group, Including Discontinued Operation, Consideration | $ 37,300 |
Summary Operating Results of Di
Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Disposal Group, Including Discontinued Operation, Revenue | $ 0 | $ 44,343 | $ 146,217 |
Disposal Group, Including Discontinued Operation, Costs of Goods Sold | 0 | 32,933 | 95,395 |
Disposal Group, Including Discontinued Operation, General and Administrative Expense | 0 | 5,869 | 13,657 |
Disposal Group, Including Discontinued Operations, Research and development expenses | 0 | 4,891 | 14,368 |
Disposal Group, Including Discontinued Operations, Restructuring and contract termination charges, net | 0 | 0 | 568 |
Loss from discontinued operations before income taxes | $ 0 | $ 650 | $ 22,229 |
Restructuring and Contract Te_3
Restructuring and Contract Termination Charges, Net (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 | |
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ (1,942) | $ 6,508 | $ 0 | $ 6,578 | $ (263) | $ 3,269 | $ 0 | $ 9,651 | $ 11,144 | $ 12,657 | $ 5,124 | |
Accrued restructuring and contract termination costs | 6,180 | 13,969 | 6,180 | 13,969 | 10,541 | $ 22,150 | ||||||
Accrued restructuring and contract termination costs | 4,834 | 8,759 | 4,834 | 8,759 | ||||||||
Restructuring Reserve, Noncurrent | 1,400 | 2,300 | 1,400 | 2,300 | ||||||||
Contract Termination [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Accrued restructuring and contract termination costs | $ 137 | $ 3,048 | 137 | 3,048 | 117 | $ 132 | ||||||
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2018 Contract Termination Charges [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ 4,971 | |||||||||||
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2017 Contract Termination Charges [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ 3,612 | |||||||||||
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2016 Contract Termination Charges [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ 88 |
Restructuring and Contract Te_4
Restructuring and Contract Termination Charges, Net Restructuring and Contract Termination Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||
Dec. 30, 2018USD ($)employees | Sep. 30, 2018USD ($)employees | Jul. 01, 2018USD ($) | Apr. 01, 2018USD ($)employees | Dec. 31, 2017USD ($)employees | Oct. 01, 2017USD ($)employees | Jul. 02, 2017USD ($) | Apr. 02, 2017USD ($)employees | Oct. 02, 2016USD ($)employees | Jul. 03, 2016USD ($)employees | Dec. 30, 2018USD ($) | Dec. 31, 2017USD ($) | Jan. 01, 2017USD ($) | |
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ (1,942) | $ 6,508 | $ 0 | $ 6,578 | $ (263) | $ 3,269 | $ 0 | $ 9,651 | $ 11,144 | $ 12,657 | $ 5,124 | ||
Q4 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 1 | ||||||||||||
Restructuring and contract termination charges, net | $ 348 | ||||||||||||
Q3 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 61 | ||||||||||||
Restructuring and contract termination charges, net | $ 1,764 | ||||||||||||
Q1 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 47 | ||||||||||||
Restructuring and contract termination charges, net | $ 5,998 | ||||||||||||
Q4 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 29 | ||||||||||||
Restructuring and contract termination charges, net | $ 1,935 | ||||||||||||
Q3 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 27 | ||||||||||||
Restructuring and contract termination charges, net | $ 2,342 | ||||||||||||
Q1 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 90 | ||||||||||||
Restructuring and contract termination charges, net | $ 6,697 | ||||||||||||
Q3 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 22 | ||||||||||||
Restructuring and contract termination charges, net | $ 1,820 | ||||||||||||
Q2 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 72 | ||||||||||||
Restructuring and contract termination charges, net | $ 4,667 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q4 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 618 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 902 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q4 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 255 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q3 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 1,021 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q1 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 1,631 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q3 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 41 | ||||||||||||
Diagnostics [Member] | Severance [Member] | Q2 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 561 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q4 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q3 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 33 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q3 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Facility Closing [Member] | Q2 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 348 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 1,146 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 5,096 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 1,680 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 1,321 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 5,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 1,779 | ||||||||||||
Discovery & Analytical Solutions [Member] | Severance [Member] | Q2 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | 4,106 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 33 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q2 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 |
Restructuring and Contract Te_5
Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |||||||||||
Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Oct. 02, 2016 | Jul. 03, 2016 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Restructuring Cost and Reserve [Line Items] | |||||||||||||
Restructuring Reserve, Current Other | $ 2,900,000 | $ 2,900,000 | |||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | $ 13,969,000 | $ 10,541,000 | $ 13,969,000 | 10,541,000 | $ 22,150,000 | ||||||||
Restructuring Charges and Changes in Estimates | 11,144,000 | 12,657,000 | 5,124,000 | ||||||||||
Amounts paid and foreign currency translation | (18,933,000) | (9,229,000) | (16,733,000) | ||||||||||
Ending balance | $ 6,180,000 | 13,969,000 | 6,180,000 | 13,969,000 | 10,541,000 | ||||||||
Restructuring and contract termination charges, net | (1,942,000) | $ 6,508,000 | $ 0 | 6,578,000 | (263,000) | $ 3,269,000 | $ 0 | 9,651,000 | 11,144,000 | 12,657,000 | 5,124,000 | ||
Employee Severance and Facility Closing [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 10,921,000 | 10,424,000 | 10,921,000 | 10,424,000 | 22,018,000 | ||||||||
Restructuring Charges and Changes in Estimates | 6,402,000 | 9,406,000 | 5,036,000 | ||||||||||
Amounts paid and foreign currency translation | (11,280,000) | (8,909,000) | (16,630,000) | ||||||||||
Ending balance | 6,043,000 | 10,921,000 | 6,043,000 | 10,921,000 | 10,424,000 | ||||||||
Contract Termination [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 3,048,000 | 117,000 | 3,048,000 | 117,000 | 132,000 | ||||||||
Restructuring Charges and Changes in Estimates | 4,742,000 | 3,251,000 | 88,000 | ||||||||||
Amounts paid and foreign currency translation | (7,653,000) | (320,000) | (103,000) | ||||||||||
Ending balance | 137,000 | 3,048,000 | 137,000 | 3,048,000 | 117,000 | ||||||||
Previous restructuring and integration plans [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 4,399,000 | 7,780,000 | 4,399,000 | 7,780,000 | 22,018,000 | ||||||||
Restructuring Charges and Changes in Estimates | 338,000 | (537,000) | (1,451,000) | ||||||||||
Amounts paid and foreign currency translation | (2,425,000) | (2,844,000) | (12,787,000) | ||||||||||
Ending balance | 2,312,000 | 4,399,000 | 2,312,000 | 4,399,000 | 7,780,000 | ||||||||
Q4 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 348,000 | ||||||||||||
Q4 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 0 | 0 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 348,000 | 0 | 0 | ||||||||||
Amounts paid and foreign currency translation | 0 | 0 | 0 | ||||||||||
Ending balance | 348,000 | 0 | 348,000 | 0 | 0 | ||||||||
Q3 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 1,764,000 | ||||||||||||
Q3 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 0 | 0 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 2,054,000 | 0 | 0 | ||||||||||
Amounts paid and foreign currency translation | (639,000) | 0 | 0 | ||||||||||
Ending balance | 1,415,000 | 0 | 1,415,000 | 0 | 0 | ||||||||
Q1 2018 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 5,998,000 | ||||||||||||
Q1 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 0 | 0 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 5,998,000 | 0 | 0 | ||||||||||
Amounts paid and foreign currency translation | (4,389,000) | 0 | 0 | ||||||||||
Ending balance | 1,609,000 | 0 | 1,609,000 | 0 | 0 | ||||||||
Q4 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 1,935,000 | ||||||||||||
Q4 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 1,919,000 | 0 | 1,919,000 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | (381,000) | 1,935,000 | 0 | ||||||||||
Amounts paid and foreign currency translation | (1,538,000) | (16,000) | 0 | ||||||||||
Ending balance | 0 | 1,919,000 | 0 | 1,919,000 | 0 | ||||||||
Q3 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 2,342,000 | ||||||||||||
Q3 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 2,072,000 | 0 | 2,072,000 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | (1,204,000) | 2,342,000 | 0 | ||||||||||
Amounts paid and foreign currency translation | (868,000) | (270,000) | 0 | ||||||||||
Ending balance | 0 | 2,072,000 | 0 | 2,072,000 | 0 | ||||||||
Q1 2017 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 6,697,000 | ||||||||||||
Q1 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 2,498,000 | 0 | 2,498,000 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | (983,000) | 6,631,000 | 0 | ||||||||||
Amounts paid and foreign currency translation | (1,232,000) | (4,133,000) | 0 | ||||||||||
Ending balance | 283,000 | 2,498,000 | 283,000 | 2,498,000 | 0 | ||||||||
Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 33,000 | 0 | 33,000 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 0 | 66,000 | 0 | ||||||||||
Amounts paid and foreign currency translation | (33,000) | (33,000) | 0 | ||||||||||
Ending balance | 0 | 33,000 | 0 | 33,000 | 0 | ||||||||
Q3 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 1,820,000 | ||||||||||||
Q3 2016 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 1,208,000 | 0 | 1,208,000 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 0 | (202,000) | 1,820,000 | ||||||||||
Amounts paid and foreign currency translation | 0 | (1,006,000) | 612,000 | ||||||||||
Ending balance | 0 | 0 | 0 | 0 | 1,208,000 | ||||||||
Q2 2016 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 4,667,000 | ||||||||||||
Q2 2016 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 1,436,000 | 0 | 1,436,000 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 232,000 | (829,000) | 4,667,000 | ||||||||||
Amounts paid and foreign currency translation | (156,000) | (607,000) | (3,231,000) | ||||||||||
Ending balance | 76,000 | 0 | 76,000 | 0 | $ 1,436,000 | ||||||||
Diagnostics [Member] | Q4 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Q4 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Q3 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 618,000 | ||||||||||||
Diagnostics [Member] | Q3 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Q1 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 902,000 | ||||||||||||
Diagnostics [Member] | Q1 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | 2017 Contract Termination Charges [Member] | Contract Termination [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 517,000 | ||||||||||||
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (200,000) | ||||||||||||
Restructuring and contract termination charges, net | 255,000 | ||||||||||||
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (400,000) | ||||||||||||
Restructuring and contract termination charges, net | 1,021,000 | ||||||||||||
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | 0 | ||||||||||||
Restructuring and contract termination charges, net | 1,631,000 | ||||||||||||
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 33,000 | ||||||||||||
Diagnostics [Member] | Q3 2016 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 41,000 | ||||||||||||
Diagnostics [Member] | Q3 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Diagnostics [Member] | Q2 2016 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 561,000 | ||||||||||||
Diagnostics [Member] | Q2 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q4 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 348,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q4 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q3 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 1,146,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q3 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q1 2018 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 5,096,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q1 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | 2017 Contract Termination Charges [Member] | Contract Termination [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 3,612,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (200,000) | ||||||||||||
Restructuring and contract termination charges, net | 1,680,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (800,000) | ||||||||||||
Restructuring and contract termination charges, net | 1,321,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | $ (1,000,000) | ||||||||||||
Restructuring and contract termination charges, net | 5,000,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 33,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q3 2016 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 1,779,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q3 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q2 2016 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 4,106,000 | ||||||||||||
Discovery & Analytical Solutions [Member] | Q2 2016 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 |
Interest and Other Expense (I_3
Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Foreign Currency Transaction Gain (Loss), before Tax | $ (9,400) | $ (29,200) | $ (1,500) |
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments | 11,700 | (4,500) | 5,400 |
Gain on disposition of businesses and assets, net | (12,844) | 309 | (5,562) |
Defined Benefit Plan, Other Cost (Credit) | 11,500 | (9,200) | 11,500 |
Interest income | (1,141) | (2,571) | (702) |
Interest expense | 66,976 | 43,940 | 41,528 |
Other expense, net | 13,210 | (42,781) | 15,250 |
Total interest and other expense, net | $ 66,201 | $ (1,103) | $ 50,514 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Income Tax Contingency [Line Items] | |||
Income Tax Holiday, Aggregate Dollar Amount | $ (10,300) | $ (10,100) | $ (11,400) |
Impact of benefits derived from tax holidays on earnings per share, basic | $ 0.09 | $ (0.09) | $ (0.10) |
Impact of benefits derived from tax holidays on earnings per share, diluted | $ (0.09) | $ (0.09) | $ (0.10) |
Valuation Allowance, Amount | $ 102,087 | $ 68,895 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Unrecognized tax benefits, beginning of period | 30,308 | 29,607 | $ 28,143 |
Gross increases - tax positions in prior period | 6,931 | 749 | 1,514 |
Gross decreases - tax positions in prior period | (1,622) | (828) | (183) |
Gross increases - current-period tax positions | 0 | 2,346 | 3,547 |
Settlements | (2,253) | (324) | 0 |
Lapse of statute of limitations | (181) | (1,371) | (4,109) |
Foreign currency translation adjustments | (174) | 129 | 695 |
Unrecognized tax benefits, end of period | 33,009 | 30,308 | 29,607 |
Income Tax Penalties and Interest Accrued | 2,500 | 1,900 | |
Income Tax Penalties and Interest Expense | 400 | (300) | (100) |
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate | 31,300 | ||
Unrecognized Tax Benefits Expected To Be Resolved With In A Year | 2,300 | ||
Undistributed Earnings of Foreign Subsidiaries Not Meeting Requirements to be Reinvested | 1,000,000 | ||
Income Tax Expense (Benefits) on Undistributed Foreign Earnings | 2,900 | ||
Foreign earnings invested outside U.S. | $ 652,100 | ||
Open Tax Years by Major Tax Jurisdiction, Begin Date | 2,010 | ||
Tax Adjustments, Settlements, and Unusual Provisions | $ 8,100 | 98,600 | (9,600) |
Excess tax benefit from exercise of common stock options | 0 | 0 | |
2017 Tax Cuts and Jobs Act [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Income Tax Expense on Repatriated Earnings | 80,400 | 85,000 | |
Tax Adjustments, Settlements, and Unusual Provisions | (2,025) | 106,500 | $ 0 |
Discrete Income Tax Expense (Benefit), Tax Reform True-up | 2,000 | ||
Other Tax Matters [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Adjustments, Settlements, and Unusual Provisions | 1,130 | ||
Excess tax benefits on stock compensation [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Adjustments, Settlements, and Unusual Provisions | 7,200 | 5,100 | |
2017 Tax Cuts and Jobs Act, Refinement [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Income Tax Expense on Repatriated Earnings | (4,600) | ||
2017 Tax Cuts and Jobs Act, Remeasurement [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Adjustments, Settlements, and Unusual Provisions | (300) | $ 21,500 | |
General Business [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Credit Carryforward, Amount | 10,900 | ||
State and Local Jurisdiction [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | 200,600 | ||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Credit Carryforward, Amount | 6,800 | ||
Foreign Tax Authority [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | 515,500 | ||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Credit Carryforward, Amount | 100 | ||
Internal Revenue Service (IRS) [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | $ 38,300 | ||
China [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Income Tax Holiday, Termination Date | 12/31/2019 | ||
Singapore [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Income Tax Holiday, Termination Date | 12/31/2023 |
Income Taxes Income Before Inco
Income Taxes Income Before Income taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 30, 2018 | [1] | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Income Tax Contingency [Line Items] | ||||||||||||
U.S. | $ 32,627 | $ 3,743 | $ 39,689 | |||||||||
Non-U.S. | 225,056 | 292,975 | 204,379 | |||||||||
Income from continuing operations before income taxes | $ 79,429 | $ 78,041 | $ 71,708 | $ 28,505 | $ 80,889 | $ 105,054 | $ 70,792 | $ 39,983 | $ 257,683 | $ 296,718 | $ 244,068 | |
[1] | The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy |
Income Taxes Components of the
Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Income Tax Contingency [Line Items] | |||
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | $ (27,281) | $ (65,836) | $ (52,648) |
Federal current | 7,938 | 62,003 | 14 |
Federal deferred expense (benefit) | (5,250) | 35,435 | 2,994 |
Federal total | 2,688 | 97,438 | 3,008 |
State current | 2,345 | 3,332 | 2,143 |
State deferred expense (benefit) | 2,572 | (792) | (575) |
State total | 4,917 | 2,540 | 1,568 |
Non-U.S. current | 61,028 | 45,639 | 30,754 |
Non-U.S.deferred expense benefit | (48,425) | (5,789) | (6,968) |
Non-U.S. total | 12,603 | 39,850 | 23,786 |
Total current | 71,311 | 110,974 | 32,911 |
Total deferred expense (benefit) | (51,103) | 28,854 | (4,549) |
Total | 20,208 | 139,828 | 28,362 |
Discontinued operations | (1,311) | 44,522 | 4,255 |
Total provision for income taxes | 18,897 | 184,350 | 32,617 |
Singapore, Finland, Netherlands and China [Member] | |||
Income Tax Contingency [Line Items] | |||
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | $ 18,700 | $ 55,900 | $ 48,200 |
Income Taxes Reconciliation of
Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Income Tax Contingency [Line Items] | |||
Tax at statutory rate | $ 54,114 | $ 103,851 | $ 85,424 |
Non-U.S. rate differential, net | (27,281) | (65,836) | (52,648) |
U.S. taxation of multinational operations | 7,047 | 5,408 | 6,941 |
State income taxes, net | 2,028 | 1,810 | 1,509 |
Prior year tax matters | (6,034) | (7,955) | (9,621) |
Federal tax credits | (3,738) | (8,249) | (7,189) |
Change in valuation allowance | (759) | 1,951 | (2,755) |
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount | 0 | 0 | 5,701 |
Tax Adjustments, Settlements, and Unusual Provisions | 8,100 | 98,600 | (9,600) |
Other, net | (3,144) | 2,310 | 1,000 |
Total | 20,208 | 139,828 | 28,362 |
Singapore, Finland, Netherlands and China [Member] | |||
Income Tax Contingency [Line Items] | |||
Non-U.S. rate differential, net | 18,700 | 55,900 | 48,200 |
2017 Tax Cuts and Jobs Act [Member] | |||
Income Tax Contingency [Line Items] | |||
Tax Adjustments, Settlements, and Unusual Provisions | $ (2,025) | $ 106,500 | $ 0 |
Income Taxes Components of Defe
Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 30, 2018 | Dec. 31, 2017 | |
Income Tax Contingency [Line Items] | ||
Inventory | $ 0 | $ 6,376 |
Reserves and accruals | 39,487 | 26,657 |
Accrued compensation | 21,709 | 17,333 |
Net operating loss and credit carryforwards | 144,421 | 88,503 |
Accrued pension | 31,146 | 34,682 |
Restructuring reserve | 1,780 | 2,586 |
Deferred revenue | 31,045 | 28,478 |
Deferred Tax Assets, Unrealized Currency Losses | 0 | 10,910 |
Deferred Tax Assets, Gross | 269,588 | 215,525 |
Deferred Tax Liabilities, Inventory | (278) | 0 |
Postretirement health benefits | (3,406) | (3,391) |
Depreciation and amortization | (309,958) | (392,293) |
Deferred Tax Liabilities, Other | (1,879) | (594) |
Total deferred tax liabilities | (315,521) | (396,278) |
Valuation allowance | (102,087) | (68,895) |
Deferred Tax Liabilities, Net | (148,020) | (249,648) |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (33,200) | |
Domestic Country [Member] | ||
Income Tax Contingency [Line Items] | ||
Net deferred tax liabilities | (52,469) | (44,974) |
Foreign Tax Authority [Member] | ||
Income Tax Contingency [Line Items] | ||
Deferred Tax Liabilities, Net | $ (200,489) | $ (294,622) |
Income Taxes Summary of Loss an
Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 30, 2018 | Dec. 31, 2017 | |
Income Tax Contingency [Line Items] | ||
Valuation Allowance, Amount | $ 102,087 | $ 68,895 |
State and Local Jurisdiction [Member] | ||
Income Tax Contingency [Line Items] | ||
Operating Loss Carryforwards | 200,600 | |
Tax Credit Carryforward, Amount | 6,800 | |
Foreign Tax Authority [Member] | ||
Income Tax Contingency [Line Items] | ||
Operating Loss Carryforwards | 515,500 | |
Tax Credit Carryforward, Amount | 100 | |
Internal Revenue Service (IRS) [Member] | ||
Income Tax Contingency [Line Items] | ||
Operating Loss Carryforwards | 38,300 | |
General Business [Member] | ||
Income Tax Contingency [Line Items] | ||
Tax Credit Carryforward, Amount | $ 10,900 | |
Minimum [Member] | Internal Revenue Service (IRS) [Member] | ||
Income Tax Contingency [Line Items] | ||
Tax Credit Carryforward, Expiration Date | Jan. 1, 2019 | |
Maximum [Member] | Internal Revenue Service (IRS) [Member] | ||
Income Tax Contingency [Line Items] | ||
Tax Credit Carryforward, Expiration Date | Dec. 31, 2038 |
Earnings Per Share (Schedule of
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Earnings Per Share [Abstract] | |||
Number of common shares-basic | 110,561 | 109,857 | 109,478 |
Effect of dilutive securities, Stock options | 761 | 708 | 640 |
Effect of dilutive securities, Restricted stock | 212 | 294 | 195 |
Number of common shares-diluted | 111,534 | 110,859 | 110,313 |
Number of potentially dilutive securities excluded from calculation due to antidilutive impact | 349 | 287 | 458 |
Accounts Receivable, Net (Detai
Accounts Receivable, Net (Details) - USD ($) $ in Millions | Dec. 30, 2018 | Dec. 31, 2017 |
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] | ||
Reserves for doubtful accounts | $ 30.6 | $ 31.3 |
Inventories, Net (Details)
Inventories, Net (Details) - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 119,115 | $ 122,100 |
Work in progress | 18,110 | 18,452 |
Finished goods | 201,122 | 211,123 |
Total inventories | $ 338,347 | $ 351,675 |
Property, Plant and Equipment_3
Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $ 680,183 | $ 630,919 | |
Accumulated depreciation | (361,593) | (332,853) | |
Total property, plant and equipment, net | 318,590 | 298,066 | |
Depreciation expense | 44,700 | 31,300 | $ 28,500 |
Land [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 5,482 | 5,624 | |
Building and leasehold Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 272,277 | 262,657 | |
Machinery and Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $ 402,424 | $ 362,638 |
Marketable Securities and Inv_3
Marketable Securities and Investments (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Debt Securities, Available-for-sale [Line Items] | |||
Unrealized (losses) gains on securities, net of tax | $ (9) | $ 79 | $ 32 |
Marketable securities | 2,447 | 2,208 | |
Cost Method Investments | 16,783 | 10,783 | |
Marketable Securities and Investments | 19,230 | 12,991 | |
Equity Securities [Member] | |||
Debt Securities, Available-for-sale [Line Items] | |||
Cost | 1,037 | 1,161 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 0 | |
Market value | 671 | 811 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (366) | (350) | |
Fixed Income Securities [Member] | |||
Debt Securities, Available-for-sale [Line Items] | |||
Cost | 22 | 22 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 0 | |
Market value | 22 | 22 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | 0 | 0 | |
Available-for-sale Securities, Other [Member] | |||
Debt Securities, Available-for-sale [Line Items] | |||
Cost | 1,817 | 1,438 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 0 | |
Market value | 1,754 | 1,375 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (63) | (63) | |
Available-for-sale Securities [Member] | |||
Debt Securities, Available-for-sale [Line Items] | |||
Cost | 2,876 | 2,621 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 0 | |
Market value | 2,447 | 2,208 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | $ (429) | $ (413) |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Dec. 29, 2013 | Dec. 30, 2012 | |
Goodwill and Intangible Assets Net [Line Items] | |||||
Total amortization expense related to finite-lived intangible assets | $ 135,900 | $ 73,700 | $ 71,500 | ||
Future Amortization Expense, Year One | 149,700 | ||||
Future Amortization Expense, Year Two | 152,000 | ||||
Future Amortization Expense, Year Three | 136,700 | ||||
Future Amortization Expense, Year Four | 126,600 | ||||
Future Amortization Expense, Year Five | 109,100 | ||||
Finite-Lived Intangible Assets, Net | 1,129,083 | 1,276,356 | |||
Goodwill | $ 2,952,608 | 3,002,198 | 2,247,966 | ||
Impairment Testing Date | 1/1/2018 | ||||
Trade Names And Trademarks [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | $ 44,345 | 52,724 | |||
Licenses [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | 7,755 | 10,665 | |||
Discovery & Analytical Solutions [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | 162,388 | 184,747 | |||
Goodwill | 1,334,992 | 1,344,235 | 1,303,936 | ||
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | 8,083 | 9,928 | |||
Discovery & Analytical Solutions [Member] | Licenses [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | 5,802 | 8,441 | |||
Diagnostics [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | 966,695 | 1,091,609 | |||
Goodwill | 1,617,616 | 1,657,963 | 944,030 | ||
Diagnostics [Member] | Trade Names And Trademarks [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | 36,262 | 42,796 | |||
Diagnostics [Member] | Licenses [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | 1,953 | 2,224 | |||
Other Asset Acquisitions [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Finite-Lived Intangible Assets, Net | $ 7,000 | $ 6,800 | |||
Prepaid Royalties | 65,000 | $ 40,300 | $ 25,000 | ||
Prepaid Royalties, Other Current Asset | 5,600 | ||||
Prepaid Royalties, Other Assets | $ 59,400 | ||||
Payments of Additional Prepaid Royalties | $ 5,100 | 9,400 | |||
Other Asset Acquisitions extension [Member] | |||||
Goodwill and Intangible Assets Net [Line Items] | |||||
Prepaid Royalties | $ 6,000 |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 30, 2018 | Dec. 31, 2017 | |
Changes in the carrying amount of goodwill | ||
Foreign currency translation | $ (67,478) | $ 66,737 |
Acquisitions, earn outs and other | 17,888 | 687,495 |
Ending balance | 2,952,608 | 3,002,198 |
Diagnostics [Member] | ||
Changes in the carrying amount of goodwill | ||
Foreign currency translation | (35,289) | 29,091 |
Acquisitions, earn outs and other | (5,058) | 684,842 |
Ending balance | 1,617,616 | 1,657,963 |
Discovery & Analytical Solutions [Member] | ||
Changes in the carrying amount of goodwill | ||
Foreign currency translation | (32,189) | 37,646 |
Acquisitions, earn outs and other | 22,946 | 2,653 |
Ending balance | $ 1,334,992 | $ 1,344,235 |
Goodwill and Intangible Asset_5
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Net amortizable intangible assets | $ 1,129,083 | $ 1,276,356 |
Totals | 1,199,667 | 1,346,940 |
Patents [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 42,646 | 39,959 |
Less: Accumulated amortization | (37,753) | (35,085) |
Net amortizable intangible assets | 4,893 | 4,874 |
Trade Names And Trademarks [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 78,146 | 80,974 |
Less: Accumulated amortization | (33,801) | (28,250) |
Net amortizable intangible assets | 44,345 | 52,724 |
Non-amortizing intangible assets | 70,584 | 70,584 |
Licenses [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 53,305 | 53,300 |
Less: Accumulated amortization | (45,550) | (42,635) |
Net amortizable intangible assets | 7,755 | 10,665 |
Core Technology [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 540,911 | 479,759 |
Less: Accumulated amortization | (265,744) | (250,343) |
Net amortizable intangible assets | 275,167 | 229,416 |
Customer Relationships [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 1,089,527 | 1,141,511 |
Less: Accumulated amortization | (293,964) | (242,840) |
Net amortizable intangible assets | 795,563 | 898,671 |
In Process Research and Development [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 1,360 | 80,006 |
Diagnostics [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Net amortizable intangible assets | 966,695 | 1,091,609 |
Totals | 966,695 | 1,091,609 |
Diagnostics [Member] | Patents [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 14,616 | 11,911 |
Less: Accumulated amortization | (11,775) | (10,637) |
Net amortizable intangible assets | 2,841 | 1,274 |
Diagnostics [Member] | Trade Names And Trademarks [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 48,335 | 51,024 |
Less: Accumulated amortization | (12,073) | (8,228) |
Net amortizable intangible assets | 36,262 | 42,796 |
Non-amortizing intangible assets | 0 | 0 |
Diagnostics [Member] | Licenses [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 3,127 | 10,239 |
Less: Accumulated amortization | (1,174) | (8,015) |
Net amortizable intangible assets | 1,953 | 2,224 |
Diagnostics [Member] | Core Technology [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 300,177 | 243,435 |
Less: Accumulated amortization | (76,711) | (59,920) |
Net amortizable intangible assets | 223,466 | 183,515 |
Diagnostics [Member] | Customer Relationships [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 866,635 | 907,938 |
Less: Accumulated amortization | (165,822) | (126,144) |
Net amortizable intangible assets | 700,813 | 781,794 |
Diagnostics [Member] | In Process Research and Development [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 1,360 | 80,006 |
Discovery & Analytical Solutions [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Net amortizable intangible assets | 162,388 | 184,747 |
Totals | 232,972 | 255,331 |
Discovery & Analytical Solutions [Member] | Patents [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 28,030 | 28,048 |
Less: Accumulated amortization | (25,978) | (24,448) |
Net amortizable intangible assets | 2,052 | 3,600 |
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 29,811 | 29,950 |
Less: Accumulated amortization | (21,728) | (20,022) |
Net amortizable intangible assets | 8,083 | 9,928 |
Non-amortizing intangible assets | 70,584 | 70,584 |
Discovery & Analytical Solutions [Member] | Licenses [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 50,178 | 43,061 |
Less: Accumulated amortization | (44,376) | (34,620) |
Net amortizable intangible assets | 5,802 | 8,441 |
Discovery & Analytical Solutions [Member] | Core Technology [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 240,734 | 236,324 |
Less: Accumulated amortization | (189,033) | (190,423) |
Net amortizable intangible assets | 51,701 | 45,901 |
Discovery & Analytical Solutions [Member] | Customer Relationships [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 222,892 | 233,573 |
Less: Accumulated amortization | (128,142) | (116,696) |
Net amortizable intangible assets | 94,750 | 116,877 |
Discovery & Analytical Solutions [Member] | In Process Research and Development [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | $ 0 | $ 0 |
Debt (Details)
Debt (Details) € in Millions | Apr. 11, 2018USD ($) | Jul. 19, 2016USD ($) | Oct. 25, 2011USD ($) | Dec. 30, 2018USD ($) | Dec. 30, 2012USD ($) | Dec. 30, 2018EUR (€) | Dec. 31, 2017USD ($) | Dec. 31, 2017EUR (€) | Aug. 11, 2016USD ($) | Jul. 19, 2016EUR (€) | Sep. 30, 2012USD ($) |
Unamortized discount and debt issuance costs | $ (14,968,000) | ||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
2,017 | 14,856,000 | ||||||||||
2,018 | 10,124,000 | ||||||||||
2,019 | 1,271,272,000 | ||||||||||
2,020 | 5,564,000 | ||||||||||
2,021 | 4,322,000 | ||||||||||
Thereafter | 578,622,000 | ||||||||||
Long-term Debt Before Unamortized Discount | 1,884,760,000 | ||||||||||
Non-cash Finance Lease, Liabilities | 21,700,000 | ||||||||||
Total | 1,891,480,000 | ||||||||||
Other Long-term Debt, Current | 14,856,000 | $ 217,306,000 | |||||||||
Line of Credit, Maturing August 11, 2021 [Member] | |||||||||||
Unsecured revolving credit facility, amount | 1,000,000,000 | $ 1,000,000,000 | |||||||||
Line of Credit Facility, Remaining Borrowing Capacity | 570,600,000 | ||||||||||
Letters of credit issued and outstanding | $ 11,400,000 | ||||||||||
Interest rate terms under amended senior unsecured revolving credit facility | The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. | ||||||||||
Weighted average interest rates under amended senior unsecured revolving credit facility | The weighted average Eurocurrency interest rate as of December 30, 2018 was 2.51%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 3.61%, | ||||||||||
Aggregate borrowings under the amended facility | $ 418,000,000 | 625,000,000 | |||||||||
Unamortized discount and debt issuance costs | (2,401,000) | ||||||||||
Unamortized Debt Issuance Expense | 2,400,000 | 3,300,000 | |||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
2,017 | 0 | ||||||||||
2,018 | 0 | ||||||||||
2,019 | 418,000,000 | ||||||||||
2,020 | 0 | ||||||||||
2,021 | 0 | ||||||||||
Thereafter | 0 | ||||||||||
Long-term Debt Before Unamortized Discount | 418,000,000 | ||||||||||
Total | $ 415,599,000 | 621,700,000 | |||||||||
Line of Credit, Maturing August 11, 2021 [Member] | Base Rate Option Three [Member] | Line of Credit [Member] | |||||||||||
Basis spread on variable rate | 1.00% | ||||||||||
Line of Credit, Maturing August 11, 2021 [Member] | Eurocurrency Rate [Member] | |||||||||||
Basis spread on variable rate | 1.10% | ||||||||||
Line of Credit, Maturing August 11, 2021 [Member] | Eurocurrency Rate [Member] | Line of Credit [Member] | |||||||||||
Basis spread on variable rate | 1.10% | ||||||||||
Line of Credit, Maturing August 11, 2021 [Member] | Base Rate Option Two [Member] | Line of Credit [Member] | |||||||||||
Basis spread on variable rate | 0.50% | ||||||||||
Line of Credit, Maturing December 16, 2016 [Member] | Eurocurrency Rate [Member] | |||||||||||
Description of variable rate basis | Eurocurrency margin | ||||||||||
Line of Credit, Maturing December 16, 2016 [Member] | Base Rate Option Two [Member] | |||||||||||
Description of variable rate basis | Federal Funds | ||||||||||
2021 Notes [Member] | |||||||||||
Interest rate terms under amended senior unsecured revolving credit facility | Interest on the November 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the November 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the November 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the November 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. | ||||||||||
Unsecured senior notes, interest rate percent | 5.00% | ||||||||||
Unsecured senior notes, face value | $ 500,000,000 | ||||||||||
Gross proceeds from the issuance of debt instrument | $ 493,600,000 | ||||||||||
Senior unsecured notes issuance as percentage of principal amount | 99.372% | ||||||||||
Unamortized discount and debt issuance costs | $ (2,628,000) | ||||||||||
Unamortized Debt Issuance Expense | 1,600,000 | 2,000,000 | |||||||||
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument | 101.00% | ||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
2,017 | 0 | ||||||||||
2,018 | 0 | ||||||||||
2,019 | 500,000,000 | ||||||||||
2,020 | 0 | ||||||||||
2,021 | 0 | ||||||||||
Thereafter | 0 | ||||||||||
Long-term Debt Before Unamortized Discount | 500,000,000 | ||||||||||
Total | $ 497,372,000 | 496,600,000 | |||||||||
2021 Notes [Member] | Treasury Rate [Member] | |||||||||||
Basis spread on variable rate | 0.45% | ||||||||||
1.875 Percent Ten Year Senior Unsecured Notes [Member] | |||||||||||
Debt Instrument, Maturity Date | Jul. 19, 2026 | ||||||||||
Unsecured senior notes, interest rate percent | 1.875% | ||||||||||
Gross proceeds from the issuance of debt instrument | $ 492,300,000 | ||||||||||
Senior unsecured notes issuance as percentage of principal amount | 99.118% | ||||||||||
Unamortized discount and debt issuance costs | $ (7,806,000) | ||||||||||
Unamortized Debt Issuance Expense | 3,800,000 | 4,300,000 | |||||||||
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument | 101.00% | ||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
2,017 | 0 | ||||||||||
2,018 | 0 | ||||||||||
2,019 | 0 | ||||||||||
2,020 | 0 | ||||||||||
2,021 | 0 | ||||||||||
Thereafter | 572,350,000 | ||||||||||
Long-term Debt Before Unamortized Discount | 572,350,000 | ||||||||||
Total | 564,544,000 | 591,700,000 | |||||||||
Financing Lease Obligations [Member] | |||||||||||
Additional Financing Lease Obligations | $ 11,500,000 | ||||||||||
Unamortized discount and debt issuance costs | 0 | ||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
2,017 | 1,532,000 | ||||||||||
2,018 | 1,597,000 | ||||||||||
2,019 | 1,665,000 | ||||||||||
2,020 | 1,657,000 | ||||||||||
2,021 | 1,681,000 | ||||||||||
Thereafter | 4,698,000 | ||||||||||
Long-term Debt Before Unamortized Discount | 12,830,000 | ||||||||||
Non-cash Finance Lease, Liabilities | 21,700,000 | ||||||||||
Total | 34,518,000 | ||||||||||
Other Long-term Debt | $ 29,300,000 | ||||||||||
Other Long-term Debt, Current | 1,500,000 | 1,400,000 | |||||||||
Other Long-term Debt, Noncurrent | $ 33,000,000 | 34,500,000 | |||||||||
Term Loan Credit Facility, 12 Months Maturity [Member] | |||||||||||
Short-term Debt, Terms | twelve months | ||||||||||
Short-term Debt, Maximum Amount Outstanding During Period | $ 200,000,000 | ||||||||||
Interest rate terms under amended senior unsecured revolving credit facility | The interest rates under the senior unsecured term loan credit facility were based on the Eurocurrency rate or the base rate at the time of the borrowing, plus a margin. The base rate was the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. | ||||||||||
Weighted average interest rates under amended senior unsecured revolving credit facility | The weighted average Eurocurrency interest rate as of December 31, 2017 was 1.56%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 2.66%, which was the interest applicable to the borrowings outstanding under the Eurocurrency rate as of December 31, 2017 | ||||||||||
Term Loan Credit Facility, Maximum Borrowing Capacity | $ 200,000,000 | ||||||||||
Term Loan Credit Facility, 12 Months Maturity [Member] | Base Rate Option Three [Member] | |||||||||||
Basis spread on variable rate | 1.00% | ||||||||||
Term Loan Credit Facility, 12 Months Maturity [Member] | Base Rate Option Two [Member] | |||||||||||
Basis spread on variable rate | 0.50% | ||||||||||
Other Debt Facilities - EUROIMMUN [Member] | |||||||||||
Interest rate terms under amended senior unsecured revolving credit facility | Of these bank loans, loans in the aggregate amount of $31.9 million bear fixed interest rates between 1.1% and 5.5% and a loan in the amount of $0.2 million bears a variable interest rate based on the Euribor rate plus a margin of 1.5%. | ||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
Long-term Debt, Percentage Bearing Fixed Interest, Amount | € | € 38 | ||||||||||
Long-term Debt, Percentage Bearing Variable Interest, Amount | € | € 0.2 | ||||||||||
Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member] | |||||||||||
Unsecured senior notes, interest rate percent | 1.10% | 1.10% | |||||||||
Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member] | |||||||||||
Unsecured senior notes, interest rate percent | 17.60% | 17.60% | |||||||||
Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member] | |||||||||||
Basis spread on variable rate | 1.50% | ||||||||||
Other Debt Facilities [Member] | |||||||||||
Unamortized discount and debt issuance costs | $ 0 | ||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
2,017 | 13,324,000 | ||||||||||
2,018 | 8,527,000 | ||||||||||
2,019 | 8,197,000 | ||||||||||
2,020 | 3,907,000 | ||||||||||
2,021 | 2,641,000 | ||||||||||
Thereafter | 1,574,000 | ||||||||||
Long-term Debt Before Unamortized Discount | 38,170,000 | ||||||||||
Total | 38,170,000 | ||||||||||
Other Unsecured Revolving Debt Facilities [Member] | |||||||||||
Other Unsecured Revolving Credit Facility | $ 5,800,000 | $ 2,700,000 | |||||||||
Interest rate terms under amended senior unsecured revolving credit facility | The unsecured revolving debt facilities bear fixed interest rates between 2.3% and 17.6%. | ||||||||||
Other Unsecured Revolving Debt Facilities [Member] | Minimum [Member] | |||||||||||
Unsecured senior notes, interest rate percent | 2.30% | 2.30% | |||||||||
Other Unsecured Revolving Debt Facilities [Member] | Maximum [Member] | |||||||||||
Unsecured senior notes, interest rate percent | 17.60% | 17.60% | |||||||||
Other Secured Bank Loan [Member] | |||||||||||
Interest rate terms under amended senior unsecured revolving credit facility | The secured bank loan of $0.3 million bears a fixed annual interest rate of 1.95% and is repaid in monthly installments until 2027. | ||||||||||
Unsecured senior notes, interest rate percent | 1.95% | 1.95% | |||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
Secured Debt | € | € 0.3 | € 0.3 | |||||||||
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | |||||||||||
Interest rate terms under amended senior unsecured revolving credit facility | Interest on the April 2021 Notes is payable annually on April 9th each year. | ||||||||||
Unsecured senior notes, interest rate percent | 0.60% | ||||||||||
Gross proceeds from the issuance of debt instrument | $ 298,700,000 | ||||||||||
Senior unsecured notes issuance as percentage of principal amount | 99.95% | ||||||||||
Unamortized discount and debt issuance costs | $ (2,133,000) | ||||||||||
Unamortized Debt Issuance Expense | 2,000,000 | ||||||||||
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument | 101.00% | ||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
2,017 | 0 | ||||||||||
2,018 | 0 | ||||||||||
2,019 | 343,410,000 | ||||||||||
2,020 | 0 | ||||||||||
2,021 | 0 | ||||||||||
Thereafter | 0 | ||||||||||
Long-term Debt Before Unamortized Discount | 343,410,000 | ||||||||||
Total | $ 341,277,000 | ||||||||||
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Treasury Rate [Member] | |||||||||||
Basis spread on variable rate | 0.15% | ||||||||||
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member] | |||||||||||
Unsecured senior notes, face value | € | € 500 | ||||||||||
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member] | |||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
Other Long-term Debt | € | 28 | 47.6 | |||||||||
Euro Member Countries, Euro | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | |||||||||||
Unsecured senior notes, face value | $ 300,000,000 | ||||||||||
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | |||||||||||
Maturities of Long-term Debt [Abstract] | |||||||||||
Other Long-term Debt | € | 32.1 | € 57.2 | |||||||||
Long-term Debt, Percentage Bearing Fixed Interest, Amount | € | 31.9 | ||||||||||
Secured Debt | € | 4.8 | ||||||||||
Unsecured Debt | € | € 27.3 | ||||||||||
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member] | |||||||||||
Unsecured senior notes, interest rate percent | 1.10% | 1.10% | |||||||||
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member] | |||||||||||
Unsecured senior notes, interest rate percent | 5.50% | 5.50% |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 |
Accounts Payable and Accrued Liabilities, Current [Abstract] | ||
Payroll and incentives | $ 86,549 | $ 66,955 |
Employee benefits | 44,060 | 37,354 |
Deferred revenue | 155,064 | 159,923 |
Federal, non-U.S. and state income taxes | 30,687 | 10,800 |
Other accrued operating expenses | 212,467 | 225,610 |
Total accrued expenses and other current liabilities | $ 528,827 | $ 500,642 |
Employee Benefit Plans (Schedul
Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Service cost | $ 6,853 | $ 4,951 | $ 4,337 |
Interest cost | 16,146 | 16,707 | 18,638 |
Expected return on plan assets | (28,939) | (26,401) | (24,245) |
Actuarial loss (gain) | 17,146 | (7,085) | 15,890 |
Amortization of prior service cost | 375 | (195) | (210) |
Net periodic benefit cost | $ 11,581 | $ (12,023) | $ 14,410 |
Employee Benefit Plans (Sched_2
Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 | |
Change in benefit obligations: | ||||
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change | $ 1,000 | $ 2,600 | $ 5,500 | |
Change in plan assets: | ||||
Employer's contributions | 8,422 | |||
Actuarial assumptions as of the year-end measurement date: | ||||
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation | 180,560 | 187,329 | ||
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets | 0 | 0 | ||
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | 183,424 | 190,265 | ||
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets | 0 | 0 | ||
Foreign Plan [Member] | ||||
Change in plan assets: | ||||
Employer's contributions | 8,500 | $ 8,400 | 9,562 | |
UNITED STATES | ||||
Change in plan assets: | ||||
Employer's contributions | 15,000 | |||
Other Pension Plan [Member] | ||||
Actuarial assumptions as of the year-end measurement date: | ||||
Rate of compensation increase | 3.50% | |||
Foreign Plan [Member] | ||||
Actuarial present value of benefit obligations: [Abstract] | ||||
Accumulated benefit obligations | 304,065 | $ 334,151 | ||
Change in benefit obligations: | ||||
Projected benefit obligations at beginning of year | 343,410 | 279,522 | ||
Service cost | 4,528 | 2,201 | ||
Interest cost | 5,484 | 4,870 | ||
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant | 176 | 189 | ||
Defined Benefit Plan, Benefit Obligation, Business Combination | 537 | 39,293 | ||
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change | 533 | 0 | ||
Actuarial loss (gain) | (13,141) | (1,486) | ||
Effect of exchange rate changes | (17,278) | 32,059 | ||
Projected benefit obligations at end of year | 311,168 | 343,410 | 279,522 | |
Change in plan assets: | ||||
Fair value of plan assets at beginning of year | 179,736 | 153,281 | ||
Actual return on plan assets | (5,653) | 15,866 | ||
Benefits paid and plan expenses | (13,081) | (13,238) | ||
Employer's contributions | 8,480 | |||
Participant's contributions | 176 | 189 | ||
Effect of exchange rate changes | (10,495) | 15,216 | ||
Fair value of plan assets at end of year | 159,163 | 179,736 | $ 153,281 | |
Net amounts recognized in the consolidated balance sheets consist of: | ||||
Net amounts recognized in the consolidated balance sheets | (152,005) | (163,674) | ||
Assets for Plan Benefits, Defined Benefit Plan | 31,419 | 26,591 | ||
Current liabilities | (6,752) | (7,017) | ||
Noncurrent liabilities | (176,672) | (183,248) | ||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||
Prior service cost | $ (278) | $ (457) | ||
Actuarial assumptions as of the year-end measurement date: | ||||
Discount rate | 2.07% | 1.99% | 2.06% | 2.88% |
Rate of compensation increase | 3.48% | 3.50% | 3.64% | 3.26% |
Expected rate of return on assets | 5.90% | 6.00% | 5.30% | |
Defined Benefit Plan, Benefit Obligation, Benefits Paid | $ 13,081 | $ 13,238 | ||
UNITED STATES | ||||
Actuarial present value of benefit obligations: [Abstract] | ||||
Accumulated benefit obligations | 283,310 | 308,713 | ||
Change in benefit obligations: | ||||
Projected benefit obligations at beginning of year | 308,713 | 300,650 | ||
Service cost | 2,325 | 2,750 | ||
Interest cost | 10,662 | 11,836 | ||
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant | 0 | 0 | ||
Defined Benefit Plan, Benefit Obligation, Business Combination | 0 | 0 | ||
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change | 0 | 0 | ||
Actuarial loss (gain) | (18,681) | 13,509 | ||
Effect of exchange rate changes | 0 | 0 | ||
Projected benefit obligations at end of year | 283,310 | 308,713 | $ 300,650 | |
Change in plan assets: | ||||
Fair value of plan assets at beginning of year | 253,427 | 243,817 | ||
Actual return on plan assets | (14,376) | 29,642 | ||
Benefits paid and plan expenses | (19,709) | (20,032) | ||
Employer's contributions | 15,000 | 0 | ||
Participant's contributions | 0 | 0 | ||
Effect of exchange rate changes | 0 | 0 | ||
Fair value of plan assets at end of year | 234,342 | 253,427 | $ 243,817 | |
Net amounts recognized in the consolidated balance sheets consist of: | ||||
Net amounts recognized in the consolidated balance sheets | (48,968) | (55,286) | ||
Assets for Plan Benefits, Defined Benefit Plan | 0 | 0 | ||
Current liabilities | 0 | 0 | ||
Noncurrent liabilities | (48,968) | (55,286) | ||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||
Prior service cost | $ 0 | $ 0 | ||
Actuarial assumptions as of the year-end measurement date: | ||||
Discount rate | 4.05% | 3.56% | 4.06% | 4.25% |
Rate of compensation increase | 0.00% | 0.00% | 0.00% | 0.00% |
Expected rate of return on assets | 7.25% | 7.25% | 7.25% | |
Defined Benefit Plan, Benefit Obligation, Benefits Paid | $ 19,709 | $ 20,032 |
Employee Benefit Plans (Sched_3
Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details) | 12 Months Ended | ||
Dec. 29, 2019 | Dec. 30, 2018 | Dec. 31, 2017 | |
Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 100.00% | 100.00% | |
UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 100.00% | 100.00% | |
Minimum [Member] | Equity Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 45.00% | ||
Minimum [Member] | Equity Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 40.00% | ||
Minimum [Member] | Debt Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 45.00% | ||
Minimum [Member] | Debt Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 50.00% | ||
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 0.00% | ||
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 0.00% | ||
Maximum [Member] | Equity Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 55.00% | ||
Maximum [Member] | Equity Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 50.00% | ||
Maximum [Member] | Debt Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 55.00% | ||
Maximum [Member] | Debt Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 60.00% | ||
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 5.00% | ||
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 5.00% | ||
Other Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 1.00% | 0.00% | |
Other Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 0.00% | 0.00% | |
Debt Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 51.00% | 49.00% | |
Debt Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 61.00% | 59.00% | |
Equity Securities [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 48.00% | 51.00% | |
Equity Securities [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 39.00% | 41.00% | |
Scenario, Forecast [Member] | Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description | 1 | ||
Scenario, Forecast [Member] | UNITED STATES | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description | 1 |
Employee Benefit Plans (Sched_4
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 |
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 393,505 | $ 433,163 | ||
Equity Securities, U.S. Small-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,928 | 2,104 | ||
Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 6,326 | 4,307 | ||
Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 35,072 | 30,008 | ||
Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,175 | 32,613 | ||
Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 11,993 | 14,348 | ||
Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 54,342 | 90,838 | ||
Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,353 | 1,401 | ||
Equity Securities, Foreign Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 22,196 | |||
Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 886 | 7,387 | ||
Debt Security, Government, Non-US [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 23,352 | 24,946 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 131,211 | 138,948 | ||
Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,848 | 27,571 | ||
Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 5,186 | 5,912 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 16,934 | 16,789 | ||
Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 33,703 | 35,991 | ||
Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 135,052 | 138,370 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Small-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,928 | 2,104 | ||
Fair Value, Inputs, Level 1 [Member] | Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 6,326 | 4,307 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 35,072 | 30,008 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,175 | 32,613 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 11,993 | 14,348 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,353 | 1,401 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Foreign Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | |||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 886 | 7,387 | ||
Fair Value, Inputs, Level 1 [Member] | Debt Security, Government, Non-US [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 48,133 | 40,290 | ||
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 5,186 | 5,912 | ||
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 219,323 | 278,004 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Small-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 54,342 | 90,838 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Foreign Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | |||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Debt Security, Government, Non-US [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 23,352 | 24,946 | ||
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 83,078 | 98,658 | ||
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,848 | 27,571 | ||
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 33,703 | 35,991 | ||
Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 39,130 | 16,789 | $ 23,790 | $ 23,416 |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Small-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Foreign Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 22,196 | |||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Debt Security, Government, Non-US [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 16,934 | 16,789 | 23,790 | 23,415 |
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Venture Capital Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | $ 0 | $ 1 |
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 0 | $ 0 |
Employee Benefit Plans (Sched_5
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Other Postretirement Benefits Plan [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | $ 17,374 | $ 15,453 | |
Realized gains (losses) | (1,621) | 741 | $ 539 |
Fair value of plan assets at end of year | 16,279 | 17,374 | 15,453 |
Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 1,151 | ||
Fair value of plan assets at end of year | 1,176 | 1,151 | |
Pension Plans, Defined Benefit | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 433,163 | ||
Fair value of plan assets at end of year | 393,505 | 433,163 | |
Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 16,789 | ||
Fair value of plan assets at end of year | 16,934 | 16,789 | |
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 1,151 | ||
Fair value of plan assets at end of year | 1,176 | 1,151 | |
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 1,151 | 1,508 | 1,374 |
Realized gains (losses) | 229 | ||
Unrealized gains (losses) | 25 | (24) | 134 |
Fair value of plan assets at end of year | 1,176 | 1,151 | 1,508 |
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase | 22,196 | ||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale | (8,189) | ||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 16,789 | 23,790 | 23,416 |
Realized gains (losses) | 1,542 | (1) | |
Unrealized gains (losses) | 145 | (354) | 375 |
Fair value of plan assets at end of year | 39,130 | 16,789 | 23,790 |
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Venture Capital Funds [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase | 0 | ||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale | 0 | ||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 0 | 0 | 1 |
Realized gains (losses) | 0 | (1) | |
Unrealized gains (losses) | 0 | 0 | 0 |
Fair value of plan assets at end of year | 0 | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Foreign Real Estate Funds [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase | 22,196 | ||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale | 0 | ||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 0 | 0 | 0 |
Realized gains (losses) | 0 | 0 | |
Unrealized gains (losses) | 0 | 0 | 0 |
Fair value of plan assets at end of year | 22,196 | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase | 0 | ||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale | (8,189) | ||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 16,789 | 23,790 | 23,415 |
Realized gains (losses) | 1,542 | 0 | |
Unrealized gains (losses) | 145 | (354) | 375 |
Fair value of plan assets at end of year | $ 16,934 | $ 16,789 | $ 23,790 |
Employee Benefit Plans (Sched_6
Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Dec. 29, 2019 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Plan Assets, Contributions by Employer | $ 8,422 | |||
Foreign Plan [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
2,018 | $ 11,313 | |||
2,019 | 11,654 | |||
2,020 | 12,200 | |||
2,021 | 12,267 | |||
2,022 | 12,551 | |||
2023-2026 | 67,457 | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | 8,500 | $ 8,400 | $ 9,562 | |
Foreign Plan [Member] | Scenario, Forecast [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Expected contributions in next fiscal year | $ 8,300 | |||
UNITED STATES | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
2,018 | 18,774 | |||
2,019 | 18,948 | |||
2,020 | 19,176 | |||
2,021 | 19,353 | |||
2,022 | 19,462 | |||
2023-2026 | 95,403 | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | $ 15,000 |
Employee Benefit Plans (Sched_7
Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Pension Plans, Defined Benefit | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Service cost | $ 6,853 | $ 4,951 | $ 4,337 |
Interest cost | 16,146 | 16,707 | 18,638 |
Expected return on plan assets | (28,939) | (26,401) | (24,245) |
Actuarial loss (gain) | (17,146) | 7,085 | (15,890) |
Amortization of prior service cost | 375 | (195) | (210) |
Net periodic benefit cost | 11,581 | (12,023) | 14,410 |
Other Postretirement Benefit Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Service cost | 106 | 92 | 101 |
Interest cost | 120 | 125 | 142 |
Expected return on plan assets | (1,254) | (1,114) | (1,035) |
Defined Benefit Plan, Amortization of Gain (Loss) | 1,621 | (741) | (539) |
Actuarial loss (gain) | (611) | 187 | |
Net periodic benefit cost | $ 593 | $ (1,638) | $ (1,331) |
Employee Benefit Plans (Sched_8
Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Other Postretirement Benefit Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate | 3.60% | 4.11% | 4.34% |
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | $ 3,413 | $ 3,131 | |
Service cost | 106 | 92 | $ 101 |
Interest cost | 120 | 125 | 142 |
Defined Benefit Plan, Benefit Obligation, Benefits Paid | 117 | 122 | |
Actuarial loss (gain) | (611) | 187 | |
Change in accumulated benefit obligations during the year | (502) | 282 | |
Projected benefit obligations at end of year | 2,911 | 3,413 | 3,131 |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 17,374 | 15,453 | |
Actual return on plan assets | (993) | 1,921 | |
Defined Benefit Plan, Plan Assets, Payment for Settlement | (102) | 0 | |
Fair value of plan assets at end of year | 16,279 | 17,374 | $ 15,453 |
Net amounts recognized in the consolidated balance sheets | 13,368 | 13,961 | |
Assets for Plan Benefits, Defined Benefit Plan | 13,368 | 13,961 | |
Prior service cost | $ 0 | $ 0 | |
Discount rate | 4.09% | 3.60% | |
Expected rate of return on assets | 7.25% | 7.25% | 7.25% |
Retirees [Member] | |||
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | $ 688 | $ 804 | |
Projected benefit obligations at end of year | 583 | 688 | $ 804 |
Active Employees Eligible to Retire [Member] | |||
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | 408 | 379 | |
Projected benefit obligations at end of year | 362 | 408 | 379 |
Other Active Employees [Member] | |||
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | 2,317 | 1,948 | |
Projected benefit obligations at end of year | $ 1,966 | $ 2,317 | $ 1,948 |
Employee Benefit Plans (Sched_9
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 |
Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 393,505 | $ 433,163 | ||
Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 16,279 | 17,374 | $ 15,453 | |
Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 135,052 | 138,370 | ||
Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 9,332 | 9,459 | ||
Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 219,323 | 278,004 | ||
Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 5,771 | 6,764 | ||
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 39,130 | 16,789 | 23,790 | $ 23,416 |
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,176 | 1,151 | ||
Cash [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 6,326 | 4,307 | ||
Cash [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 390 | 268 | ||
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 6,326 | 4,307 | ||
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 390 | 268 | ||
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Large-cap [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 35,072 | 30,008 | ||
Equity Securities, U.S. Large-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 2,436 | 2,057 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 35,072 | 30,008 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 2,436 | 2,057 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, International large-cap value[Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,175 | 32,613 | ||
Equity Securities, International large-cap value[Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,679 | 2,236 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,175 | 32,613 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,679 | 2,236 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Equity Index Funds [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 54,342 | 90,838 | ||
Equity Securities, Equity Index Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 833 | 984 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 833 | 984 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 54,342 | 90,838 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,353 | 1,401 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 94 | 96 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,353 | 1,401 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 94 | 96 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Foreign Real Estate Funds [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 22,196 | |||
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | |||
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | |||
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 22,196 | |||
Equity Securities, Commodity Funds [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 886 | 7,387 | ||
Equity Securities, Commodity Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 62 | 506 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 886 | 7,387 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 62 | 506 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 131,211 | 138,948 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 9,115 | 9,526 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 48,133 | 40,290 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 3,344 | 2,762 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 83,078 | 98,658 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 5,771 | 6,764 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, Corporate Bonds [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,848 | 27,571 | ||
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 24,848 | 27,571 | ||
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, High Yield Bonds [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 5,186 | 5,912 | ||
Fixed Income Funds, High Yield Bonds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 360 | 406 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 5,186 | 5,912 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 360 | 406 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 16,934 | 16,789 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,176 | 1,151 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 16,934 | 16,789 | 23,790 | 23,415 |
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,176 | 1,151 | 1,508 | 1,374 |
Other Types of Investments, Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | $ 0 | $ 1 |
Equity Securities, U.S. Small-cap [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,928 | 2,104 | ||
Equity Securities, U.S. Small-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 134 | 144 | ||
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,928 | 2,104 | ||
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 134 | 144 | ||
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 0 | $ 0 |
Employee Benefit Plans (Sche_10
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Other Postretirement Benefit Plans) (Details) - Other Postretirement Benefits Plan [Member] - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | $ 17,374 | $ 15,453 | |
Realized gains (losses) | (1,621) | 741 | $ 539 |
Fair value of plan assets at end of year | 16,279 | 17,374 | 15,453 |
Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | 1,151 | ||
Fair value of plan assets at end of year | 1,176 | 1,151 | |
Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | 1,151 | ||
Fair value of plan assets at end of year | 1,176 | 1,151 | |
Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement | (562) | ||
Fair value of plan assets at beginning of year | 1,151 | 1,508 | 1,374 |
Realized gains (losses) | 229 | ||
Unrealized gains (losses) | 25 | (24) | 134 |
Fair value of plan assets at end of year | $ 1,176 | $ 1,151 | $ 1,508 |
Employee Benefit Plans (Sche_11
Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands | Dec. 29, 2019 | Dec. 30, 2018 |
Foreign Plan [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
2,018 | $ 11,313 | |
2,019 | 11,654 | |
2,020 | 12,200 | |
2,021 | 12,267 | |
2,022 | 12,551 | |
2023-2026 | 67,457 | |
UNITED STATES | ||
Defined Benefit Plan Disclosure [Line Items] | ||
2,018 | 18,774 | |
2,019 | 18,948 | |
2,020 | 19,176 | |
2,021 | 19,353 | |
2,022 | 19,462 | |
2023-2026 | 95,403 | |
Other Postretirement Benefit Plans, Defined Benefit [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
2,018 | 136 | |
2,019 | 149 | |
2,020 | 168 | |
2,021 | 184 | |
2,022 | 194 | |
2023-2026 | $ 1,050 | |
Scenario, Forecast [Member] | Foreign Plan [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year | $ 8,300 |
Employee Benefit Plans (Savings
Employee Benefit Plans (Savings Plan) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation | 100.00% | ||
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match | 5.00% | ||
Defined Benefit, 401(k) Savings Plan Expense | $ 13.2 | $ 12.5 | $ 12.8 |
Employee Benefit Plans (Supplem
Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Projected benefit obligation | $ 22.1 | $ 23.7 | |
Fair value of plan assets | 1.8 | 1.4 | |
Pension expense | $ (0.3) | $ 3.2 | $ 1.6 |
Employee Benefit Plans (Nonqual
Employee Benefit Plans (Nonqualified Deferred Compensation Plans) (Details) - USD ($) $ in Millions | Dec. 30, 2018 | Dec. 31, 2017 |
Management [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Deferred Compensation Arrangement with Individual, Recorded Liability | $ 1.1 | $ 1 |
Contingencies (Details)
Contingencies (Details) $ in Millions | 12 Months Ended | |
Dec. 30, 2018USD ($)years | Dec. 31, 2017USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | ||
Management's estimate of total cost of ultimate disposition of known environmental matters | $ | $ 7.9 | $ 9.4 |
Number of years over which estimated environmental cost will be paid | years | 10 |
Warranty Reserves (Details)
Warranty Reserves (Details) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018USD ($)years | Dec. 31, 2017USD ($) | Jan. 01, 2017USD ($) | |
Warranty reserve activity | |||
Period of warranty protection beyond date of sale (in years) | years | 1 | ||
Balance beginning of period | $ 9,050 | $ 9,012 | $ 9,843 |
Provision charged to income | 13,545 | 13,700 | 14,901 |
Payments | (13,775) | (14,245) | (14,749) |
Adjustments to previously provided warranties, net | (157) | (815) | (850) |
Foreign currency and acquisitions | (270) | 1,398 | (133) |
Balance end of period | $ 8,393 | $ 9,050 | $ 9,012 |
Stock Plans (Narrative) (Detail
Stock Plans (Narrative) (Details) | 12 Months Ended | ||
Dec. 30, 2018USD ($)plan$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Jan. 01, 2017USD ($)$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of Stock-based Compensation Plans | plan | 1 | ||
Total income tax benefit recognized for stock-based compensation | $ 13,600,000 | $ 14,500,000 | $ 10,500,000 |
Stock-based compensation costs capitalized as part of inventory | 300,000 | ||
Options related excess tax benefit, classified as a financing cash activity | 0 | 0 | |
Aggregate intrinsic value for stock options outstanding | $ 43,800,000 | ||
Weighted average remaining contractual term of options (in years) | 4 years 2 months | ||
Aggregate intrinsic value for stock options exercisable | $ 31,600,000 | ||
Weighted average remaining contractual term of options exercisable (in years) | 3 years 2 months | ||
Number of shares vested and expected to vest in the future | shares | 1,800,000 | ||
Aggregate intrinsic value of vested and expected to vest stock options | $ 43,000,000 | ||
Weighted average remaining contractual term for options vested and expected to vest | 4 years 2 months | ||
Total pre-tax stock-based compensation expense | $ 28,767,000 | $ 25,421,000 | $ 17,158,000 |
Deferred compensation liability | $ 14,000,000 | ||
Performance Units [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 73.23 | $ 52.69 | $ 42.79 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | 0 | 15,139 | 19,584 |
Total pre-tax stock-based compensation expense | $ 7,700,000 | $ 8,700,000 | $ 2,700,000 |
Shares/units granted | shares | 37,281 | 49,845 | 72,164 |
Awards/units outstanding | shares | 144,151 | ||
Stock Awards [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 72.17 | $ 63.14 | $ 54.58 |
Total pre-tax stock-based compensation expense | $ 800,000 | $ 800,000 | |
Shares/units granted | shares | 11,088 | 12,006 | 15,419 |
Stock award program for non-employees Directors, fair market value | $ 100,000 | $ 100,000 | |
Restricted Stock Awards [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 76 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | 39,000 | ||
Fair value of restricted stock awards vested | $ 10,400,000 | 10,600,000 | $ 8,400,000 |
Total pre-tax stock-based compensation expense | 11,700,000 | $ 10,300,000 | $ 9,300,000 |
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted | $ 16,000,000 | ||
Shares/units granted | shares | 214,000 | ||
Awards/units outstanding | shares | 465,000 | 496,000 | |
Weighted-average period for recognition of unrecognized compensation cost, years | 1 year 5 months | ||
Option vesting period (in years) | 3 years | ||
Employee Stock Purchase Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares authorized under plan | shares | 5,000,000 | ||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 69.57 | $ 67.09 | $ 49.67 |
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date | 95.00% | ||
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate | 10.00% | ||
Shares/units granted | shares | 21,321 | 36,769 | 49,578 |
Shares available for grant under employee stock purchase plan | shares | 800,000 | ||
Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average grant-date fair value of options | $ / shares | $ 17.56 | $ 11.83 | $ 10.20 |
Total intrinsic value of options exercised | $ 35,000,000 | $ 17,600,000 | $ 16,600,000 |
Cash received from option exercises | 24,800,000 | 18,000,000 | 14,400,000 |
Total pre-tax stock-based compensation expense | 5,400,000 | $ 4,700,000 | $ 4,400,000 |
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted | $ 6,700,000 | ||
Weighted-average period for recognition of unrecognized compensation cost, years | 1 year 9 months | ||
Option vesting period (in years) | 3 years | ||
Stock Options Expiration Period After Date of Grant | 7 years | ||
Performance Restricted Stock Units [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 80.31 | $ 52.78 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | 5,797 | ||
Total pre-tax stock-based compensation expense | $ 3,200,000 | $ 900,000 | |
Shares/units granted | shares | 39,133 | 54,337 | |
Awards/units outstanding | shares | 87,673 | ||
Two Thousand Nine Incentive Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares authorized under plan | shares | 10,000,000 |
Stock Plans (Summary of Total C
Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | $ 28,767 | $ 25,421 | $ 17,158 |
Cost of sales [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 1,466 | 1,254 | 1,031 |
Research and development expenses [Member ] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 1,359 | 1,389 | 902 |
Selling, general and administrative and other expenses [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | $ 25,942 | $ 22,778 | $ 15,225 |
Stock Plans (Weighted-Average A
Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details) | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||
Risk-free interest rate | 3.00% | 2.00% | 1.70% |
Expected dividend yield | 0.40% | 0.40% | 0.60% |
Expected lives, years | 5 years | 5 years | 5 years |
Expected stock volatility | 20.70% | 22.40% | 25.20% |
Stock Plans (Summary of Stock O
Stock Plans (Summary of Stock Option Activity) (Details) shares in Thousands | 12 Months Ended |
Dec. 30, 2018$ / sharesshares | |
Stock option activity | |
Shares outstanding at beginning of the year | 2,154 |
Shares granted | 364 |
Shares exercised | (709) |
Shares forfeited | (44) |
Shares outstanding at end of year | 1,765 |
Shares exercisable at end of year | 965 |
Number of shares vested and expected to vest in the future | 1,800 |
Weighted-average price, outstanding at beginning of year (per share) | $ / shares | $ 42.77 |
Weighted-average price, granted (per share) | $ / shares | 77.84 |
Weighted-average price, exercised (per share) | $ / shares | 35.02 |
Weighted-average price, forfeited (per share) | $ / shares | 51.56 |
Weighted-average price, outstanding at end of year (per share) | $ / shares | 52.91 |
Weighted-average price, exercisable at end of year (per share) | $ / shares | $ 44.60 |
Stock Plans (Summary of Restric
Stock Plans (Summary of Restricted Stock Award Activity) (Details) shares in Thousands | 12 Months Ended |
Dec. 30, 2018$ / sharesshares | |
Restricted Stock Units (RSUs) [Member] | |
Restricted stock award activity | |
Performance factor percentage minimum | 0.00% |
Performance factor percentage maximum | 200.00% |
Restricted Stock Awards [Member] | |
Restricted stock award activity | |
Nonvested at beginning of year | shares | 496 |
Shares, granted | shares | 214 |
Shares, vested | shares | (206) |
Shares, forfeited | shares | (39) |
Nonvested at end of year | shares | 465 |
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ / shares | $ 50.30 |
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | 76 |
Weighted-average grant-date fair value, vested (per share) | $ / shares | 50.37 |
Weighted-average grant-date fair value, forfeited (per share) | $ / shares | 55.73 |
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ / shares | $ 61.72 |
Stockholders' Equity (Narrative
Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||
Mar. 31, 2019 | Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Jun. 30, 2019 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jul. 23, 2018 | Jul. 27, 2016 | |
Schedule of Stockholders' Equity [Line Items] | |||||||||||||||
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans | 66,506 | 78,644 | 75,198 | ||||||||||||
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans | $ 5,200 | $ 4,400 | $ 3,600 | ||||||||||||
Stock repurchase program, number of shares authorized to be repurchased | 8,000,000 | ||||||||||||||
Cash dividends (per share) | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.28 | $ 0.28 | |||||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | $ 57,393 | $ 4,367 | 151,801 | ||||||||||||
Dividends accrued | $ 7,700 | 7,700 | |||||||||||||
Unrecognized prior service costs, net of tax | $ (77) | $ (77) | $ (860) | ||||||||||||
Dividends Payable, Date Declared | Oct. 24, 2018 | ||||||||||||||
Dividends Payable, Date to be Paid | Feb. 8, 2019 | ||||||||||||||
New Repurchase Program, 07/23/2018 [Member] | |||||||||||||||
Schedule of Stockholders' Equity [Line Items] | |||||||||||||||
Number of common stock repurchased in open market | 650,000 | ||||||||||||||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | $ 52,200 | ||||||||||||||
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 197,800 | $ 197,800 | |||||||||||||
Stock Repurchase Program, Authorized Amount | $ 250,000 | ||||||||||||||
Subsequent Event [Member] | |||||||||||||||
Schedule of Stockholders' Equity [Line Items] | |||||||||||||||
Cash dividends (per share) | $ 0.07 | ||||||||||||||
Dividends Payable, Date Declared | Jan. 24, 2019 | ||||||||||||||
Dividends Payable, Date to be Paid | May 10, 2019 |
Stockholders' Equity (Component
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 | |
Cumulative Translation Adjustment Summary [Roll Forward] | ||||
Foreign currency translation adjustment, net of tax, beginning of year | $ (46,582) | $ (100,923) | $ (46,846) | |
Current year change | (123,388) | 54,341 | (54,077) | |
Foreign currency translation adjustment, net of tax, end of year | (176,459) | (46,582) | (100,923) | |
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax | 0 | |||
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax | 0 | |||
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | (6,489) | |||
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax | (123,474) | |||
Unrecognized prior service costs, net of tax | 245 | 322 | 399 | $ 1,259 |
Unrecognized prior service costs, net of tax, current year change | (77) | (77) | (860) | |
Unrealized (losses) gains on securities, net of tax | (267) | (258) | (337) | (369) |
Unrealized (losses) gains on securities, net of tax, current year change | (9) | 79 | 32 | |
Other comprehensive (loss) income | (129,963) | 54,343 | (54,905) | |
Accumulated other comprehensive income (loss) | (176,481) | (46,518) | (100,861) | $ (45,956) |
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02 | $ 6,489 | $ 0 | $ 0 |
Derivatives And Hedging Activ_2
Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions | 3 Months Ended | 12 Months Ended | ||||||
Apr. 01, 2018USD ($) | Dec. 30, 2018USD ($) | Dec. 31, 2017USD ($) | Jan. 01, 2017USD ($) | Dec. 30, 2018EUR (€) | Apr. 27, 2018EUR (€) | Dec. 31, 2017EUR (€) | Jan. 01, 2017EUR (€) | |
Derivative [Line Items] | ||||||||
Proceeds from Derivative Instrument, Investing Activities | $ 0 | $ 36,541 | $ 0 | |||||
Company's business conducted outside United States | 70.00% | |||||||
Payments for (Proceeds from) Hedge, Financing Activities | $ 34,132 | $ 13,824 | 1,900 | |||||
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months | 0 | |||||||
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax | $ 2,600 | |||||||
European And Asian Currencies [Member] | ||||||||
Derivative [Line Items] | ||||||||
Maximum maturity period for foreign exchange contracts, in months | 12 months | |||||||
Duration of foreign currency derivative contract, days | 30 days | 30 days | ||||||
Fair Value Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | $ 223,300 | $ 212,100 | 137,500 | |||||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | ||||||||
Derivative [Line Items] | ||||||||
Foreign Currency Contract, Asset, Fair Value Disclosure | (750) | (1,431) | ||||||
Notional Amount of SEK Derivatives [Member] | Cash Flow Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | € | € 969.5 | |||||||
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | 5,700 | $ 1,253,000 | $ 8,700 | |||||
Notional Amount of Euro Derivatives [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | € | € 298.7 | |||||||
Notional Amount of Euro Derivatives [Member] | Cash Flow Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | € | € 37.3 | € 57.2 | € 58.6 | |||||
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Net Investment Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Notional Amount of Nonderivative Instruments | 216,000 | |||||||
Unrealized Gain (Loss) on Net Investment Hedge in AOCI | $ (2,100) | (9,300) | ||||||
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Net Investment Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Notional Amount of Nonderivative Instruments | 298,700 | |||||||
Unrealized Gain (Loss) on Net Investment Hedge in AOCI | $ (27,500) |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) € in Millions | 12 Months Ended | |||||||||||
Dec. 30, 2018USD ($) | Dec. 31, 2017USD ($) | Jan. 01, 2017USD ($) | Jan. 03, 2016USD ($) | Dec. 30, 2018EUR (€) | Apr. 11, 2018USD ($) | Dec. 31, 2017EUR (€) | Aug. 11, 2016USD ($) | Jul. 19, 2016USD ($) | Jul. 19, 2016EUR (€) | Sep. 30, 2012USD ($) | Oct. 25, 2011USD ($) | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 76,500,000 | |||||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | 69,661,000 | $ 65,328,000 | $ 63,201,000 | $ 57,350,000 | ||||||||
Long-term Debt | $ 1,891,480,000 | |||||||||||
Business Combination, Contingent Consideration Arrangements, Maximum Period | 1 year 9 months 11 days | |||||||||||
Business Combination, Contingent Consideration Arrangements, Weighted Average Period | 5 years | |||||||||||
Non-cash Finance Lease, Liabilities | $ 21,700,000 | |||||||||||
Payments for acquisition related contingent consideration | (12,800,000) | (8,940,000) | $ (155,000) | |||||||||
Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Long-term Debt, Percentage Bearing Fixed Interest, Amount | € | € 38 | |||||||||||
Long-term Debt, Percentage Bearing Variable Interest, Amount | € | € 0.2 | |||||||||||
Line of Credit, Maturing August 11, 2021 [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Unsecured revolving credit facility, amount | 1,000,000,000 | $ 1,000,000,000 | ||||||||||
Long-term Debt | 415,599,000 | 621,700,000 | ||||||||||
Revolving credit facility outstanding balance | 418,000,000 | 625,000,000 | ||||||||||
Unamortized Debt Issuance Expense | 2,400,000 | 3,300,000 | ||||||||||
Term Loan Credit Facility, 12 Months Maturity [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Short-term Debt, Maximum Amount Outstanding During Period | 200,000,000 | |||||||||||
Term Loan Credit Facility, Maximum Borrowing Capacity | 200,000,000 | |||||||||||
2021 Notes [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Unsecured senior notes, face value | $ 500,000,000 | |||||||||||
Long-term Debt | 497,372,000 | 496,600,000 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||||||||
Discount on senior unsecured notes | (1,100,000) | (1,400,000) | $ (3,100,000) | |||||||||
Unamortized Debt Issuance Expense | 1,600,000 | 2,000,000 | ||||||||||
Unsecured senior notes, fair value | 516,100,000 | 536,600,000 | ||||||||||
Financing Lease Obligations [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Long-term Debt | 34,518,000 | |||||||||||
Other Long-term Debt | $ 29,300,000 | |||||||||||
Finance Lease, Liability | 34,500,000 | 35,900,000 | ||||||||||
Non-cash Finance Lease, Liabilities | 21,700,000 | |||||||||||
1.875 Percent Ten Year Senior Unsecured Notes [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Long-term Debt | 564,544,000 | 591,700,000 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.875% | 1.875% | ||||||||||
Discount on senior unsecured notes | (4,000,000) | (4,700,000) | $ (4,400,000) | |||||||||
Unamortized Debt Issuance Expense | 3,800,000 | 4,300,000 | ||||||||||
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Long-term Debt | 341,277,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.60% | |||||||||||
Discount on senior unsecured notes | (100,000) | $ (200,000) | ||||||||||
Unamortized Debt Issuance Expense | $ 2,000,000 | |||||||||||
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.10% | 1.10% | ||||||||||
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 17.60% | 17.60% | ||||||||||
Vanadis Diagnostics AB [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Payments to Acquire Businesses, Net of Cash Acquired | 32,000,000 | |||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 93,000,000 | |||||||||||
Payment for Contingent Consideration Liability, Financing Activities | $ 12,800,000 | |||||||||||
Payment for Contingent Consideration Liability, Operating Activities | 3,700,000 | |||||||||||
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value | 63,200,000 | $ (56,878,000) | ||||||||||
Payments for acquisition related contingent consideration | $ 16,500,000 | |||||||||||
Vanadis Diagnostics AB [Member] | Minimum [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Projected milestone date | 2,016 | |||||||||||
Conditional probability of success | 95.00% | 85.00% | 95.00% | |||||||||
Cumulative probability of success | 89.30% | 53.00% | 89.30% | |||||||||
Vanadis Diagnostics AB [Member] | Minimum [Member] | Measurement Input, Discount Rate [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Measurement Inputs, Discount Rate | 3.70% | 3.10% | ||||||||||
Vanadis Diagnostics AB [Member] | Maximum [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Projected milestone date | 2,019 | 2,019 | ||||||||||
Conditional probability of success | 100.00% | 95.00% | 100.00% | |||||||||
Cumulative probability of success | 100.00% | 90.00% | 100.00% | |||||||||
Vanadis Diagnostics AB [Member] | Maximum [Member] | Measurement Input, Discount Rate [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Measurement Inputs, Discount Rate | 6.80% | 11.30% | ||||||||||
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Other Long-term Debt | € | € 28 | € 47.6 | ||||||||||
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Unsecured senior notes, face value | € | € 500 | |||||||||||
Unsecured senior notes, fair value | $ 496,100,000 | $ 508,900,000 | ||||||||||
Euro Member Countries, Euro | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Unsecured senior notes, face value | $ 300,000,000 | |||||||||||
Unsecured senior notes, fair value | $ 300,500,000 | |||||||||||
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Other Long-term Debt | € | 32.1 | 57.2 | ||||||||||
Long-term Debt, Percentage Bearing Fixed Interest, Amount | € | € 31.9 | |||||||||||
United States of America, Dollars | Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.10% | 1.10% | ||||||||||
United States of America, Dollars | Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | 5.50% | ||||||||||
United States of America, Dollars | Fiscal Year 2018 Other Acquisitions [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value | $ 6,500,000 | |||||||||||
Fair Value, Inputs, Level 2 [Member] | Other Debt Facilities - EUROIMMUN [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Other Long-term Debt | € | € 38.2 | € 60.2 | ||||||||||
Fair Value, Inputs, Level 2 [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | ||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
Long-term Debt | $ 341,300,000 |
Fair Value Measurements (Assets
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | $ 69,661 | $ 65,328 | $ 63,201 | $ 57,350 |
Fair Value, Measurements, Recurring [Member] | Carrying Value [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | (2,447) | (2,208) | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 750 | 1,431 | ||
Foreign exchange derivative liabilities, net | (594) | (23,638) | ||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | 69,661 | 65,328 | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | (2,447) | (2,208) | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 | ||
Foreign exchange derivative liabilities, net | 0 | 0 | ||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | 0 | 0 | ||
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | 0 | 0 | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 750 | 1,431 | ||
Foreign exchange derivative liabilities, net | (594) | (23,638) | ||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | 0 | 0 | ||
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | 0 | 0 | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 | ||
Foreign exchange derivative liabilities, net | 0 | 0 | ||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | $ 69,661 | $ 65,328 |
Fair Value Measurements (Reconc
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||
Balance beginning of period | $ (65,328) | $ (63,201) | $ (57,350) |
Additions | (6,200) | 0 | 0 |
Payments | (16,507) | (34) | (332) |
Reclassified to other current liabilities for milestone achieved | 10,000 | ||
Change in fair value (included within selling, general and administrative expenses) | (14,640) | (2,161) | (16,183) |
Balance end of period | $ (69,661) | $ (65,328) | $ (63,201) |
Leases (Details)
Leases (Details) - USD ($) $ in Millions | 12 Months Ended | |||||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | Dec. 28, 2014 | Dec. 29, 2013 | Aug. 22, 2013 | |
Sale Leaseback Transaction [Line Items] | ||||||
Sale Leaseback Transaction, Description of Accounting for Leaseback | The lease is accounted for as an operating lease and the excess of the net proceeds over the net carrying amount of the property are being amortized on a straight-line basis over the initial lease term of 15 years. | |||||
Sale Leaseback Transaction, Date | 8/22/2013 | |||||
Sale Leaseback Transaction, Gross Proceeds | $ 47.6 | |||||
Sale Leaseback Transaction, Lease Terms | 15 years | |||||
Sale Leaseback Transaction, Current Period Gain Recognized | $ 1.8 | |||||
Sale Leaseback Transaction, Deferred Gain, Gross | $ 26.5 | |||||
Sale Leaseback Transaction, Deferred Gain, Net | 17 | $ 18.8 | ||||
Sales Leaseback Transaction, Short-Term Deferred Gain | 1.8 | 1.8 | ||||
Sales Leaseback Transaction, Long-Term Deferred Gain | 15.3 | 17 | ||||
Rental expense charged to continiuing operations | 62.3 | $ 54 | $ 52 | |||
Minimum rental commitments in next fiscal year | 56.4 | |||||
Minimum rental commitments due in two years | 46.6 | |||||
Minimum rental commitments due in three year | 33.5 | |||||
Minimum rental commitments due in four years | 22.1 | |||||
Minimum rental commitments due in five years | 15.6 | |||||
Minimum rental commitments due in six years and thereafter | $ 67.6 |
Schedule of Sales and Operating
Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||
Dec. 30, 2018USD ($) | [1] | Sep. 30, 2018USD ($) | Jul. 01, 2018USD ($) | Apr. 01, 2018USD ($) | Dec. 31, 2017USD ($) | Oct. 01, 2017USD ($) | Jul. 02, 2017USD ($) | Apr. 02, 2017USD ($) | Dec. 30, 2018USD ($)segments | Dec. 31, 2017USD ($) | Jan. 01, 2017USD ($) | ||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Operating income from continuing operations | $ 115,683 | $ 80,202 | $ 88,064 | $ 39,935 | $ 93,583 | $ 78,038 | $ 74,183 | $ 49,811 | $ 323,884 | $ 295,615 | $ 294,582 | ||
Number of Operating Segments | segments | 2 | ||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 2,777,996 | 2,256,982 | 2,115,517 | ||||||||||
Interest and other expense (income), net | 66,201 | (1,103) | 50,514 | ||||||||||
Income from continuing operations before income taxes | $ 79,429 | $ 78,041 | $ 71,708 | $ 28,505 | $ 80,889 | $ 105,054 | $ 70,792 | $ 39,983 | 257,683 | 296,718 | 244,068 | ||
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market | 21,400 | (2,100) | |||||||||||
Diagnostics [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Operating income from continuing operations | 153,196 | 146,862 | 147,996 | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,084,785 | 678,523 | 602,533 | ||||||||||
Discovery & Analytical Solutions [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Operating income from continuing operations | [2] | 230,481 | 205,259 | 196,508 | |||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,693,211 | 1,578,459 | 1,512,984 | ||||||||||
Corporate [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Operating income from continuing operations | [3],[4] | (59,793) | (56,506) | (49,922) | |||||||||
Particular Diagnostics Case [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Legal Fees | 200 | ||||||||||||
Particular Discovery & Analytical Solutions Case [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Legal Fees | 5,300 | 2,700 | |||||||||||
Product [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,935,493 | 1,477,414 | 1,396,896 | ||||||||||
Product [Member] | Diagnostics [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 924,594 | 536,086 | 462,798 | ||||||||||
Product [Member] | Discovery & Analytical Solutions [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 1,010,899 | 941,328 | 934,098 | ||||||||||
Service [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 842,503 | 779,568 | 718,621 | ||||||||||
Service [Member] | Diagnostics [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | 160,191 | 142,437 | 139,735 | ||||||||||
Service [Member] | Discovery & Analytical Solutions [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 682,312 | $ 637,131 | $ 578,886 | ||||||||||
[1] | The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy | ||||||||||||
[2] | Legal costs for significant litigation matters in the Company's Discovery & Analytical Solutions segment were $5.3 million for fiscal year 2018 and $2.7 million for fiscal year 2017. | ||||||||||||
[3] | {F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjE5Mjc4NGYxNGMyMjRkNzdhNDM2MTgwZDEyNWRjY2U1fFRleHRTZWxlY3Rpb246MkI1RUExQkZDNkIxQTYxOEI5RjkyNDY2QzQ3MEFCRTEM} | ||||||||||||
[4] | {F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjE5Mjc4NGYxNGMyMjRkNzdhNDM2MTgwZDEyNWRjY2U1fFRleHRTZWxlY3Rpb246MzdBQjdGQjZCNEY1RjNFM0M1QkYyNDY2QzQ3MEVFOTYM} |
Industry Segment and Geograph_3
Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | $ 180,588 | $ 105,000 | $ 99,972 |
Payments to Acquire Property, Plant, and Equipment | 93,253 | 39,089 | 31,702 |
Diagnostics [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 107,434 | 31,204 | 25,339 |
Payments to Acquire Property, Plant, and Equipment | 54,737 | 11,262 | 8,556 |
Discovery & Analytical Solutions [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 70,362 | 72,590 | 72,484 |
Payments to Acquire Property, Plant, and Equipment | 34,852 | 26,200 | 21,486 |
Corporate [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 2,792 | 1,206 | 2,149 |
Payments to Acquire Property, Plant, and Equipment | 3,664 | 1,627 | 1,660 |
Continuing Operations [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 180,588 | 105,000 | 99,972 |
Payments to Acquire Property, Plant, and Equipment | 93,253 | 39,089 | 31,702 |
Discontinued Operations [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 0 | 929 | 6,266 |
Payments to Acquire Property, Plant, and Equipment | $ 0 | $ 182 | $ 1,302 |
Industry Segment and Geograph_4
Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 |
Schedule of Total Assets, by segment [Line Items] | |||
Assets | $ 5,975,522 | $ 6,091,463 | |
Diagnostics [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | 3,358,964 | 3,447,437 | $ 1,505,381 |
Discovery & Analytical Solutions [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | 2,567,054 | 2,611,737 | 2,612,757 |
Corporate [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | 49,504 | 32,289 | 31,171 |
Net current and long-term assets of discontinued operations [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | $ 0 | $ 0 | 127,374 |
Total assets [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | $ 4,276,683 |
Industry Segment and Geograph_5
Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | |
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 2,777,996 | $ 2,256,982 | $ 2,115,517 |
UNITED STATES | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 906,398 | 837,018 | 842,364 |
CHINA | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 559,865 | 374,931 | 336,728 |
UNITED KINGDOM | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 72,124 | 65,164 | 65,904 |
GERMANY | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 142,411 | 91,669 | 89,839 |
INDIA | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 92,327 | 84,812 | 43,891 |
ITALY | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 95,908 | 77,477 | 70,948 |
FRANCE | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 97,990 | 80,153 | 71,104 |
JAPAN | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 79,238 | 76,322 | 65,980 |
Other International [Member] | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | 731,735 | 569,436 | 528,759 |
Total international [Member] | |||
Sales by Geographic Area [Line Items] | |||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 1,871,598 | $ 1,419,964 | $ 1,273,153 |
Industry Segment and Geograph_6
Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($) $ in Thousands | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 |
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | $ 490,311 | $ 476,044 | $ 275,050 |
UNITED STATES | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 201,649 | 210,116 | 182,186 |
CHINA | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 61,261 | 64,815 | 36,458 |
UNITED KINGDOM | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 33,429 | 28,028 | 14,638 |
INDIA | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 14,636 | 14,820 | 2,020 |
FINLAND | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 16,211 | 14,764 | 12,295 |
SINGAPORE | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 14,942 | 9,240 | 6,820 |
BRAZIL | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 8,237 | 7,963 | 1,452 |
NETHERLANDS | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 3,750 | 4,281 | 4,162 |
ITALY | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 11,324 | 10,334 | 3,398 |
SWEDEN | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 3,038 | 3,869 | 2,645 |
GERMANY | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 99,181 | 88,249 | 1,292 |
Other International [Member] | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 22,653 | 19,565 | 7,684 |
Total international [Member] | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | $ 288,662 | $ 265,928 | $ 92,864 |
Quarterly Financial Informati_3
Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Dec. 30, 2018 | Dec. 31, 2017 | Jan. 01, 2017 | ||
Quarterly Financial Data [Abstract] | ||||||||||||
Revenue | $ 756,349 | $ 674,313 | $ 703,362 | $ 643,972 | $ 641,630 | $ 554,275 | $ 546,962 | $ 514,115 | $ 2,777,996 | $ 2,256,982 | ||
Gross profit | 376,250 | 332,327 | 340,140 | 292,222 | 307,429 | 268,967 | 257,602 | 239,756 | 1,340,939 | 1,073,754 | ||
Restructuring and contract termination charges, net | (1,942) | 6,508 | 0 | 6,578 | (263) | 3,269 | 0 | 9,651 | 11,144 | 12,657 | $ 5,124 | |
Operating income from continuing operations | 115,683 | [1] | 80,202 | 88,064 | 39,935 | 93,583 | 78,038 | 74,183 | 49,811 | 323,884 | 295,615 | 294,582 |
Income from continuing operations before income taxes | 79,429 | [1] | 78,041 | 71,708 | 28,505 | 80,889 | 105,054 | 70,792 | 39,983 | 257,683 | 296,718 | 244,068 |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | (30) | 1,103 | (610) | (11) | (2,673) | (5,468) | 141,343 | 2,541 | 452 | 135,743 | 18,593 | |
Operating income from continuing operations | 71,322 | [1] | 75,445 | 64,673 | 26,035 | (38,444) | 96,546 | 62,726 | 36,062 | 237,475 | 156,890 | 215,706 |
Net income | $ 71,292 | [1] | $ 76,548 | $ 64,063 | $ 26,024 | $ (41,117) | $ 91,078 | $ 204,069 | $ 38,603 | $ 237,927 | $ 292,633 | $ 234,299 |
Basic earnings per share: | ||||||||||||
Income from continuing operations | $ 0.64 | [1] | $ 0.68 | $ 0.59 | $ 0.24 | $ (0.35) | $ 0.88 | $ 0.57 | $ 0.33 | $ 2.15 | $ 1.43 | $ 1.97 |
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share | 0 | 0.01 | (0.01) | 0 | (0.02) | (0.05) | 1.29 | 0.02 | 0 | 1.24 | 0.17 | |
Net income | 0.64 | [1] | 0.69 | 0.58 | 0.24 | (0.37) | 0.83 | 1.86 | 0.35 | 2.15 | 2.67 | 2.14 |
Diluted earnings per share: | ||||||||||||
Income from continuing operations | 0.64 | [1] | 0.68 | 0.58 | 0.23 | (0.35) | 0.87 | 0.57 | 0.33 | 2.13 | 1.42 | 1.96 |
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share | 0 | 0.01 | (0.01) | 0 | (0.02) | (0.05) | 1.28 | 0.02 | 0 | 1.22 | 0.17 | |
Net income | 0.64 | [1] | 0.69 | 0.57 | 0.23 | (0.37) | 0.82 | 1.84 | 0.35 | 2.13 | 2.64 | $ 2.12 |
Cash dividends per common share | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.28 | $ 0.28 | ||
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market | $ 21,400 | $ (2,100) | ||||||||||
Tax Adjustments, Settlements, and Unusual Provisions | 8,100 | 98,600 | $ (9,600) | |||||||||
Diagnostics [Member] | ||||||||||||
Quarterly Financial Data [Abstract] | ||||||||||||
Operating income from continuing operations | $ 153,196 | $ 146,862 | $ 147,996 | |||||||||
[1] | The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2017 includes a pre-tax gain of $2.1 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy |
Uncategorized Items - pki-20181
Label | Element | Value |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $ 238,270,000 |
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | 10,209,000 |
Accounting Standards Update 2016-16 [Member] | Retained Earnings [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | $ (2,062,000) |